

2023 Medicines in Development – Cancer

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
177Lu-FAP-2286 (ionizing radiation emitter)	Novartis Pharmaceuticals East Hanover, NJ	solid tumors	Phase I www.novartis.com
177Lu FC705 (PSMA-targeted radiotherapy)	FutureChem Seoul, South Korea	metastatic castration-resistant prostate cancer	Phase I/II www.futurechem.co.kr
212Pb-GRPR (GRPR-targeted radiotherapy)	Orano Med Plano, TX	solid tumors	Phase I www.oranomed.com
23ME-00610 (mAb)	23andMe South San Francisco, CA	advanced solid tumors	Phase I www.23andme.com
7HP349 (VLA-4/LFA-1 activator)	7 Hills Pharma Houston, TX	solid tumors	Phase I completed www.7hillspharma.com
A166 (antibody drug conjugate)	Klus Pharma Princeton, NJ	solid tumors	Phase I/II www.kluspharma.com
A2B530 (CAR-T cell therapy)	A2 Biotherapeutics Agoura Hills, CA	solid tumors, including non-small cell lung cancer (NSCLC)	Phase I www.a2bio.com
AAA603 (177Lu-NeoB) (GRPR radioligand therapy)	Novartis Pharmaceuticals East Hanover, NJ	solid tumors	Phase I www.novartis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AAA817 (225Ac-PSMA-617) (PSMA radioligand therapy)	Novartis Pharmaceuticals East Hanover, NJ	metastatic castration-resistant prostate cancer (Breakthrough Therapy)	Phase I www.novartis.com
AB-101 (natural killer cell therapy)	Artiva Biotherapeutics San Diego, CA	non-Hodgkin lymphoma (Fast Track)	Phase I www.artivabio.com
AB-1015 (circuit T-cell therapy)	ArsenalBio South San Francisco, CA	ovarian cancer	Phase I www.arsenalbio.com
AB-16B5 (anti-clusterin mAb)	Alethia BioTherapeutics Montreal, Canada	NSCLC	Phase II www.alethiabio.com
AB-201 (CAR-NK cell therapy)	Artiva Biotherapeutics San Diego, CA	HER2+ solid tumors	Phase I www.artivabio.com
AB-218 (safusidenib) (mIDH1 inhibitor)	AnHeart New York, NY	1L-2L lower-grade glioma	Phase II www.anhearttherapeutics.com
		cholangiosarcoma, solid tumors	Phase I www.anhearttherapeutics.com
AB248 (cis-targeted IL-2-based therapy)	Asher Biotherapeutics South San Francisco, CA	solid tumors (+/-pembrolizumab)	Phase I www.asherbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AB308 (TIGIT inhibitor)	Arcus Biosciences Hayward, CA Gilead Sciences Foster City, CA	hematologic malignancies, solid tumors (+zimberelimab)	Phase I www.gilead.com
AB-329 (AXL inhibitor)	AnHeart Therapeutics New York, NY	solid tumors, including NSCLC	Phase I www.anhearttherapeutics.com
AB521 (HIF-2 alpha inhibitor)	Arcus Biosciences Hayward, CA	2L+ solid tumors, including kidney cancer	Phase I www.arcusbio.com
AB598 (anti-CD39 mAb)	Arcus Biosciences Hayward, CA	solid tumors	Phase I www.arcusbio.com
AB801 (AXL inhibitor)	Arcus Biosciences Hayward, CA	cancer	Phase I www.arcusbio.com
AB8939 (tubulin polymerization inhibitor)	AB Science Paris, France	acute myeloid leukemia (AML)	Phase I www.ab-science.com
ABBV-011 (antibody drug conjugate)	AbbVie North Chicago, IL	small cell lung cancer (SCLC)	Phase I www.abbvie.com
ABBV-101 (BTK degrader)	AbbVie North Chicago, IL	hematologic malignancies	Phase I www.abbvie.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ABBV-151 (livmoniplimab) (GARP-TGF- β 1 inhibitor)	AbbVie North Chicago, IL	liver cancer	Phase II www.abbvie.com
		solid tumors	Phase I www.abbvie.com
ABBV-181 (budigalimab) (anti-PD-1 mAb)	AbbVie North Chicago, IL	solid tumors	Phase I www.abbvie.com
ABBV-319 (antibody drug conjugate)	AbbVie North Chicago, IL	hematologic malignancies	Phase I www.abbvie.com
ABBV-383 (BCMA x CD3 bispecific antibody) <small>ORPHAN DRUG</small>	AbbVie North Chicago, IL SpringWorks Therapeutics Stamford, CT	multiple myeloma	Phase I www.abbvie.com
ABBV-400 (antibody drug conjugate)	AbbVie North Chicago, IL	solid tumors, including gastroesophageal cancer, NSCLC	Phase I www.abbvie.com
ABBV-453 (BCL2 inhibitor)	AbbVie North Chicago, IL	r/r multiple myeloma	Phase I www.abbvie.com
ABBV-514 (biologic therapeutic)	AbbVie North Chicago, IL	solid tumors, including head and neck cancer, NSCLC	Phase I www.abbvie.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ABBV-525 (MALT1 inhibitor)	AbbVie North Chicago, IL	hematologic malignancies	Phase I www.abbvie.com
ABBV-637 (antibody drug conjugate)	AbbVie North Chicago, IL	solid tumors	Phase I www.abbvie.com
ABBV-647/PF-06647020 (PTK7 targeted antibody drug conjugate)	AbbVie North Chicago, IL Pfizer New York, NY	NSCLC	Phase I www.abbvie.com www.pfizer.com
ABBV-706 (antibody drug conjugate)	AbbVie North Chicago, IL	SCLC	Phase I www.abbvie.com
ABBV-744 (BET BDII inhibitor)	AbbVie North Chicago, IL	myelofibrosis	Phase I www.abbvie.com
ABBV-927 (gilorlimab) (agnostic anti-CD40 mAb)	AbbVie North Chicago, IL	solid tumors	Phase I www.abbvie.com
ABBV-CLS-484 (PTPN2 inhibitor)	AbbVie North Chicago, IL Calico South San Francisco, CA	solid tumors	Phase I www.abbvie.com www.calicolabs.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ABBV-CLS-579 (PTNP2 inhibitor)	AbbVie North Chicago, IL Calico South San Francisco, CA	solid tumors	Phase I www.abbvie.com www.calicolabs.com
ABC008 (KLRG1 depleter)	Abcuro Newton, MA	large granular lymphocytic leukemia	Phase I www.abcuro.com
Abecma [®] idecabtagene vicleucel	2seventy bio Cambridge, MA Bristol Myers Squibb Lawrenceville, NJ	1-4L+ multiple myeloma	Phase II www.2seventybio.com www.bms.com
abequolixron (RGX-104) (LXR agonist)	Inspirna New York, NY	advanced endometrial cancer, NSCLC	Phase I www.inspirna.com
abexinostat (HDAC inhibitor)	Xynomic Pharmaceuticals Poway, CA	renal cell carcinoma	Phase III www.xynomicpharma.com
		follicular lymphoma	Phase II www.xynomicpharma.com
ABL503 (bispecific antibody)	ABL Bio Gyeonggi-Do, South Korea	solid tumors	Phase I www.ablbio.com
ABM-1310 (BRAF inhibitor)	ABM Therapeutics San Diego, CA	melanoma with brain metastases	Phase I www.abmtx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ABM-168 (MEK inhibitor)	ABM Therapeutics San Diego, CA	solid tumors with brain metastases	Phase I www.abmtx.com
ABN401 (c-MET inhibitor)	Abion Seoul, South Korea	solid tumors	Phase II www.abionbio.com
ABP 206 (nivolumab biosimilar)	Amgen Thousand Oaks, CA	bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal junction cancer, head and neck cancer, classical Hodgkin lymphoma, kidney cancer, liver cancer, melanoma, mesothelioma, NSCLC, urothelial cancer	Phase III www.amgen.com
ABSK-021 (CSF-1R inhibitor)	Abbisko Therapeutics Shanghai, China	solid tumors	Phase I www.abbisko.com
ABTL0812 (DHFR/Akt/PI3K inhibitor) <small>ORPHAN DRUG</small>	Ability Pharmaceuticals Barcelona, Spain	pancreatic cancer (+FOLFIRINOX)	Phase I/II www.abilitypharma.com
ABX196 (iNKT cell agonist)	Abivax Paris, France	liver cancer (+nivolumab)	Phase I/II www.abivax.com
AC0176 (androgen receptor degrader)	Accutar Biotechnology Cranbury, NJ	prostate cancer (Fast Track)	Phase I www.accutarbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AC0676 (BTK degrader)	Accutar Biotechnology Cranbury, NJ	hematologic malignancies	Phase I www.accutarbio.com
AC0682 (estrogen receptor degrader)	Accutar Biotechnology Cranbury, NJ	breast cancer	Phase I www.accutarbio.com
AC0699 (estrogen receptor degrader)	Accutar Biotechnology Cranbury, NJ	HER2- breast cancer	Phase I www.accutarbio.com
acapatamab (AMG 160) (bispecific T cell engager)	Amgen Thousand Oaks, CA	NSCLC, prostate cancer	Phase I www.amgen.com
ACE1702 (natural killer cell therapy)	Acepodia Biotech Alameda, CA	HER2-expressing solid tumors	Phase I www.acepodia.com
ACE1831 (T cell therapy)	Acepodia Biotech Alameda, CA	CD20-expressing B-cell lymphoma	Phase I www.acepodia.com
ACLX-001 (CAR-T cell therapy)	Arcellx Gaithersburg, MD	multiple myeloma	Phase I www.arcellx.com
ACLX-002 (CAR-T cell therapy)	Arcellx Gaithersburg, MD	AML, myelodysplastic syndromes (MDS)	Phase I www.arcellx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ACR-368 (prexasertib) (CHK1/CHK2 inhibitor) <small>ORPHAN DRUG</small>	Acrivon Therapeutics Watertown, MA	bladder cancer, endometrial cancer, platinum-resistant ovarian cancer, HPV+ squamous cell carcinoma (anal, cervical, head and neck)	Phase II www.acrivon.com
		bladder cancer, endometrial cancer, platinum-resistant ovarian cancer, HPV+ squamous cell carcinoma (anal, cervical, head and neck) (combinations)	Phase I www.acrivon.com
ACT001 (NF-Kappa B inhibitor)	Accendatech USA Houston, TX	glioblastoma	Phase I/II www.accendatechusa.com
Actimab-A (radiopharmaceutical)	Actinium Pharmaceuticals New York, NY	r/r AML (combination therapy)	Phase I www.actiniumpharma.com
Ad/PNP (purine nucleoside phosphorylase gene therapy) <small>ORPHAN DRUG</small>	GeoVax Labs Smyrna, GA	head and neck cancer, multiple myeloma	Phase I/II www.geovax.com
ADA-011 (mAb)	Adanate Palo Alto, CA	solid tumors	Phase I www.adanate.com
adagloxad simolenin (cancer immunotherapy)	OBI Pharma Taipei, Taiwan	triple negative breast cancer (+OBI-821)	Phase III www.obipharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AdAPT-001 (oncolytic adenovirus)	EpicentRx La Jolla, CA	solid tumors	Phase I www.epicentrx.com
Adcetris® brentuximab vedotin	Seagen Bothell, WA	diffuse large B-cell lymphoma (DLBCL) (combination therapy)	Phase III www.seagen.com
		1L Hodgkin lymphoma (combination therapy), 1L Hodgkin lymphoma, 1L peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma or PTCL (retreatment), Hodgkin lymphoma (pediatric), 1L PTCL (<10% CD32 expression), solid tumors	Phase II www.seagen.com
ADCT-601 (mipasetamab uzoptirine) (antibody drug conjugate)	ADC Therapeutics New Providence, NJ	solid tumors	Phase I www.adctherapeutics.com
ADCT-901 (DNA cross linking agent)	ADC Therapeutics New Providence, NJ	solid tumors	Phase I www.adctherapeutics.com
ADG106 (anti-CD137 mAb)	Adagene San Diego, CA	solid tumors	Phase I www.adagene.com
ADG116 (anti-CTLA4 mAb)	Adagene San Diego, CA	solid tumors	Phase I www.adagene.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ADG126 (anti-CTLA4 mAb)	Adagene San Diego, CA	solid tumors	Phase I www.adagene.com
ADG206 (anti-CD137 mAb)	Adagene San Diego, CA	solid tumors	Phase I www.adagene.com
ADI-001 (CAR-T cell therapy)	Adicet Bio Redwood City, CA	non-Hodgkin lymphoma (Fast Track)	Phase I www.adicetbio.com
ADP-A2AFP (alpha fetoprotein targeted T-cell therapy)	Adaptimmune Philadelphia, PA	liver cancer	Phase I www.adaptimmune.com
ADP-A2M4CD8 (TCR T-cell therapy)	Adaptimmune Philadelphia, PA	esophageal cancer, esophagogastric junction cancer, head and neck cancer, urothelial cancer, endometrial cancer, ovarian cancer, gastric cancer, melanoma, NSCLC	Phase II www.adaptimmune.com
ADRX-0706 (antibody drug conjugate)	Adcentrx Therapeutics San Diego, CA	solid tumors	Phase I www.adcentrx.com
ADU-1805 (anti-CTLA4 antibody)	Sairopa Rotterdam, The Netherlands	solid tumors	Phase I www.sairopa.com
ADX-2191 (methotrexate intravitreal) <small>ORPHAN DRUG</small>	Aldeyra Therapeutics Lexington, MA	primary vitreoretinal lymphoma	application submitted www.aldeyra.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
afamitresgene autoleucel (afami-cel) (MAGE A4 T cell therapy) <small>ORPHAN DRUG</small>	Adaptimmune Philadelphia, PA	synovial sarcoma myxoid/round cell liposarcoma	application submitted www.adaptimmune.com Phase II/III www.adaptimmune.com
AFM13 (bispecific antibody) <small>ORPHAN DRUG</small>	Affimed Therapeutics Heidelberg, Germany	transformed mycosis fungoides, PTCL	Phase II www.affimed.com
AFM24 (bispecific antibody)	Affimed Therapeutics Heidelberg, Germany	EGFR-expressing solid tumors	Phase I/II www.affimed.com
AGEN1423 (dalutrafusp alfa) (bispecific antibody)	Agenus Lexington, MA	pancreatic cancer (combination therapy)	Phase I www.agenusbio.com
AGEN1571 (ILT-2 antagonist antibody)	Agenus Lexington, MA	solid tumors (combination therapy)	Phase I www.agenusbio.com
AGEN2373 (anti-CD137 mAb)	Agenus Lexington, MA	malignant melanoma (+bostensilimab), solid tumors	Phase I www.agenusbio.com
AGENT-797 (native iNKT cell therapy)	MiNK Therapeutics New York, NY	multiple myeloma, solid tumors, including head and neck cancer, kidney cancer, NSCLC	Phase I www.minktherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AGI-134 (cancer vaccine)	BioLineRx Modi'in, Israel	solid tumors	Phase I www.biolinerx.com
AGX-148 (adoptive TIL cell therapy)	AgonOx Portland, OR	solid tumors	Phase I www.agonox.com
AIC100 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	AffyImmune Therapeutics Natick, MA	thyroid cancer (Fast Track)	Phase I www.affyimmune.com
AIV001 (multi kinase inhibitor)	AiViva BioPharma Costa Mesa, CA	non-melanoma skin cancer	Phase I/II www.aiviva.com
Akeega [®] niraparib and abiraterone acetate DAT	J&J Innovative Medicine Raritan, NJ	M1 metastatic castration-sensitive prostate cancer	Phase III www.janssen.com
AL101 (gamma secretase inhibitor) <small>ORPHAN DRUG</small>	Ayala Pharmaceuticals Wilmington, DE	adenoid cystic carcinoma (Fast Track)	Phase II www.ayalapharma.com
AL102 (pan-NOTCH inhibitor)	Ayala Pharmaceuticals Wilmington, DE	desmoid tumor (Fast Track)	Phase III www.ayalapharma.com
AL3818 (tyrosine inhibitor) <small>ORPHAN DRUG</small>	Advenchen Laboratories Moorpark, CA	cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneal cancer	Phase III www.advenchen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AL8326 (aurora kinase B inhibitor)	Advenchen Laboratories Moorpark, CA	SCLC	Phase II www.advenchen.com
ALE.CO4 (anti-CLDN1 mAb)	Alentis Therapeutics Basel, Switzerland	head and neck cancer (Fast Track)	Phase I/II www.alentis.ch
Alecensa [®] alectinib	Roche/Genentech South San Francisco, CA	ALK+ NSCLC (adjuvant)	Phase III www.roche.com
ALG.APV-527 (bispecific antibody)	Alligator Bioscience Lund, Sweden Aptevo Therapeutics Seattle, WA	solid tumors	Phase I www.alligatorbioscience.se www.aptevotherapeutics.com
Aliqopa [®] copanlisib	Bayer Pharmaceuticals Whippany, NJ	non-Hodgkin lymphoma	Phase III www.bayer.com
alisertib (aurora kinase V inhibitor) <small>ORPHAN DRUG</small>	Puma Biotechnology Los Angeles, CA	HR+ HER2- metastatic breast cancer, triple negative breast cancer, SCLC	Phase II www.pumabiotechnology.com
ALLO-316 (anti-CD70 CAR-T cell therapy)	Allogene Therapeutics South San Francisco, CA	renal cell carcinoma (Fast Track)	Phase I www.allogene.com
ALLO-501A (anti-CD19 CAR-T cell therapy)	Allogene Therapeutics South San Francisco, CA	3L+ DLBCL, DLBCL (+ALLO-647) (Fast Track)	Phase II www.allogene.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ALLO-605 (anti-BCMA CAR-T cell therapy) <small>ORPHAN DRUG</small>	Allogene Therapeutics South San Francisco, CA	multiple myeloma (Fast Track)	Phase I www.allogene.com
ALLO-715 (anti-BCMA CAR-T cell therapy)	Allogene Therapeutics South San Francisco, CA	multiple myeloma	Phase I www.allogene.com
AlloStim (T-cell vaccine)	Immunovative Therapies Jerusalem, Israel	3L metastatic colorectal cancer	Phase II
alnuctamab (BCMA TCE) (bispecific antibody)	Bristol Myers Squibb Lawrenceville, NJ	r/r multiple myeloma	Phase I www.bms.com
alomfilimab (SAR445256) (anti-ICOS mAb)	Sanofi Bridgewater, NJ	solid tumors	Phase II www.sanofi.com
AlphaMedix (targeted alpha-emitter therapy) <small>ORPHAN DRUG</small>	RadioMedix Houston, TX	neuroendocrine tumors	Phase II www.radiomedix.com
Ameluz® aminolevulinic acid and BFRhodoLED	Biofrontera Woburn, MA	basal cell carcinoma	Phase III www.biofrontera-us.com
AMG 119 (CAR-T cell therapy)	Amgen Thousand Oaks, CA	SCLC	Phase I www.amgen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AMG 176 (tapotoclax) (MCL-1 inhibitor)	Amgen Thousand Oaks, CA	hematologic malignancies	Phase I www.amgen.com
AMG 193 (PRMT5 inhibitor)	Amgen Thousand Oaks, CA	solid tumors	Phase I www.amgen.com
AMG 305 (bispecific T cell engager)	Amgen Thousand Oaks, CA	colorectal cancer	Phase I www.amgen.com
AMG 340 (bispecific T cell engager)	Amgen Thousand Oaks, CA	prostate cancer	Phase I www.amgen.com
AMG 651 (CX904) (bispecific T cell engager)	Amgen Thousand Oaks, CA CytomX Therapeutics South San Francisco, CA	colorectal cancer	Phase I www.amgen.com www.cytomx.com
AMG 794 (bispecific antibody)	Amgen Thousand Oaks, CA	solid tumors, including NSCLC, ovarian cancer	Phase I www.amgen.com
aminolevulinic acid (SONALA-001) (sonodynamic therapy) <small>ORPHAN DRUG</small>	SonALAsense Berkeley, CA	diffuse intrinsic pontine glioma, recurrent glioblastoma	Phase II www.sonalasense.com
aminolevulinic acid hydrochloride (sonodynamic therapy) <small>ORPHAN DRUG</small>	Alpheus Medical North Oakdale, MN	glioblastoma (Fast Track)	Phase I www.alpheusmedial.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
amivantamab-vmjw/lazertinib (bispecific antibody/EGFR inhibitor)	J&J Innovative Medicine Raritan, NJ	NSCLC, 2L NSCLC	Phase III www.janssen.com
Ampligen® rintatolimod <small>ORPHAN DRUG</small>	AIM ImmunoTech Ocala, FL	locally advanced pancreatic cancer	Phase II www.aimimmuno.com
AMT-151 (antibody drug conjugate)	Multitude Therapeutics Redwood City, CA	solid tumors	Phase I www.multitudetherapeutics.com
AMXI-5001 (PARP inhibitor)	AtlasMedx San Ramon, CA	solid tumors	Phase I/II www.atlasmedx.com
AMXT 1501 (polyamine uptake inhibitor)	Aminex Therapeutics Seattle, WA	solid tumors	Phase I/II www.aminextx.com
AN0025 (palupirant) (PGE2 antagonist)	Adlai Nortye North Brunswick, NJ	bladder cancer, cervical cancer, colorectal cancer, NSCLC, triple negative breast cancer	Phase I www.adlainortye.com
AN2025 (buparlisib) (pan-PI3K inhibitor)	Adlai Nortye North Brunswick, NJ	2L/3L head and neck cancer (+paclitaxel) (Fast Track)	Phase III www.adlainortye.com
		PI3KCAm solid tumors (+AN0025 +atezolizumab)	Phase I www.adlainortye.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AN4005 (PD-L1 inhibitor)	Adlai Nortye North Brunswick, NJ	lymphoma, solid tumors	Phase I www.adlainortye.com
AND019 (SERD)	Kind Pharmaceuticals Redwood City, CA	HER2- breast cancer	Phase I www.kindpharmaceuticals.com
Anktiva inbakicept	ImmunityBio Culver City, CA	BCG naïve non-muscle invasive bladder cancer (+BCG), 1L NSCLC (+pembrolizumab)	Phase III www.immunitybio.com
		BCG unresponsive non-muscle invasive bladder cancer (+BCG) (in situ/papillary) (Fast Track) (Breakthrough Therapy)	Phase II/III www.immunitybio.com
		3L pancreatic cancer (+Aldox +PD-L1 and t-haNK), cancer prevention in Lynch Syndrome (+Tri-Ad5 vaccine)	Phase II www.immunitybio.com
		non-Hodgkin lymphoma, solid tumors (+CD19 t-haNK) ((+M-ceNK)	Phase I www.immunitybio.com
annamycin liposomal (2nd generation annamycin) <small>ORPHAN DRUG</small>	Moleculin Biotech Houston, TX	AML (Fast Track), soft tissue sarcoma (Fast Track)	Phase I/II www.moleculin.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ANP-302	ANP Technologies Newark, DE	pancreatic cancer	Phase I www.anptinc.com
ANP-303	ANP Technologies Newark, DE	lung cancer	Phase I www.anptinc.com
anti-ILT4 (biologic therapeutic)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
anti-SIRPα (anzurstobart) (SIRPA protein modulator)	Bristol Myers Squibb Lawrenceville, NJ	hematologic malignancies	Phase I www.bms.com
antroquinonol (isoprenyltransferase inhibitor) <small>ORPHAN DRUG</small>	Golden Biotech Jersey City, NJ	pancreatic cancer	Phase I/II www.goldenbiotech.com
ANV419 (IL-2 agonist)	Anaveon Basel, Switzerland	cutaneous melanoma	Phase I/II www.anaveon.com
AO-176 (anti-CD47 mAb)	Arch Oncology Brisbane, CA	multiple myeloma, solid tumors	Phase I/II www.archoncology.com
Apealea [®] paclitaxel micellar <small>ORPHAN DRUG</small>	Elevar Therapeutics Fort Lee, NJ	ovarian cancer	Phase III www.elevartherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
APG-115 (alrizomadlin) (MDM2-p53 inhibitor) <small>ORPHAN DRUG</small>	Ascentage Pharma Rockville, MD	T-cell prolymphocytic leukemia	Phase II www.ascentage.com
		AML, chronic myelomonocytic leukemia (CMML), MDS, melanoma, solid tumors	Phase I/II www.ascentage.com
APG-1252 (Bcl-1/Bcl-xL inhibitor) <small>ORPHAN DRUG</small>	Ascentage Pharma Rockville, MD	SCLC	Phase I completed www.ascentage.com
APG-1387 (IAP/XIAP)	Ascentage Pharma Rockville, MD	hematologic malignancies, solid tumors	Phase I completed www.ascentagepharma.com
APG-157	Aveta Biomics Bedford, MA	head and neck cancer	Phase II www.avetabiomics.com
		glioma (+bevacizumab)	Phase I/II www.avetabiomics.com
APG-2575 (Bcl-2 inhibitor) <small>ORPHAN DRUG</small>	Ascentage Pharma Rockville, MD	AML, breast cancer, multiple myeloma	Phase I/II www.ascentage.com
		chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstrom macroglobulinemia	early Phase I www.ascentage.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
APG-5918 (EED inhibitor)	Ascentage Pharma Rockville, MD	lymphoma, solid tumors	Phase I www.ascentagepharma.com
APL-101 (vebreltinib) (c-Met inhibitor) ORPHAN DRUG	Apollomics Rockville, MD	solid tumors, including NSCLC	Phase I/II www.apollomics.com
APL-102 (multiple kinase inhibitor)	Apollomics Rockville, MD	solid tumors	Phase I www.apollomics.com
APL-1202 (MetAP2 inhibitor)	Asieris Pharmaceuticals Radnor, PA	muscle invasive bladder cancer	Phase I/II www.asieris.com
APR003 (oral TLR7 agonist)	Apros Therapeutics San Diego, CA	colorectal cancer with malignant liver lesions	Phase I completed www.aproctx.com
APVO436 (bispecific T cell engaging antibody) ORPHAN DRUG	Aptevo Therapeutics Seattle, WA	AML, MDS	Phase I www.aptevotherapeutics.com
arfolitixorin (thymidylate synthase inhibitor)	Isofol Medical Gothenburg, Sweden	colorectal cancer (Fast Track)	Phase III www.isofofmedical.com
ART0380 (ATR Inhibitor)	Artios Pharma Cambridge, United Kingdom	solid tumors	Phase II www.artios.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ART4215 (POL inhibitor)	Artios Pharma Cambridge, United Kingdom	solid tumors	Phase I/II www.artios.com
ART6043 (DNA-directed inhibitor)	Artios Pharma Cambridge, United Kingdom	solid tumors	Phase I/II www.artios.com
ARV-766 (androgen receptor degrader)	Arvinas New Haven, CT	metastatic castration-resistant prostate cancer	Phase I/II www.arvinas.com
ARX517 (antibody drug conjugate)	Ambrx La Jolla, CA	metastatic castration-resistant prostate cancer (Fast Track)	Phase I www.ambrx.com
ARX788 (antibody drug conjugate)	Ambrx La Jolla, CA	HER2+ breast cancer (Fast Track)	Phase II www.ambrx.com
AS-1763 (BTK inhibitor)	Carna Biosciences Kobe, Japan	CLL/SLL, non-Hodgkin lymphoma	Phase I www.carnabio.com
ASC61 (PD-L1 inhibitor)	Ascleptis Zhejiang, China	solid tumors	Phase I www.ascleptis.com
AsiDNA (DNA repair enzyme inhibitor)	Valerio Therapeutics Paris, France	solid tumors	Phase I/II www.valeriotx.com
ASKG915 (anti-PD1/IL-15 fusion protein)	AskGene Pharma Camarillo, CA	solid tumors	Phase I www.ask-gene.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ASN004 (antibody drug conjugate)	Kirilys Therapeutics San Francisco, CA	solid tumors	Phase I www.kirilys.com
ASP1002 (bispecific antibody)	Astellas Pharma US Northbrook, IL	solid tumors	Phase I www.astellas.com
ASP1570 (DGKζ inhibitor)	Astellas Pharma US Northbrook, IL	solid tumors	Phase I www.astellas.com
ASP-1929 (cetuximab sarotalocan)	Rakuten Medical San Diego, CA	head and neck cancer (Fast Track)	Phase III www.rakuten-med.com
ASP2074 (bispecific antibody)	Astellas Pharma US Northbrook, IL	solid tumors	Phase I www.astellas.com
ASP2138 (bispecific antibody)	Astellas Pharma US Northbrook, IL	gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer	Phase I www.astellas.com
ASP3082 (KRAS G12D degrader)	Astellas Pharma US Northbrook, IL	solid tumors	Phase I www.astellas.com
Asparlas [®] calasparagase pegol-mknl	Servier Boston, MA	hematologic malignancies	Phase II www.servier.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AST-201 (cancer vaccine)	Aston Sci Seoul, South Korea	ovarian cancer	Phase II www.astonsci.com
ASTX029 (ERK1/2 inhibitor)	Astex Pharmaceuticals Pleasanton, CA	solid tumors	Phase I/II www.astx.com
ASTX030 (azacitidine/cedazuridine)	Astex Pharmaceuticals Pleasanton, CA	hematologic malignancies	Phase I www.astx.com
ASTX295 (MDM2 antagonist)	Astex Pharmaceuticals Pleasanton, CA	solid tumors	Phase I/II www.astx.com
ATA2271 (CAR-T cell therapy)	Atara Biotherapeutics Thousand Oaks, CA	mesothelioma, solid tumors	Phase I www.atarabio.com
ATG-101	Antengene Shanghai, China	non-Hodgkin lymphoma, solid tumors	Phase I www.antengene.com
ATL001 (T lymphocyte cell therapy)	Achilles Therapeutics London, United Kingdom	NSCLC	Phase I/II www.achillestx.com
ATRC-101 (novel RNP complex)	Atreca San Carlos, CA	solid tumors	Phase I www.atreca.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ATRN-119 (ATR inhibitor)	Aprea Therapeutics Boston, MA	solid tumors	Phase I/II www.aprea.com
AU-007 (anti-IL-2 mAb)	Aulos Bioscience Larkspur, CA	solid tumors	Phase I/II www.aulosbio.com
aumolertinib (EGFR inhibitor)	EQRx Cambridge, MA	EGFRm NSCLC	Phase III www.eqr.com
AUTO1 (CAR-T cell therapy)	Autolus London, United Kingdom	B-cell acute lymphoblastic leukemia (ALL)	Phase I/II www.autolus.com
autogene cevumeran (RG6180/BNT122) (RNA cancer vaccine)	BioNTech Mainz, Germany Roche/Genentech South San Francisco, CA	1L melanoma (+pembrolizumab), pancreatic ductal adenocarcinoma (combination therapy)	Phase II www.roche.com
		solid tumors (+atezolizumab)	Phase I www.roche.com
AV-203 (anti-ERBB3 antibody)	AVEO Oncology Boston, MA	solid tumors	Phase I www.aveooncology.com
AVA 6000 (type II DNA topoisomerase inhibitor)	Avacta Life Sciences London, United Kingdom	solid tumors	Phase I www.avacta.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AVB-001 (cell-based immunotherapy)	Avenge Bio Natick, MA	ovarian cancer	Phase I/II www.avengebio.com
AV-GBM-1 (tumor-initiating cell vaccine)	AiVita Biomedical Irvine, CA	glioblastoma	Phase III www.aivitabiomedical.com
AVM0703 (NK T cell stimulant)	AVM Biotechnology Seattle, WA	lymphoid malignancies	Phase I/II www.avmbiotech.com
AV-MEL-1 (tumor-initiating cell vaccine)	AiVita Biomedical Irvine, CA	melanoma	Phase III www.avitabiomedical.com
		melanoma (+checkpoint inhibitor)	Phase I www.aivitabiomedical.com
avutometinib (RAS/MAPK inhibitor)	Verastem Oncology Boston, MA	low-grade serous ovarian cancer (Breakthrough Therapy), NSCLC (+defactinib), pancreatic ductal cancer, colorectal cancer (combinations)	Phase II www.verastem.com
		NSCLC (+sotorasib), NSCLC (+adagrasib)	Phase I www.verastem.com
Ayvakit [®] avapritinib	Blueprint Medicines Cambridge, MA	solid tumors (pediatric)	Phase I/II www.blueprintmedicines.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AZD0171 (LIFR antagonist)	AstraZeneca Wilmington, DE	1L pancreatic cancer (combination therapy)	Phase II www.astrazeneca.com
AZD0486 (TNB-486) (CD19 x CD3 bispecific antibody)	AstraZeneca Wilmington, DE	non-Hodgkin lymphoma	Phase II www.astrazeneca.com
AZD1390 (ATM inhibitor)	AstraZeneca Wilmington, DE	glioblastoma	Phase I www.astrazeneca.com
AZD5305 (PARP1 inhibitor)	AstraZeneca Wilmington, DE	solid tumors	Phase II www.astrazeneca.com
AZD5335 (antibody drug conjugate)	AstraZeneca Wilmington, DE	ovarian cancer, lung cancer	Phase I www.astrazeneca.com
AZD7789 (bispecific antibody)	AstraZeneca Wilmington, DE	hematologic malignancies, solid tumors	Phase II www.astrazeneca.com
AZD8205 (antibody drug conjugate)	AstraZeneca Wilmington, DE	solid tumors	Phase II www.astrazeneca.com
AZD9574 (PARP1 inhibitor)	AstraZeneca Wilmington, DE	solid tumors	Phase I www.astrazeneca.com
AZD9592 (bispecific antibody drug conjugate)	AstraZeneca Wilmington, DE	solid tumors	Phase I www.astrazeneca.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
azeliragon (RAGE inhibitor) <small>ORPHAN DRUG</small>	Cantex Pharmaceuticals Weston, FL vTv Therapeutics High Point, NC	pancreatic cancer	Phase II www.cantex.com www.vtvtherapeutics.com
azercabtagene zapreleucel (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Imugene Sydney, Australia	B-cell ALL, non-Hodgkin lymphoma	Phase I/II www.imugene.com
BA3011 (mecbotamab vedotin) (AXL antibody drug conjugate) <small>ORPHAN DRUG</small>	BioAtla San Diego, CA	melanoma, NSCLC, ovarian cancer, head and neck cancer	Phase II www.bioalta.com
BA3021 (ozuriftamab vedotin) (ROR2 antibody drug conjugate)	BioAtla San Diego, CA	solid tumors	Phase I www.bioalta.com
BA3071 (CTLA4 inhibitor)	BioAtla San Diego, CA	solid tumors	Phase I www.bioalta.com
BA3182 (EpCAM/CD3 bispecific antibody)	BioAtla San Diego, CA	solid tumors	Phase I www.bioalta.com
bafisontamab (EMB01) (bispecific antibody)	EpimAb Biotherapeutics Shanghai, China	EGFRm lung cancer, gastrointestinal cancer, solid tumors	Phase I/II www.epimab.com
BAL0891 (TTK/PLK1 inhibitor)	SillaJen Biotherapeutics San Francisco, CA	solid tumors	Phase I www.sillajen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
balstilimab (anti-PD-1 mAb)	Agenus Lexington, MA	cervical cancer (+zalifrelimab) (Fast Track)	Phase II www.agenusbio.com
Balversa [®] erdafitinib	J&J Innovative Medicine Raritan, NJ	urothelial cancer	application submitted www.janssen.com
		non-muscle invasive bladder cancer, tumor agnostic cancers	Phase II www.janssen.com
		localized bladder cancer (intravesical delivery system)	Phase I www.janssen.com
batiraxcept (GAS6-AXL pathway inhibitor) <small>ORPHAN DRUG</small>	Aravive Houston, TX	platinum-resistant ovarian cancer (combination therapy) (Fast Track)	Phase III www.aravive.com
		1L clear cell renal cancer (combination therapy), 2L clear cell renal cancer (combination therapy) (Fast Track)	Phase II www.aravive.com
		clear cell renal cancer (ineligible for curative intent therapy)	Phase I www.aravive.com
bavdegalutamide (ARV-110) (androgen receptor degrader enhancer)	Arvinas New Haven, CT	metastatic castration-resistant prostate cancer (Fast Track)	Phase II www.arvinas.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Bavencio® avelumab	EMD Serono Rockland, MA	urothelial cancer (combination therapy)	Phase II www.emdserono.com
bavituximab (chimeric mAb)	OncXerna Therapeutics Waltham, MA	gastric cancer, gastroesophageal junction cancer (+pembrolizumab)	Phase II completed www.oncxerna.com
BAY 2416964 (AhR inhibitor)	Bayer Pharmaceuticals Whippany, NJ	solid tumors	Phase I www.bayer.com
BAY 2862789 (DGK α inhibitor)	Bayer Pharmaceuticals Whippany, NJ	solid tumors, including NSCLC	Phase I www.bayer.com
BAY 2927088 (mEGFR inhibitor)	Bayer Pharmaceuticals Whippany, NJ	NSCLC (EGFRm and/or HER2m)	Phase I www.bayer.com
BAY 2965501 (DGK ζ inhibitor)	Bayer Pharmaceuticals Whippany, NJ	solid tumors	Phase I www.bayer.com
BAY 3375968 (CCR8 mAb)	Bayer Pharmaceuticals Whippany, NJ	solid tumors	Phase I www.bayer.com
BAY 3605349 (NRF2 inhibitor)	Bayer Pharmaceuticals Whippany, NJ	solid tumors	Phase I www.bayer.com
BB-1701 (antibody drug conjugate)	Bliss Biopharmaceuticals Hangzhou, China	solid tumors	Phase I

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BBI-355 (CHK1 inhibitor)	Boundless Bio San Diego, CA	solid tumors	Phase I www.boundlessbio.com
BBP-398 (SHP2 inhibitor)	Bristol Myers Squibb Lawrenceville, NJ BridgeBio Palo Alto, CA	solid tumors, including KRAS ^m NSCLC (Fast Track)	Phase I www.bms.com
bbT369 (CAR-T cell therapy)	2seventy bio Cambridge, MA	non-Hodgkin lymphoma	Phase I www.2seventybio.com
BCA101 (bifunctional fusion protein)	Bicara Therapeutics Cambridge, MA	solid tumors	Phase I www.bicara.com
BCL6 LDD (B-cell lymphoma 6 ligand-directed degrader)	Bristol Myers Squibb Lawrenceville, NJ	lymphoma	Phase I www.bms.com
BDB001 (TLR7/8 agonist)	Seven and Eight Biopharmaceuticals Edison, NJ	solid tumors	Phase I www.7and8biopharma.com
BDB018 (TLR7/8 agonist)	Seven and Eight Biopharmaceuticals Edison, NJ	solid tumors	Phase I www.7and8biopharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BDC-1001 (immune stimulating antibody conjugate)	Bolt Biotherapeutics Redwood City, CA	HER2+ breast cancer	Phase II www.boltbio.com
		solid tumors	Phase I www.boltbio.com
BDC-3042 (myeloid-modulating mAb)	Bolt Biotherapeutics Redwood City, CA	solid tumors	Phase I www.boltbio.com
BDTX-1535 (EGFR inhibitor)	Black Diamond Therapeutics Cambridge, MA	EGFRm glioblastoma, EGFRm NSCLC	Phase I www.blackdiamondtherapeutics.com
BDTX-4933 (BRAF inhibitor)	Black Diamond Therapeutics Cambridge, MA	solid tumors	Phase I www.blackdiamondtherapeutics.com
belvarafenib (RG6185) (pan-RAF inhibitor)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
belzupacap sarotalocan (light-activated therapeutic) <small>ORPHAN DRUG</small>	Aura Biosciences Boston, MA	uveal melanoma (Fast Track)	Phase III www.aurabiosciences.com
		non-muscle invasive bladder cancer (Fast Track)	Phase I www.aurabiosciences.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
bemarituzumab (FGFR2b inhibitor) <small>ORPHAN DRUG</small>	Amgen Thousand Oaks, CA	gastric cancer, gastroesophageal junction cancer (Breakthrough Therapy)	Phase III www.amgen.com
		solid tumors	Phase II www.amgen.com
		NSCLC	Phase I www.amgen.com
bemcentinib (AXL inhibitor) <small>ORPHAN DRUG</small>	BerGenBio Bergen, Norway	AML, NSCLC (Fast Track)	Phase II www.bergenbio.com
berubicin (anthracycline derivative) <small>ORPHAN DRUG</small>	CNS Pharmaceuticals Houston, TX	glioblastoma (Fast Track)	Phase II www.cnspharma.com
betalutin (radioimmunotherapy)	Nordic Nanovector Oslo, Norway	follicular lymphoma (Fast Track), non-Hodgkin lymphoma	Phase I/II www.nordicnanovector.com
bevacizumab-ADNAB (bevacizumab biosimilar)	Sorrento Therapeutics San Diego, CA	endometrial cancer, ovarian cancer	Phase I www.sorrentotherapeutics.com
bezucastinib (KIT inhibitor) <small>ORPHAN DRUG</small>	Cogent Biosciences Waltham, MA	gastrointestinal stromal tumors	Phase III www.cogentbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BF-200 ALA (aminolevulinic acid)	Biofrontera Leverkusen, Germany	basal cell cancer	Phase I www.biofrontera.com
BGB-11417 (BCL2 inhibitor)	BeiGene Cambridge, MA	multiple myeloma, myeloid malignancies, Waldenström's macroglobulinemia	Phase II www.beigene.com
		B-cell malignancies	Phase I www.beigene.com
BGB-15025 (HPK1 inhibitor)	BeiGene Cambridge, MA	solid tumors (+/- tislelizumab)	Phase I www.beigene.com
BGB-16673 (BTK degrader)	BeiGene Cambridge, MA	B-cell malignancies	Phase I www.beigene.com
BGB-24714 (SMAC mimetic)	BeiGene Cambridge, MA	solid tumors	Phase I www.beigene.com
BGB-3245 (brimarafenib) (BRAF inhibitor)	BeiGene Cambridge, MA SpringWorks Therapeutics Stamford, CT	BRAFm solid tumors	Phase I www.beigene.com
BGB-A445 (OX40 agonist)	BeiGene Cambridge, MA	solid tumors (+/- tislelizumab)	Phase I www.beigene.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BGB-B167 (CEA x 4-1BB bispecific antibody)	BeiGene Cambridge, MA	solid tumors (+/- tislelizumab)	Phase I www.beigene.com
BHV-1100 (anti-CD38 antibody) ORPHAN DRUG	Biohaven Pharmaceuticals New Haven, CT	multiple myeloma	Phase I www.biohaven.com
BI-1206 (anti-CD32b mAb) ORPHAN DRUG	BioInvent International Lund, Sweden	non-Hodgkin lymphoma, solid tumors	Phase I/II www.bioinvent.com
BI 1701963 (pan KRAS SOS1 inhibitor)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com
BI 1703880 (2nd generation STING agonist)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com
BI 1810631 (zongertinib) (HER2 inhibitor)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com
BI 1821736 (oncolytic virus therapy)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com
BI 1831169 (VSV-GP)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BI 764532 (DLL3/CD3 T-cell engager)	Boehringer Ingelheim Ridgefield, CT	neuroendocrine tumors, SCLC	Phase I www.boehringer-ingelheim.com
BI 765049 (B7-H6/CD3 T-cell engager)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com
BI 765063 (SIRP α antagonist)	Boehringer Ingelheim Ridgefield, CT	solid tumors	Phase I www.boehringer-ingelheim.com
BI 765179 (CD137/FAP agonist)	Boehringer Ingelheim Ridgefield, CT	solid tumors (+/- ezabenlimab)	Phase I www.boehringer-ingelheim.com
BI 770371 (anti-PD-1 mAb)	Boehringer Ingelheim Ridgefield, CT	solid tumors (+/- ezabenlimab)	Phase I www.boehringer-ingelheim.com
BI 907828 (brigimadlin) (MDM2-p53 inhibitor)	Boehringer Ingelheim Ridgefield, CT	dedifferentiated liposarcoma (Fast Track)	Phase III www.boehringer-ingelheim.com
		2L+ biliary tract cancer	Phase II www.boehringer-ingelheim.com
		solid tumors	Phase I www.boehringer-ingelheim.com
bicalutamide implant (androgen receptor antagonist)	Alessa Therapeutics San Carlos, CA	prostate cancer (+radiation therapy)	Phase I www.alessatherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
bifikafusp alfa + onfekafusp alfa (L19-IL2/L19-TNF recombinant fusion protein) <small>ORPHAN DRUG</small>	Philogen Siena, Italy	stage III melanoma	Phase III www.philogen.com
		stage IV melanoma	Phase II www.philogen.com
BIO-106 (tubulin inhibitor)	BiOneCure Therapeutics Germantown, MD	solid tumors	Phase I/II www.bionecure.com
BJ-001 (IL-15 fusion protein)	BJ Bioscience Zhejiang, China	solid tumors	Phase I www.bjbioscience.com
BJ-005 (recombinant fusion protein)	BJ Bioscience Zhejiang, China	lymphoma, solid tumors	Phase I www.bjbioscience.com
BL-B01D1 (antibody drug conjugate)	SystImmune Redmond, WA	NSCLC	Phase I www.systimmune.com
Blenrep [®] belantamab mafodotin-blmf	GSK Durham, NC	2L+ multiple myeloma (combination therapy)	Phase III www.gsk.com
		multiple myeloma (combination therapy)	Phase II www.gsk.com
		1L multiple myeloma (combination therapy)	Phase I www.gsk.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Blincyto® blinatumomab	Amgen Thousand Oaks, CA	newly-diagnosed Ph- B-cell precursor ALL (adults)	Phase III www.amgen.com
		ALL (subcutaneous administration)	Phase I www.amgen.com
BLU-222 (CDK2 inhibitor)	Blueprint Medicines Cambridge, MA	ER+ HER2- breast cancer, CDK2-vulnerable solid tumors	Phase I/II www.blueprintmedicines.com
BLU-451 (EGFR inhibitor)	Blueprint Medicines Cambridge, MA	EGFR+ NSCLC	Phase I/II www.blueprintmedicines.com
BLU-945 (EGFR inhibitor)	Blueprint Medicines Cambridge, MA	EGFR+ NSCLC	Phase I/II www.blueprintmedicines.com
BMF-219 (menin inhibitor)	Biomea Fusion Redwood City, CA	leukemia, lymphoma, multiple myeloma, KRAS-driven colorectal cancer, KRAS-driven NSCLC, KRAS-driven pancreatic cancer	Phase I www.biomeafusion.com
BMF-500 (FLT3 inhibitor)	Biomea Fusion Redwood City, CA	leukemia	Phase I www.biomeafusion.com
BMS-986012 (anti-fucosyl GM1)	Bristol Myers Squibb Lawrenceville, NJ	r/r SCLC	Phase II www.bms.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BMS-986158 (BET inhibitor)	Bristol Myers Squibb Lawrenceville, NJ	1L myelofibrosis	Phase II www.bms.com
BMS-986253 (anti-IL-8)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase II www.bms.com
BMS-986288 (anti-CTLA4 NF probody)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase II www.bms.com
BMS-986315 (anti-NKG2A mAb)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
BMS-986340 (anti-CCR8)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
BMS-986360 (JNK inhibitor)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
BMS-986378 (trotabresib) (BET inhibitor)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase II www.bms.com
		r/r non-Hodgkin lymphoma	Phase I www.bms.com
BMS-986393 (CC-95266) (GPC5D CAR-T cell therapy)	Bristol Myers Squibb Lawrenceville, NJ	multiple myeloma	Phase I www.bms.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BMS-986397 (CC-91633) (CELMoD)	Bristol Myers Squibb Lawrenceville, NJ	AML, MDS	Phase I www.bms.com
BMS-986416 (TGFβ inhibitor)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
BMS-986442 (TIGIT bispecific antibody)	Agenus Lexington, MA Bristol Myers Squibb Lawrenceville, NJ	solid tumors, including NSCLC	Phase I www.bms.com
BMS-986449	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
BMS-986476 (TPX-4589) (Claudin 18.2 antibody drug conjugate)	Bristol Myers Squibb Lawrenceville, NJ LaNova Medicines Shanghai, China	advanced solid tumors	Phase I www.bms.com
BMX-001 (mangano prophyrin antioxidant mimetic)	BioMimetix Greenwood Village, CO	astrocytoma, glioblastoma, high grade glioma	Phase II www.biomimetix.com
		brain metastases, head and neck cancer	Phase I/II www.biomimetix.com
BND-22 (ILT2 inhibitor)	Biond Biologics Misgav, Israel	solid tumors	Phase I www.biondbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BNT111 (mRNA-based cancer vaccine) <small>ORPHAN DRUG</small>	BioNTech Mainz, Germany	r/r melanoma (Fast Track)	Phase I www.biontech.com
BNT112 (mRNA-based cancer vaccine)	BioNTech Mainz, Germany	prostate cancer	Phase I/II www.biontech.com
BNT113 (mRNA-based cancer vaccine)	BioNTech Mainz, Germany	HPV16+ head and neck cancer	Phase II www.biontech.com
BNT116 (mRNA-based cancer vaccine)	BioNTech Mainz, Germany	2L NSCLC	Phase I www.biontech.com
BNT142 (mRNA-encoded bispecific antibody)	BioNTech Mainz, Germany	solid tumors	Phase I/II www.biontech.com
BNT151 (mRNA-encoded recombinant IL-2)	BioNTech Mainz, Germany	solid tumors	Phase I/II www.biontech.com
BNT152 + BNT153 (mRNA-encoded cytokines)	BioNTech Mainz, Germany	solid tumors	Phase I www.biontech.com
BNT321 (targeted cancer antibody)	BioNTech Mainz, Germany	pancreatic cancer	Phase II www.biontech.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BNT411 (TLR7 agonist)	BioNTech Mainz, Germany	solid tumors, including extensive-stage SCLC	Phase I/II www.biontech.com
BOLD-100 (CRP inhibitor) ORPHAN DRUG	Bold Therapeutics Vancouver, Canada	solid tumors, including colorectal cancer, cholangiocarcinoma, gastric cancer, pancreatic cancer	Phase I/II www.bold-therapeutics.com
bomedemstat (MK-3543) (LSD1 inhibitor) ORPHAN DRUG	Merck Rahway, NJ	myeloproliferative disorders (Fast Track)	Phase II www.merck.com
borestrant (SERD)	EnhancedBio Guro-dong, South Korea Zenopharm New Orleans, LA	HER2- breast cancer	Phase I/II www.zenopharm.com
BOS-342/PRS-342 (bispecific fusion protein)	Boston Pharmaceuticals Cambridge, MA Pieris Pharmaceuticals Boston, MA	liver cancer	Phase I www.bostonpharmaceuticals.com www.pieris.com
botensilimab (Fc-enhanced CTLA-4)	Agenus Lexington, MA	non-MSI-H colorectal cancer (Fast Track), melanoma, pancreatic cancer, solid tumors	Phase II www.agenusbio.com
BOXR1030 (CAR-T cell therapy)	SOTIO Biotech Boston, MA	hepatocellular carcinoma, squamous cell carcinoma of the lung	Phase I www.sotio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BP1001-A (GRB2 inhibitor)	Bio-Path Holdings Bellaire, TX	solid tumors	Phase I www.biopathholdings.com
BP1002 (c-bcl-2 inhibitor)	Bio-Path Holdings Bellaire, TX	AML, lymphoid malignancies	Phase I www.biopathholdings.com
BPM31510 (ubidecaranone) ORPHAN DRUG	BPGbio Framingham, MA	glioblastoma, pancreatic cancer	Phase II www.bpgbio.com
Braftovi [®] encorafenib	Pfizer New York, NY	1L BRAFm metastatic colorectal cancer (+cetuximab +chemotherapy)	Phase III www.pfizer.com
Braftovi [®] + Mektovi [®] encorafenib + binimetinib	Pfizer New York, NY	BRAFm metastatic or unresectable locally advanced melanoma (+pembrolizumab)	Phase III www.pfizer.com
breast cancer vaccine	Anixa Biosciences San Jose, CA	triple negative breast cancer	Phase I www.anixa.com
Breyanzi [®] lisocabtagene maraleucel ORPHAN DRUG	Bristol Myers Squibb Lawrenceville, NJ	3L+ CLL, r/r marginal zone lymphoma, r/r follicular lymphoma, r/r mantle cell lymphoma	Phase II www.bms.com
Bria-IMT [™] SV-BR-1-GM cancer vaccine	BriaCell Therapeutics Philadelphia, PA	metastatic breast cancer (Fast Track)	Phase III www.briacell.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Brukinsa® zanubrutinib	BeiGene Cambridge, MA	r/r follicular lymphoma (+obinutuzumab) (Fast Track)	application submitted www.beigene.com
		1L CLL/SLL, 1L mantle cell lymphoma, r/r marginal zone lymphoma	Phase III www.beigene.com
		B-cell malignancies (previously treated)	Phase II www.beigene.com
		bioavailability between tablets vs. capsules	Phase I www.beigene.com
BST-236 (DNA synthesis inhibitor) <small>ORPHAN DRUG</small>	BioSight Lod, Israel	AML (Fast Track), MDS	Phase II www.biosight-pharma.com
BT5528 (EphA2 inhibitor)	Bicycle Therapeutics Cambridge, MA	solid tumors	Phase I/II www.bicycletherapeutics.com
BT7480 (CD137 agonist)	Bicycle Therapeutics Cambridge, MA	solid tumors	Phase I/II www.bicycletherapeutics.com
BT8009 (nectin-4 inhibitor)	Bicycle Therapeutics Cambridge, MA	solid tumors	Phase I/II www.bicycletherapeutics.com
BTX-1188 (CRBN protein modulator)	BioTheryX San Diego, CA	hematologic malignancies, solid tumors	Phase I www.biotheryx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BTX-A51 (CDK7/9 inhibitor)	BioTheryX San Diego, CA	AML, MDS, non-Hodgkin lymphoma	Phase I www.biotheryx.com
BXCL701 (talabostat) (DPP inhibitor)	BioXcel Therapeutics New Haven, CT	metastatic castration-resistant prostate cancer (small cell neuroendocrine adenocarcinoma phenotype)	Phase II www.bioxceltherapeutics.com
BXQ-350 (S1P activator) <small>ORPHAN DRUG</small>	Bexion Pharmaceuticals Covington, KY	glioma, glioblastoma, colorectal cancer	Phase I www.bexionpharma.com
CA-170 (VISTA/PD-L1 inhibitor)	Curis Lexington, MA	lymphoma, solid tumors	Phase I www.curis.com
Cabometyx [®] cabozantinib	Exelixis Alameda, CA	1L metastatic castration-resistant prostate cancer, 1L kidney cancer	Phase III www.exelixis.com
		NSCLC	Phase I www.exelixis.com
cadonilimab (AK104) (IgG1 tetrameric bispecific antibody) <small>ORPHAN DRUG</small>	Akeso Biopharma Fremont, CA	cervical cancer (Fast Track)	Phase II www.akesobio.com
CAL056	Calgent Biotechnology Taipei City, Taiwan	solid tumors	Phase I www.calgent.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Calquence® acalbrutinib	AstraZeneca Wilmington, DE	1L DLBCL (combination therapy), 1L CLL (combination therapy), 1L mantle cell lymphoma	Phase III www.astrzeneca.com
camidanlumab tesirine (antibody drug conjugate)	ADC Therapeutics New Providence, NJ Genmab Plainsboro, NJ	r/r Hodgkin lymphoma	Phase II www.adctherapeutics.com www.genmab.com
camizestrant (SERD)	AstraZeneca Wilmington, DE	1L HR+ HER2- ESR1m breast cancer (Fast Track), 1L HR+ HER2- breast cancer, (combination therapy) HR+ HER2- breast cancer (adjuvant)	Phase III www.astrazeneca.com
		ER+ breast cancer	Phase II www.astrazeneca.com
camrelizumab (IgG4-kappa mAb) <small>ORPHAN DRUG</small>	Hengrui Pharmaceuticals Shanghai, China	liver cancer	Phase III www.hengrui.com
camsirubicin (type II DNA topoisomerase inhibitor) <small>ORPHAN DRUG</small>	Monopar Therapeutics Wilmette, IL	soft tissue sarcoma	Phase I www.monopartx.com
CAN04 (IL1RAP-binding antibody)	Cantargia Lund, Sweden	solid tumors	Phase I www.cantargia.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CAN1012	CanWell Pharma Newton, MA	solid tumors	Phase I www.canwellbiotech.com
CAN-2409 (aglatimagene besadenovec) (adenovirus gene therapy)	Candel Therapeutics Needham, MA	prostate cancer (Fast Track)	Phase III www.candeltx.com
		NSCLC (Fast Track), pancreatic cancer	Phase II www.candeltx.com
CAN-3110 (oncolytic virus gene therapy)	Candel Therapeutics Needham, MA	glioma	Phase I www.candeltx.com
CAP-100 (anti-CCR7 antibody)	Catapult Therapeutics Lelystad, The Netherlands	CLL	Phase I www.catapult-therapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
capiwasertib (AKT inhibitor)	AstraZeneca Wilmington, DE	HR+ HER2- locally advanced or metastatic breast cancer	application submitted www.astrazeneca.com
		PTEN-deficient hormone sensitive prostate cancer, 1L triple negative breast cancer, metastatic castration-resistant prostate cancer, 1L triplet breast cancer, 2L aromatase inhibitor-resistant breast cancer (combination therapies)	Phase III www.astrazeneca.com
		prostate cancer	Phase II www.astrazeneca.com
CART-ddBCMA (anti-BCMA T cell therapy) <small>ORPHAN DRUG</small>	Arcellx Gaithersburg, MD	multiple myeloma (Fast Track)	Phase II www.arcellx.com
Carvykti® ciltacabtagene autoleucel	J&J Innovative Medicine Raritan, NJ	r/r multiple myeloma w/1-3PL	application submitted www.janssen.com
		1L multiple myeloma TNi	Phase III www.janssen.com
casdozokitug (IL-27 mAb) <small>ORPHAN DRUG</small>	Coherus BioSciences Cambridge, MA	liver cancer (Fast Track), NSCLC	Phase II www.coherus.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CB-010 (CAR-T cell therapy) ORPHAN DRUG	Caribou Biosciences Berkeley, CA	non-Hodgkin lymphoma (Fast Track)	Phase I www.cariboubio.com
CB-011 (CAR-T cell therapy)	Caribou Biosciences Berkeley, CA	multiple myeloma (Fast Track)	Phase I www.cariboubio.com
CB-03-10 (steroidal corticosterone derivative)	Cosmo Pharmaceuticals Dublin, Ireland	solid tumors	early Phase I www.cosmopharma.com
CB-5339 (VCP/p97 inhibitor)	CASI Pharmaceuticals Rockville MD	hematologic malignancies, solid tumors	Phase I www.casipharmaceuticals.com
CBP501 (immune igniter)	CanBas Shizuoka, Japan	pancreatic cancer (combination therapy)	Phase II www.canbas.co.jp
CBP-1019 (bispecific ligand drug conjugate)	Coherent Biopharma Jiangsu, China	solid tumors	Phase I www.coherentbio.com
CBX-12 (DNA topoisomerase I inhibitor)	Cybrexa Therapeutics New Haven, CT	solid tumors	Phase I www.cybrexa.com
CC-92328 (BCMA NKE/DF3001) (BCMA NK cell engager)	Bristol Myers Squibb Lawrenceville, NJ Dragonfly Therapeutics Waltham, MA	r/r multiple myeloma	Phase I www.bms.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CC-94676 (AR-LDD) (androgen receptor ligand directed degrader)	Bristol Myers Squibb Lawrenceville, NJ	1L, 2L metastatic castration-resistant prostate cancer	Phase I www.bms.com
CC-96191 (CD33 NKE/DF2001) (NK cell engager)	Bristol Myers Squibb Lawrenceville, NJ Dragonfly Therapeutics Waltham, MA	r/r AML	Phase I www.bms.com
CC-99282 (golcadomide) (A/I CELMoD)	Bristol Myers Squibb Lawrenceville, NJ	r/r non-Hodgkin lymphoma	Phase II www.bms.com
CCS1477 (inobrodib) (P300/CBP inhibitor) <small>ORPHAN DRUG</small>	CellCentric Cambridge, United Kingdom	hematologic malignancies, multiple myeloma (Fast Track), solid tumors	Phase I/II www.cellcentric.com
CD200AR L (peptide checkpoint inhibitor)	OX2 Therapeutics Minneapolis, MN	glioblastoma	Phase I www.ox2therapeutics.com
CDX-585 (ILT4 x PD-1 bispecific antibody)	CellDex Therapeutics Hampton, NJ	solid tumors	Phase I www.celldex.com
ceralasertib (ATR inhibitor)	AstraZeneca Wilmington, DE	melanoma (+durvalumab), NSCLC (+durvalumab)	Phase III www.astrazeneca.com
		solid tumors	Phase II www.astrazeneca.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CFI-400945 (PLK4 inhibitor)	Treadwell Therapeutics New York, NY	AML (Fast Track), CMML, MDS	Phase I www.treadwelltx.com
CFI-402257 (TTK inhibitor)	Treadwell Therapeutics New York, NY	2L ER+ breast cancer (Fast Track)	Phase I www.treadwelltx.com
CFI-401411 (HPK1 inhibitor)	Treadwell Therapeutics New York, NY	solid tumors	Phase I www.treadwelltx.com
CFT1946 (BRAF V600)	C4 Therapeutics Watertown, MA	V600-mutant solid tumors	Phase I www.c4therapeutics.com
CFT7455 (IKZF1/3) ORPHAN DRUG	C4 Therapeutics Watertown, MA	multiple myeloma, non-Hodgkin lymphoma	Phase I www.c4therapeutics.com
CFT8634 (BRD9) ORPHAN DRUG	C4 Therapeutics Watertown, MA	synovial sarcoma, SMARCB1-null solid tumors	Phase I www.c4therapeutics.com
CGX1321 (PORCN inhibitor)	Curegenix Burlingame, CA	solid tumors, including gastrointestinal cancer	Phase I www.curegenix.com
chiauranib (aurora kinase B inhibitor) ORPHAN DRUG	Chipscreen Biosciences Shenzhen, China	SCLC, solid tumors	Phase I www.chipscreen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CHO-HO1 (anti-CD20 antibody)	Cho Pharma Taipei City, Taiwan	non-Hodgkin lymphoma	Phase I/II www.chopharma.com
CHS-006 (TIGIT inhibitor)	Coherus BioSciences Redwood City, CA	solid tumors including, liver cancer, NSCLC	Phase I www.coherus.com
CHS-114 (anti-CCR8 IgG1 mAb)	Coherus BioSciences Redwood City, CA	solid tumors, including head and neck cancer	Phase I www.coherus.com
CI-8993 (VISTA inhibitor)	Curis Lexington, MA	solid tumors	Phase I www.curis.com
CID-103 (anti-CD38 mAb)	CASI Pharmaceuticals Rockville, MD	multiple myeloma	Phase I www.casipharmaceuticals.com
ciforadenant (CPI-444) (A2A receptor antagonist)	Corvus Pharmaceuticals Burlingame, CA	renal cell carcinoma	Phase II www.corvuspharma.com
cirtuvuvint (SM08502) (CLK2/DYRK inhibitor)	Biosplice Therapeutics San Diego, CA	solid tumors	Phase I www.biosplice.com
CISH inactivated tumor infiltrating lymphocyte cell therapy	Intima Bioscience New York, NY	gastrointestinal cancer	Phase I/II www.intimabioscience.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CK1α degrader (casein kinase 1 alpha degrader)	Bristol Myers Squibb Lawrenceville, NJ	hematologic malignancies	Phase I www.bms.com
CLBR001 + SWI019 (CAR-T cell therapy)	AbbVie North Chicago, IL Calibr La Jolla, CA	hematologic malignancies (Fast Track)	Phase I www.abbvie.com
CLD-101 (neural stem cell virotherapy)	Calidi Biotherapeutics San Diego, CA	newly-diagnosed high-grade glioma	Phase I www.calidibio.com
CLN-049 (FLT3 + CD3 bispecific antibody)	Cullinan Oncology Cambridge, MA	r/r AML, MDS	Phase I www.cullinanoncology.com
CLN-418 (bispecific antibody)	Cullinan Oncology Cambridge, MA Harbour Biomed Hong Kong	solid tumors	Phase I www.cullinanoncology.com
CLN-619 (anti-MICA/B IgG1 mAb)	Cullinan Oncology Cambridge, MA	solid tumors	Phase I www.cullinanoncology.com
CLN-978 (CD19/CD3 T cell antibody)	Cullinan Oncology Cambridge, MA	non-Hodgkin lymphoma	Phase I www.cullinanoncology.com
CM24 (anti-CEACAM1 IgG4 antibody)	Purple Biotech Rehovot, Israel	solid tumors	Phase I www.purple-biotech.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CMG1A46 (tri-specific antibody)	Chimagen Biosciences Sichuan, China	ALL, non-Hodgkin lymphoma	Phase I/II www.chimagen.com
CNTY-101 (CAR-iNK cell therapy)	Century Therapeutics Philadelphia, PA	B-cell malignancies, non-Hodgkin lymphoma	Phase I www.centurytx.com
cobolimab (GSK4069889/TSR-022) (anti-T-cell immunoglobulin/ TIM-3 antibody)	AnaptysBio San Diego, CA GSK Durham, NC	2L NSCLC (+ dostarlimab)	Phase III www.anaptysbio.com www.gsk.com
codrituzumab (GPC-3 inhibitor)	Chugai Pharma USA Berkeley Heights, NJ	liver cancer	Phase I www.chugai-pharm.com
Columvi™ glofitamab	Roche/Genentech South San Francisco, CA	1L DLBCL (ctDNA high risk)	Phase II www.roche.com
		hematologic malignancies	Phase I www.roche.com
COM701 (PVRIG inhibitor)	Compugen USA San Francisco, CA	solid tumors (combination therapy)	Phase I/II www.cgen.com
COM902 (TIGIT inhibitor)	Compugen USA San Francisco, CA	solid tumors	Phase I www.cgen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Copiktra® duvelisib <small>ORPHAN DRUG</small>	Secura Bio Las Vegas, NV	PTCL (Fast Track), CLL, Richter syndrome or transformed follicular lymphoma (Fast Track), CLL/SLL, non-Hodgkin lymphoma	Phase II www.securabio.com
		PTCL (Fast Track)	Phase I www.securabio.com
Cosela® trilaciclib	G1 Therapeutics Research Triangle Park, NC	1L triple negative breast cancer (Fast Track)	Phase III www.g1therapeutics.com
		triple negative breast cancer (combination therapy), 1L bladder cancer	Phase II www.g1therapeutics.com
cosibelimab (anti-PD-L1 antibody)	Checkpoint Therapeutics Waltham, MA	squamous cell cancer	application submitted www.checkpointtx.com
CPI-300 (antitumor nanomedicine)	Coordination Pharmaceuticals Elk Grove Village, IL	solid tumors	Phase I www.coordinationpharma.com
CPI-818 (soquelitinib) (ITK inhibitor)	Corvus Pharmaceuticals Burlingame, CA	T-cell lymphoma	Phase I www.corvuspharma.com
CPO100 (albumin-bound docetaxel)	Conjupro Biotherapeutics Princeton, NJ CSPC ZhongQi Pharmaceutical Shijiazhuang, China	solid tumors	Phase I www.conjuprobio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CPO107 (bispecific fusion protein)	Conjupro Biotherapeutics Princeton, NJ	non-Hodgkin lymphoma	Phase I/II www.conjuprobio.com
CPO301 (antibody drug conjugate)	Conjupro Biotherapeutics Princeton, NJ	solid tumors	Phase I www.conjuprobio.com
CPX-POM (fosciclopirox) (mitosis inhibitor)	CicloMed Kansas City, MO	bladder cancer	Phase II www.ciclomed.com
		AML	Phase I/II www.ciclomed.com
CRB-701 (antibody drug conjugate)	Corbus Pharmaceuticals Norwood, MA	nectin-4 enriched solid tumors	Phase I www.corbuspharma.com
crenolinab (PDGFR inhibitor) <small>ORPHAN DRUG</small>	AROG Pharmaceuticals Dallas, TX	FLT3m AML (Fast Track)	Phase III www.arogpharma.com
cretostimogene grenadenorepvec (oncolytic immunotherapy)	CG Oncology Irvine, CA	non-muscle invasive bladder cancer	Phase III www.cgoncology.com
CRX-100 (oncolytic virus therapy)	BioEclipse Therapeutics South San Francisco, CA	solid tumors	Phase I www.bioeclipse.com
CS5001 (antibody drug conjugate)	CStone Pharmaceuticals Shanghai, China	lymphoma, solid tumors	Phase I www.cstonepharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CT041 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	CARsgen Shanghai, China	gastric cancer, pancreatic cancer	Phase I/II www.carsgen.com
CT-0508 (CAR-macrophage)	Carisma Therapeutics Philadelphia, PA	solid tumors (Fast Track)	Phase I www.carismatx.com
C-TIL051 (autologous TIL therapy)	Cellular Biomedicine Rockville, MD	NSCLC	Phase I www.cellbiomedgroup.com
CTT1403 (PSMA-targeted radiotherapeutic)	Cancer Targeted Technology Woodinville, WA	prostate cancer	Phase I www.cancertargetedtechnology.com
CTX-009 (DLL4/VEGF-A inhibitor)	Compass Therapeutics Boston, MA	biliary tract cancer, colorectal cancer	Phase II www.compasstherapeutics.com
CTX110 (allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy) <small>ORPHAN DRUG</small>	CRISPR Therapeutics Boston, MA	CD19+ B-cell malignancies	Phase I www.crisprtx.com
CTX112 (allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy)	CRISPR Therapeutics Boston, MA	CD19+ B-cell malignancies	Phase I www.crisprtx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CTX130 (allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy) <small>ORPHAN DRUG</small>	CRISPR Therapeutics Boston, MA	B-cell lymphoma, T-cell lymphoma	Phase I www.crisprtx.com
CTX131 (allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy)	CRISPR Therapeutics Boston, MA	solid tumors	Phase I www.crisprtx.com
CTX-471 (CD137 agonist)	Compass Therapeutics Boston, MA	solid tumors (+pembrolizumab), including mesothelioma, NSCLC, SCLC	Phase I www.bostontherapeutics.com
CTX-712 (pan-CLK inhibitor)	Chordia Therapeutics Kanagawa, Japan	AML, MDS	Phase I/II www.chordiatherapeutics.com
CUE-101 (HPV16 tumor-specific T cell activator)	Cue Biopharma Boston, MA	HPV16+ driven head and neck squamous cell carcinoma (Fast Track)	Phase I www.cuebiopharma.com
CUE-102 (fusion protein)	Cue Biopharma Boston, MA	solid tumors	Phase I www.cuebiopharma.com
CX-2029 (CD71-MMAE)	CytomX Therapeutics South San Francisco, CA	esophageal cancer, gastric cancer, NSCLC	Phase II www.cytomx.com
CX-4945 (silmitsertib) (CK2 inhibitor)	Senhwa Biosciences San Diego, CA	basal cell carcinoma	Phase I www.senwhabio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
CX-5461 (G-quadruplex stabilizer)	Senhwa Biosciences San Diego, CA	solid tumors	Phase I www.senwhabio.com
CYAD-02 (CAR-T cell therapy)	Celyad Oncology New York, NY	AML, MDS	Phase I www.celyad.com
CYAD-101 (CAR-T cell therapy)	Celyad Oncology New York, NY	colorectal cancer	Phase I www.celyad.com
CYAD-211 (CAR-T cell therapy)	Celyad Oncology New York, NY	multiple myeloma	Phase I www.celyad.com
CYNK-001 (natural killer cell therapy)	Celularity Florham Park, NJ	AML (Fast Track)	Phase I/II www.celularity.com
CYTO NK-102 (CAR-NK cell therapy)	CytoImmune Therapeutics Duarte, CA	NSCLC	Phase I www.cytoimmune.com
D-0502 (SERD)	InventisBio Shanghai, China	ER+ HER2- breast cancer	Phase I www.inventisbio.com
D-1553 (KRAS inhibitor)	InventisBio Shanghai, China	solid tumors	Phase I www.inventisbio.com
D3S-001 (KRAS inhibitor)	D3 Bio Jiangsu, China	solid tumors	Phase I www.d3bio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
DAN-222 (DNA topoisomerase I inhibitor)	Dantari Thousand Oaks, CA	HER2- breast cancer	Phase I/II www.dantari.com
danvatirsen (STAT3 inhibitor)	Flamingo Therapeutics San Diego, CA	head and neck cancer	Phase II www.flaminotx.com
Danyelza® naxitamab	Y-mAbs Therapeutics New York, NY	1L high-risk neuroblastoma (pediatric), 2L osteosarcoma	Phase II www.ymabs.com
DARIC33 (CAR-T cell therapy)	2seventy bio Cambridge, MA	AML (pediatric)	Phase I www.2seventybio.com
darovasertib (PKC inhibitor) <small>ORPHAN DRUG</small>	IDEAYA Biosciences South San Francisco, CA	uveal melanoma (Fast Track)	Phase III www.ideayabio.com
		uveal melanoma (adjuvant)	Phase II www.ideayabio.com
Darzalex® daratumumab	J&J Innovative Medicine Raritan, NJ	1L multiple myeloma transplant eligible and ineligible, smoldering multiple myeloma	Phase III www.janssen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
datopotamab deruxtecan (Dato-DXd) (antibody drug conjugate)	AstraZeneca Wilmington, DE Daiichi Sankyo Basking Ridge, NJ	2/3L NSCLC, 2/3L breast cancer, 1L NSCLC (+pembrolizumab), 1L triple negative breast cancer, triple negative breast cancer (adjuvant)	Phase III www.astrazeneca.com www.daiichisankyo.com
		EGFRm NSCLC, NSCLC, triple negative breast cancer (+durvalumab), early-stage NSCLC, ovarian cancer, solid tumors	Phase II www.astrazeneca.com www.daiichisankyo.com
		solid tumors, NSCLC	Phase I www.astrazeneca.com www.daiichisankyo.com
DB102 (enzastaurin) (PKC-β/PI3K/AKT inhibitor)	Denovo Biopharma San Diego, CA	1L glioblastoma (Fast Track)	Phase III www.denovobiopharma.com
DB107 (vocimagene amiretrorepevec- flucytisine gene therapy) <small>ORPHAN DRUG</small>	Denovo Biopharma San Diego, CA	newly diagnosed glioma (Fast Track) (Breakthrough Therapy)	Phase II www.denovobiopharma.com
DB-1303 (BNT323) (HER2 antibody drug conjugate)	BioNTech Mainz, Germany Duality Bio Shanghai, China	solid tumors	www.biontech.com www.dualitybiologics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
DB-1305 (antibody drug conjugate)	BioNTech Mainz, Germany Duality Bio Shanghai, China	solid tumors	Phase I www.dualitybiologics.com
DB-1310 (antibody drug conjugate)	Duality Bio Shanghai, China	solid tumors	Phase I www.dualitybiologics.com
DB-1311 (antibody drug conjugate)	Duality Bio Shanghai, China	solid tumors	Phase I www.dualitybiologics.com
DCBY02 (anti-CD93 antibody)	DynamiCure Biotechnology Waltham, MA	solid tumors	Phase I www.dynamicure.com
DCC-3116 (ULK inhibitor)	Deciphera Pharmaceuticals Waltham, MA	MAPK-mutant solid tumors	Phase I/II www.deciphera.com
DCSZ11 (anti-CD93 antibody)	DynamiCure Biotechnology Waltham, MA	solid tumors	Phase I www.dynamicure.com
DCVax[®]-L brain cancer vaccine <small>ORPHAN DRUG</small>	Northwest Biotherapeutics Bethesda, MD	glioblastoma	Phase III www.nwbio.com
Debio 0123 (Wee1 inhibitor)	Debiopharm Lausanne, Switzerland	glioblastoma (+ temozolomide), solid tumors	Phase I www.debiopharm.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Decoy20 (microbiome modulator)	Indaptus Therapeutics New York, NY	solid tumors	Phase I www.indaptusrx.com
delolimogene mupadenorepvec (oncolytic virus immunotherapy) ORPHAN DRUG	Lokon Pharma Uppsala, Sweden	melanoma (+atezolizumab) pancreatic cancer	Phase I/II www.lokonpharma.com
denifanstat (FASN inhibitor)	Sagimet Biosciences San Mateo, CA	solid tumors	Phase I completed www.sagimet.com
Descartes-25 (allogeneic MSC therapy)	Cartesian Therapeutics Gaithersburg, MD	multiple myeloma	Phase I www.cartesiantherapeutics.com
devimistat (CPI-613) (dehydrogenase complex inhibitor) ORPHAN DRUG	Cornerstone Pharmaceuticals Cranbury, NJ	1L pancreatic cancer (Fast Track), clear cell sarcoma, biliary tract cancer, leukemia, B-cell lymphoma, Burkitt's lymphoma	Phase II www.cornerstonepharma.com
DF1001 (HER2 targeting NK cell engager)	Dragonfly Therapeutics Waltham, MA	solid tumors	Phase I/II www.dragonflytx.com
DF6002 (IL-12 targeting cytokine)	Dragonfly Therapeutics Waltham, MA	solid tumors	Phase I/II www.dragonflytx.com
DF9001 (EGFR targeting NK cell therapy)	Dragonfly Therapeutics Waltham, MA	solid tumors	Phase I/II www.dragonflytx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
DFF332 (HIF2A inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	kidney cancer	Phase I www.novartis.com
DFP-10917 (DNA polymerase inhibitor) ORPHAN DRUG	Delta-Fly Pharma Tokushima, Japan	AML	Phase III www.delta-flypharma.co.jp
DFP-14927 (DNA polymerase inhibitor)	Delta-Fly Pharma Tokushima, Japan	solid tumors	Phase I www.delta-flypharma.co.jp
DFV890 (NLRP3 inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	low-risk MDS	Phase I www.novartis.com
DGK inhibitor	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
disitamab vedotin (antibody drug conjugate)	Seagen Bothell, WA	2L HER2-expressing urogenital cancer (Breakthrough Therapy)	Phase III www.seagen.com
		solid tumors	Phase II www.seagen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
divarasisb (RG6330) (KRAS G12C)	Roche/Genentech South San Francisco, CA	2L NSCLC	Phase III www.roche.com
		solid tumors	Phase I www.roche.com
DK210 (targeted cytokine therapy)	Deka Biosciences Germantown, MD	solid tumors	Phase I www.dekabiosciences.com
DKN-01 (sirexatamab) (anti-DKK1 antibody) <small>ORPHAN DRUG</small>	Leap Therapeutics Cambridge, MA	gastric cancer (combination therapy) (Fast Track), colorectal cancer combination therapy), endometrial cancer (combination therapy)	Phase II www.leaptx.com
DM-CHOC-PEN (cell death stimulant)	Dekk-Tec New Orleans, LA	brain tumors	Phase II completed www.dekk-tec.com
DNX-2401 (tasadenoturev) (oncolytic virus therapy) <small>ORPHAN DRUG</small>	DNatrix Carlsbad, CA	recurrent glioblastoma (Fast Track), diffuse intrinsic pontine glioma (pediatric) (Fast Track)	Phase II www.dnatrix.com
DNX-2440 (OX40L-armed virus)	DNatrix Carlsbad, CA	colorectal cancer, liver metastases	Phase I www.dnatrix.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
domvanalimab (TIGIT inhibitor)	Arcus Biosciences Hayward, CA Gilead Sciences Foster City, CA	1L NSCLC, stage 3 NSCLC, 1L upper gastrointestinal cancer (combination therapy)	Phase III www.arcusbio.com www.gilead.com
		NSCLC (combination therapy)	Phase II www.arcusbio.com www.gilead.com
dovitinib (pan-tyrosine kinase inhibitor)	Allarity Therapeutics Boston, MA	2L+ ovarian cancer	Phase III www.allarity.com
doxorubicin microneedle array	SkinJect Pittsburgh, PA	basal cell cancer	Phase I www.skinjectpatch.com
DR-01 (IgG1 monoclonal antibody)	Dren Bio Foster City, CA	large granular lymphocytic leukemia, cytotoxic lymphomas	Phase I/II www.drenbio.com
DRL_RI (rituximab biosimilar)	Dr Reddy's Laboratories Princeton, NJ	follicular lymphoma	application submitted www.drreddysusa.com
DS-1055 (anti-GARP antibody)	Daiichi Sankyo Basking Ridge, NJ	solid tumors	Phase I www.daiichisankyo.com
DS-1103 (anti-SIRP α antibody)	Daiichi Sankyo Basking Ridge, NJ	HER2 expressing or mutant solid tumors	Phase I www.daiichisankyo.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
DS-1594 (menin-MLL binding inhibitor)	Daiichi Sankyo Basking Ridge, NJ	ALL, AML	Phase I www.daiichisankyo.com
DS-6000 (raludotatug deruxtecan) (antibody drug conjugate)	Daiichi Sankyo Basking Ridge, NJ	ovarian cancer, renal cell carcinoma	Phase I www.daiichisankyo.com
DS-7300 (ifinatumab deruxtecan) (B7-H3-directed antibody drug conjugate)	Daiichi Sankyo Basking Ridge, NJ	extensive-stage SCLC	Phase II www.daiichisankyo.com
		solid tumors, including NSCLC, SCLC, esophageal cancer, prostate cancer	Phase I www.daiichisankyo.com
DS-9606 (antibody drug conjugate)	Daiichi Sankyo Basking Ridge, NJ	solid tumors	Phase I www.daiichisankyo.com
DSP-107 (bi-functional fusion protein)	Kahr Medical Jerusalem, Israel	hematologic malignancies, solid tumors	Phase I www.kahrbio.com
DSP-5336 (menin-MLL binding inhibitor) <small>ORPHAN DRUG</small>	Sumitomo Pharma Oncology Cambridge, MA	ALL, AML	Phase I/II www.oncology.sumitomo-pharma.com
DT2216 (proteolysis-targeting chimera) <small>ORPHAN DRUG</small>	Dialectic Therapeutics Dallas, TX	hematologic malignancies (Fast Track), solid tumors	Phase I www.dtsciences.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
DTRM-555	DTRM Biopharma Zhejiang, China	CLL, non-Hodgkin lymphoma	Phase II
DVX201 (natural killer cell therapy)	Coceptis Therapeutics Wexford, PA	AML, MDS	Phase I www.coeptisix.com
DZ-002 (drug conjugate)	Da Zen Theranostics San Jose, CA	lymphoma, solid tumors	Phase I www.dazetheranostic.com
DZD1516 (HER2 inhibitor)	Dizal Pharmaceutical Shanghai, China	solid tumors	Phase I www.dizalpharma.com
DZD2269 (AZAR antagonist)	Dizal Pharmaceutical Shanghai, China	solid tumors	Phase I completed www.dizalpharma.com
DZD4205 (golidocitinib) (JAK1 inhibitor) ORPHAN DRUG	Dizal Pharmaceutical Shanghai, China	PTCL (Fast Track)	Phase II www.dizalpharma.com
DZD8586	Dizal Pharmaceutical Shanghai, China	hematologic malignancies	Phase I completed www.dizalpharma.com
DZD9008 (sunvozertinib) (EGFR inhibitor)	Dizal Pharmaceutical Shanghai, China	NSCLC (Breakthrough Therapy)	Phase I/II www.dizalpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
E-602 (neuraminidase replacement)	Palleon Pharmaceuticals Waltham, MA	solid tumors	Phase I www.palleonpharma.com
E7386 (CBP/ β -catenin inhibitor)	Eisai Nutley, NJ	solid tumors (+pembrolizumab)	Phase I/II www.eisai.com
E7766 (STING agonist)	Eisai Nutley, NJ	solid tumors	Phase I www.eisai.com
EBTATE (ionizing radiation emitter)	Molecular Targeting Technologies West Chester, PA	neuroendocrine tumors	Phase I www.mtarget.com
ECT-001-CB (stem cell therapy)	ExCellThera Montreal, Canada	high-risk hematologic malignancies	Phase II www.excellthera.com
		high-risk myeloid malignancies (pediatric / young adults)	Phase I/II www.excellthera.com
ECT204 (GPC3-targeting T cell therapy) <small>ORPHAN DRUG</small>	Eureka Therapeutics Emeryville, CA	liver cancer	Phase I/II www.eurekatherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
efineptakin alfa (NT-I7) (IL-7 T-cell amplifier)	NeoImmuneTech Rockville, MD	gastric cancer, gastroesophageal junction cancer, esophageal cancer, NSCLC	Phase II www.neoimmunetech.com
		high-risk skin cancers, solid tumors	Phase I/II www.neoimmunetech.com
		large B-cell lymphoma	Phase I www.neoimmunetech.com
eflornithine oral (ornithine decarboxylase inhibitor) <small>ORPHAN DRUG</small>	Orbus Therapeutics Palo Alto, CA	anaplastic astrocytoma (Breakthrough Therapy)	Phase III www.orbustherapeutics.com
		glioblastoma	Phase I www.orbustherapeutics.com
eflornithine oral (CPP-1X-S) (ornithine decarboxylase inhibitor) <small>ORPHAN DRUG</small>	Panbela Therapeutics Waconia, MN	neuroblastoma	Phase II www.panbela.com
		NSCLC	Phase I www.panbela.com
eftilagimod alpha (APC activating LAG-3 protein)	Immutep Sydney, Australia	breast cancer	Phase II/III www.immutep.com
		head and neck cancer (FastTrack), NSCLC (Fast Track)	Phase II www.immutep.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
eftozanermin alfa (Eftoza) (TRAIL agonist)	AbbVie North Chicago, IL	hematologic malignancies, solid tumors	Phase I www.abbvie.com
EG-70 (DDX58 inhibitor)	enGene Waltham, MA	superficial bladder cancer	Phase I/II www.engene.com
eganelisib (PI3K- γ inhibitor)	Infinity Pharmaceuticals Cambridge, MA	triple negative breast cancer (Fast Track), 2L urogenital cancer (Fast Track)	Phase II www.infi.com
		ovarian cancer, triple negative breast cancer, head and neck cancer, melanoma	Phase I www.infi.com
Elahere™ mirvetuximab soravtansine	ImmunoGen Waltham, MA	FR α -high platinum-sensitive ovarian cancer (combination therapy)	Phase III www.immunogen.com
		FR α -high platinum-sensitive ovarian cancer, FR α -low-medium platinum- sensitive ovarian cancer (combination therapy)	Phase II www.immunogen.com
ELI-002 (amphiphile cancer vaccine)	Elicio Therapeutics Boston, MA	KRAS ^m /NAS ^m solid tumors, including colorectal cancer, NSCLC, pancreatic ductal cancer	Phase I www.elicio.com
elimusertib (BAY 1895344) (ATR inhibitor)	Bayer Pharmaceuticals Whippany, NJ	solid tumors, non-Hodgkin lymphoma, mantle cell lymphoma	Phase I www.bayer.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
elraglusib (GSK-3β inhibitor) <small>ORPHAN DRUG</small>	Actuate Therapeutics Fort Worth, TX	metastatic melanoma, pancreatic cancer (Fast Track), salivary gland carcinoma, pediatric refractory tumors, T-cell leukemia/lymphoma, myelofibrosis, advanced cancers	Phase II www.actuatetherapeutics.com
Elrexio™ elranatamab-bcmm <small>ORPHAN DRUG</small>	Pfizer New York, NY	multiple myeloma (double-class exposed), newly-diagnosed multiple multiple myeloma (post-transplant maintenance), newly-diagnosed multiple myeloma (transplant ineligible)	Phase III www.pfizer.com
eltanexor (SINE inhibitor) <small>ORPHAN DRUG</small>	Karyopharm Therapeutics Newton, MA	refractory MDS (Fast Track)	Phase II www.karyopharm.com
		newly-diagnosed MDS	Phase I www.karyopharm.com
ELU001 (DNA topoisomerase I inhibitor)	Elucida Oncology Monmouth Junction, NJ	solid tumors	Phase I/II www.elucidaoncolog.com
ELVN-001 (BCR-ABL inhibitor)	Enliven Therapeutics Boulder, CO	chronic myeloid leukemia (CML)	Phase I www.enliventherapeutics.com
ELVN-002 (HER2 inhibitor)	Enliven Therapeutics Boulder, CO	solid tumors, including NSCLC	Phase I www.enliventherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Elzonris® tagraxofusp <small>ORPHAN DRUG</small>	Stemline Therapeutics New York, NY	AML, CMML, myelofibrosis	Phase II www.stemline.com
emavusertib (IRAK4 inhibitor) <small>ORPHAN DRUG</small>	Curis Lexington, MA	IRAK4-driven leukemia and lymphoma	Phase I/II www.curis.com
EMB-01 (EGFR x cMET bispecific antibody)	EpimAb Biotherapeutics Shanghai, China	solid tumors, including NSCLC	Phase I/II www.epimab.com
EMB-02 (LAG3 x PD-1 bispecific antibody)	EpimAb Biotherapeutics Shanghai, China	solid tumors	Phase I/II www.epimab.com
ENB-003 (endothelin B receptor antagonist) <small>ORPHAN DRUG</small>	ENB Therapeutics New York, NY	solid tumors	Phase I/II www.enbpharma.com
EndoTAG-1® paclitaxel liposomal <small>ORPHAN DRUG</small>	SynCore Biotechnology Taipei City, Taiwan	pancreatic cancer	Phase III completed www.syncorebio.com
endoxifen (SERM)	Atossa Therapeutics Seattle, WA	ER+ HER2- breast cancer	Phase II www.atossatherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Enhertu® fam-trastuzumab deruxtecan-nxki (T-DXd)	AstraZeneca Wilmington, DE Daiichi Sankyo Basking Ridge, NJ	HER2+ breast cancer (adjuvant), HER2-low breast cancer, 1L HER2+ breast cancer, HER2+ breast cancer (neoadjuvant), 2L/3L HER2+ low breast cancer, 1L NSCLC with exon 19m or 20m	Phase III www.astrazeneca.com www.daiichisankyo.com
		triple negative breast cancer, HER2 expressing solid tumors, 3L HER2+ colorectal cancer, HER2m solid tumors, 2L NSCLC	Phase II www.astrazeneca.com www.daiichisankyo.com
		1L/2L+ HER2+ breast cancer, breast cancer (+pembrolizumab), NSCLC (+pembrolizumab), HER2-low breast cancer, solid tumors (+AZD5305), 1L/2L+ HER2+ gastric cancer, 1L HER2+ NSCLC (+durvalumab), bladder cancer (+nivolumab), breast cancer (+nivolumab)	Phase I www.astrazeneca.com www.daiichisankyo.com
enobosarm (selective androgen receptor agonist)	Veru Miami, FL	AR+ ER+ HER2- metastatic breast cancer (+abemaciclib) (Fast Track)	Phase III www.verupharma.com
ENV-101 (taladegib) (PTCH1 inhibitor)	Endeavor BioMedicines San Diego, CA	solid tumors with PTCH1m	Phase II www.endeavormedicines.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
envafolimab (anti-PD-L1 inhibitor) <small>ORPHAN DRUG</small>	TRACON Pharmaceuticals San Diego, CA	undifferentiated pleomorphic sarcoma/ myxofibrosarcoma (Fast Track)	Phase II www.traconpharma.com
		solid tumors	Phase I www.traconpharma.com
EO2040 (cancer vaccine)	Enterome Paris, France	colorectal cancer	Phase II www.enterome.com
EO2401 (cancer vaccine)	Enterome Paris, France	adrenocortical carcinoma, malignant pheochromocytoma/paraganglioma	Phase I/II www.enterome.com
EO2463 (cancer vaccine)	Enterome Paris, France	non-Hodgkin lymphoma	Phase II www.enterome.com
EO-3021 (antibody drug conjugate)	Elevation Oncology Boston, MA	solid tumors	Phase I www.elevationoncology.com
EP0031 (RET inhibitor)	Ellipses Pharma London, United Kingdom	RET-altered solid tumors	Phase I/II www.ellipses.life
EP0057 (nanoparticle drug conjugate)	Ellipses Pharma London, United Kingdom	ovarian cancer	Phase II www.ellipses.life
EP0062 (vosilasarm) (SARM)	Ellipses Pharma London, United Kingdom	breast cancer	Phase I/II www.ellipses.life

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
EP31670 (NEO2734) (BET/CBP/p300 inhibitor)	Epigenetix Miami, FL	castration-resistant prostate cancer, NUT midline carcinoma	Phase I www.epigenetix.com
EPI-7386 (androgen receptor antagonist)	ESSA Pharma Houston, TX	castration-resistant prostate cancer (Fast Track)	Phase I/II www.essapharma.com
Epkinly® epcoritamab <small>ORPHAN DRUG</small>	AbbVie North Chicago, IL Genmab US Plainsboro, NJ	1L large B-cell lymphoma, r/r follicular lymphoma	Phase III www.abbvie.com
		B-cell non-Hodgkin lymphoma	Phase II www.abbvie.com
		r/r CLL, Richter's syndrome	Phase I www.abbvie.com
equecabtagene autoleucel (CT103A) (CAR-T cell therapy)	IASO Biotherapeutics Nanjing, China	multiple myeloma (Fast Track)	Phase I www.iasobio.com
eRapa (encapsulated rapamycin)	Emtora Biosciences San Antonio, TX	non-muscle invasive bladder cancer	Phase II www.emtorabio.com
ERAS-007 (ERK1/2 inhibitor)	Erasca San Diego, CA	gastrointestinal cancer, NSCLC, solid tumors	Phase I/II www.erasca.com
ERAS-601 (SHP2 inhibitor)	Erasca San Diego, CA	solid tumors	Phase I www.erasca.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ERAS-801 (EGFR antagonist) <small>ORPHAN DRUG</small>	Erasca San Diego, CA	glioblastoma (Fast Track)	Phase I/II www.erasca.com
ERC1671 (cancer vaccine) <small>ORPHAN DRUG</small>	Epitopoietic Research Pasadena, CA	glioma, glioblastoma (Fast Track)	Phase II www.erc-immunotherapy.com
Erleada® apalutamide	J&J Innovative Medicine Raritan, NJ	prostate cancer (tablet reduction)	application submitted www.janssen.com
		high-risk prostate cancer, localized prostate cancer	Phase III www.janssen.com
ERY974 (glypican-3 x CD3 bispecific antibody)	Chugai Pharma USA Berkeley Heights, NJ	solid tumors	Phase I www.chugai-pharm.com
ES002 (anti-CD39 antibody)	Elpiscience Biopharmaceuticals USA Germantown, MD	solid tumors	Phase I www.elpiscience.com
EscharEx (EX-02) (peptide hydrolase replacement)	MediWound USA Wilmington, DE	basal cell cancer	Phase I/II www.mediwound.com
ESP-001 (LY2880070) (Chk1 inhibitor)	Esperas Pharma Montreal, Canada	solid tumors	Phase I

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ET140203 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Eureka Therapeutics Emeryville, CA	liver cancer (Fast Track)	Phase I/II www.eurekatherapeutics.com
ETC-1922159 (PORCN inhibitor)	EDDC Singapore	solid tumors	Phase I
etigilimab (TIGIT inhibitor)	Mereo BioPharma London, United Kingdom	solid tumors	Phase I/II www.mereopharma.com
etrumadenant (A2A/A2B receptor antagonist)	Arcus Biosciences Hayward, CA Gilead Sciences Foster city, CA	colorectal cancer (+zimberelimab)	Phase II www.arcusbio.com www.gilead.com
		metastatic castration-resistant prostate cancer	Phase I/II www.arcusbio.com www.gilead.com
EU101 (anti-41BB mAb)	Eutilex Seoul, South Korea	solid tumors	Phase I/II www.eutilex.com
evexomostat (SDX-7320) (MetAP2 inhibitor)	SynDevRx Cambridge, MA	HR+ HER2- breast cancer	Phase I/II www.syndevrx.com
evofosfamide (hypoxia reversing agent) <small>ORPHAN DRUG</small>	Immunogenesis Houston, TX	head and neck cancer, pancreatic cancer, prostate cancer	Phase I www.immunogenesis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
evorpacept (ALX148) (CD47 antigen inhibitor) <small>ORPHAN DRUG</small>	ALX Oncology South San Francisco, CA	gastric/gastroesophageal junction cancer, (combinations), head and neck cancer (Fast Track (combinations))	Phase II www.alxonology.com
		gastric/gastroesophageal cancer, breast cancer, urothelial cancer, AML, MDS, non-Hodgkin lymphoma (combination studies)	Phase I www.alxonology.com
ezabenlimab (BI 754091) (anti-PD-1 antibody)	Boehringer Ingelheim Ridgefield, CT	solid tumors (combination studies)	Phase I www.boehringer-ingelheim.com
fadraciclib (CYC065) (CDK N2/9 inhibitor)	Cyclacel Pharmaceuticals Berkeley Heights, NJ	solid tumors	Phase I/II www.cyclacel.com
farletuzumab ecteribulin (MORAb-202) (antibody drug conjugate)	Bristol Myers Squibb Nutley, NJ Eisai Nutley, NJ	NSCLC, ovarian cancer	Phase II www.eisai.com
		solid tumors	Phase I/II www.eisai.com
felezonexor (SL-801) (XPO1 inhibitor)	Stemline Therapeutics New York, NY	solid tumors	Phase I www.stemline.com
FF-10502-01 (DNA synthesis inhibitor)	Fujifilm Pharmaceuticals USA Cambridge, MA	advanced solid tumors	Phase II www.fujifilmpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
FF-10832 (DNA synthesis inhibitor)	Fujifilm Pharmaceuticals USA Cambridge, MA	NSCLC, urothelial cancer	Phase II www.fujifilmpharma.com
		biliary tract cancer	Phase I www.fujifilmpharma.com
FF-10850 (topoisomerase I inhibitor)	Fujifilm Pharmaceuticals USA Cambridge, MA	Merkel cell carcinoma, ovarian cancer	Phase I www.fujifilmpharma.com
FHD-286 (BRG1/BRM inhibitor)	Foghorn Therapeutics Cambridge, MA	metastatic uveal melanoma	Phase I www.foghornrx.com
FHD-609 (BRD9 inhibitor)	Foghorn Therapeutics Cambridge, MA	SMARCB1-loss tumors, synovial sarcoma	Phase I www.foghornrx.com
fianlimab (anti-LAG3 antibody)	Regeneron Pharmaceuticals Tarrytown, NY	1L metastatic melanoma, 1L melanoma (adjuvant)	Phase III www.regeneron.com
		1L advanced NSCLC	Phase II/III www.regeneron.com
		hematologic malignancies, solid tumors	Phase I www.regeneron.com
fibromun (recombinant fusion protein) <small>ORPHAN DRUG</small>	Philogen Siena, Italy	1L leiomyosarcoma	Phase II www.philogen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ficlatuzumab (anti-HGF/c-MET IgG1 mAb)	AVEO Oncology Boston, MA	AML, head and neck cancer, (Fast Track), pancreatic cancer	Phase II www.aveooncology.com
fimepinostat (HDAC/pan-PI3K inhibitor)	Curis Lexington, MA	MYC-altered cancers	Phase II www.curis.com
FLX475 (CCR4 receptor antagonist)	RAPT Therapeutics South San Francisco, CA	advanced cancer	Phase I/II www.rapt.com
Flynpovi® eflornithine/sulindac	Panbela Therapeutics Waconia, MN	colorectal cancer risk reduction	Phase III www.panbela.com
FOR46 (antibody drug conjugate)	Fibrogen San Francisco, CA	prostate cancer	Phase I/II www.fibrogen.com
FORE8394 (plixorafenib) (B-raf inhibitor) <small>ORPHAN DRUG</small>	Fore Biotherapeutics Philadelphia, PA	solid tumors with BRAF alterations, including CNS tumors	Phase II www.fore.bio
Fotivda® tivozanib	AVEO Oncology Boston, MA	renal cell carcinoma (+nivolumab)	Phase III www.aveooncology.com
FP-1305 (bexmarilimab) (STAB1 inhibitor) <small>ORPHAN DRUG</small>	Faron Pharmaceuticals Turku, Finland	hematologic malignancies, solid tumors	Phase I/II www.faron.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
FPI-1434 (ionizing radiation emitter)	Fusion Pharmaceuticals Hamilton, Canada	solid tumors	Phase I www.fusionpharma.com
FPI-1966 (targeted alpha therapy)	Fusion Pharmaceuticals Hamilton, Canada	solid tumors	Phase I www.fusionpharma.com
FPI-2059 (radioconjugate)	Fusion Pharmaceuticals Hamilton, Canada	solid tumors	Phase I www.fusionpharma.com
fruquintinib (VEGFR inhibitor)	Takeda Northbrook, IL	metastatic colorectal cancer (Fast Track)	application submitted www.takeda.com
FS118 (LAG-3 x PD-L1 bispecific antibody)	F-star Therapeutics Cambridge, MA	DLBCL, head and neck cancer, NSCLC	Phase II www.f-star.com
FS120 (CD137 x OX40 bispecific antibody)	F-star Therapeutics Cambridge, MA	cancer	Phase I www.f-star.com
FS222 (CD137 x PD-L1 bispecific antibody)	F-star Therapeutics Cambridge, MA	cancer	Phase I www.f-star.com
FT576 (CAR-NK cell therapy)	Fate Therapeutics San Diego, CA	multiple myeloma	Phase I www.fatetherapeutics.com
FT819 (CAR-T cell therapy)	Fate Therapeutics San Diego, CA	B-cell malignancies	Phase I www.fatetherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Fujovee™ abivertinib	Sorrento Therapeutics San Diego, CA	NSCLC	Phase III www.sorrentotherapeutics.com
		B-cell lymphomas	Phase II www.sorrentotherapeutics.com
furmonertinib (EGFR inhibitor)	ArriVent Biopharma Newtown Square, PA	NSCLC with EGFR exon 20 insertion (Fast Track)	Phase III www.arrivent.com
		NSCLC with other EGFRm, NSCLC with HER2 exon 20 insertion	Phase I www.arrivent.com
fuzuloparib (PARP1/PARP2 inhibitor)	Hengrui Pharmaceuticals Shanghai, China	metastatic castration-resistant prostate cancer	Phase III www.hengrui.com
FWD1509 (EGFR inhibitor)	Forward Pharmaceuticals Shenzhen, China	NSCLC	Phase I/II www.forward-pharma.com
FX-909 (PPARG inhibitor)	Flare Therapeutics Cambridge, MA	solid tumors, including urothelial cancer	Phase I www.flaretx.com
Fyarro® sirolimus protein-bound particles	Aadi Biosciences Los Angeles, CA	tumor-agnostic solid tumors (TSC1/TSC2 alterations) (Fast Track)	Phase II www.aadibio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
galinpepimut-S (WT1 cancer vaccine) <small>ORPHAN DRUG</small>	Sellas Life Sciences Group New York, NY	AML (Fast Track)	Phase III www.sellaslifesciences.com
		malignant pleural mesothelioma (Fast Track), multiple myeloma (Fast Track)	Phase II www.sellaslifesciences.com
		malignant pleural mesothelioma (combination therapy) (Fast Track), ovarian cancer	Phase I www.sellaslifesciences.com
gavocabtagene autoleucel (T-cell therapy) <small>ORPHAN DRUG</small>	TCR2 Therapeutics Cambridge, MA	cholangiocarcinoma, malignant pleural mesothelioma, NSCLC, ovarian cancer	Phase II www.tcr2.com
Gavreto [®] pralsetinib	Blueprint Medicines Cambridge, MA	RET+ solid tumors	Phase II www.blueprintmedicines.com
GC012F (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Gracell Biopharmaceuticals Suzhou, China	r/r multiple myeloma	Phase I/II www.gracellbio.com
GCC19CART (CAR-T cell therapy)	Innovative Cellular Therapeutics Rockville, MD	colorectal cancer (Fast Track)	Phase I www.ictbio.com
GD2-SADA (177Lu-DOTA complex)	Y-mAbs Therapeutics New York, NY	melanoma, sarcoma, SCLC	Phase I www.ymabs.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
GDA201 (NK cell therapy)	Gamida-Cell Boston, MA	non-Hodgkin lymphoma	Phase I/II www.gamida-cell.com
GDT002 (TEG002) (T cell therapy)	Clade Therapeutics Boston, MA	multiple myeloma	Phase I www.cladetxt.com
GDX012 (T cell therapy) ORPHAN DRUG	Takeda Cambridge, MA	r/r AML	Phase I/II www.takeda.com
gedatolisib (PI3K/mTOR inhibitor)	Celcuity Minneapolis, MN	2L/3L ER+ HER2- breast cancer (Fast Track) (Breakthrough Therapy)	Phase III www.celcuity.com
GEN-001 (microbiome-based therapeutic)	Genome & Company Gyeonggi-do, South of Korea	solid tumors	Phase I www.genomecom.co.kr
GEN1046/BNT311 (DuoBody®-PD-L1x4-1BB)	BioNTech Mainz, Germany Genmab Plainsboro, NJ	endometrial cancer, NSCLC	Phase II www.biontech.com www.genmab.com
GEN1053/BNT313 (CD27 antibody)	BioNTech Mainz, Germany Genmab Plainsboro, NJ	solid tumors	Phase I/II www.biontech.com www.genmab.com
GEN3014 (CD38 mAb)	Genmab Plainsboro, NJ	hematologic malignancies	Phase I www.genmab.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
GEN3017 (bispecific antibody)	Genmab Plainsboro, NJ	Hodgkin lymphoma, non-Hodgkin lymphoma	Phase I/II www.genmab.com
GFH009 (CDK9 inhibitor) <small>ORPHAN DRUG</small>	GenFleet Therapeutics Zhejiang, China	hematologic malignancies	Phase I www.genfleet.com
GI-101 (bispecific fusion protein)	GI Innovation Seoul, South Korea	solid tumors	Phase I/II www.gi-innovation.com
GI-102 (fusion protein)	GI Innovation Seoul, South Korea	solid tumors	Phase I/II www.gi-innovation.com
giredestrant (RG6171) (SERD)	Roche/Genentech South San Francisco, CA	1L ER+ HER2- metastatic breast cancer, 1L ER+ HER2+ breast cancer, ER+ breast cancer (adjuvant)	Phase III www.roche.com
		endometrial cancer	Phase II www.roche.com
		solid tumors	Phase I www.roche.com
givastomig (TJ-CD4B) (bispecific antibody)	I-MAB Biopharma Rockville, MD	solid tumors	Phase I www.i-mabbipharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
GLR2007 (CDK4/6 inhibitor) <small>ORPHAN DRUG</small>	Gan & Lee Pharmaceuticals Bridgewater, NJ	glioblastoma (Fast Track), NSCLC	Phase I/II www.ganlee.com
GLSI-100 (HER2/neu GP2 vaccine)	Greenwich LifeSciences Stafford, TX	breast cancer	Phase III www.greenwichlifesciences.com
glufosfamide (DNA synthesis inhibitor) <small>ORPHAN DRUG</small>	Eleison Pharmaceuticals Princeton, NJ	2L pancreatic cancer (Fast Track)	Phase III www.eleison-pharma.com
glumetinib (c-met inhibitor) <small>ORPHAN DRUG</small>	HaiHe Biopharma Shanghai, China	NSCLC (Fast Track)	Phase I/II www.haihepharma.com
GNOS-PV02 + INO-9012 (personalized neoantigen vaccine/ plasmid-encoded IL-12)	Geneos Therapeutics Plymouth Meeting, PA	2L hepatocellular carcinoma (+pembrolizumab)	Phase I/II www.geneostx.com
gotistobat (ONC-392/BNT316) (CTLA4 inhibitor)	BioNTech Mainz, Germany OncoC4 Rockville, MD	NSCLC (Fast Track)	Phase III www.biontech.com www.oncoc4.com
GP-2250 (metabolic enzyme inhibitor) <small>ORPHAN DRUG</small>	Panavance Therapeutics Berwyn, PA Geistlich Pharma North America Princeton, NJ	pancreatic cancer	Phase I www.panavance.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
GPC-100 (CXCR4-ADRB2 inhibitor)	GPCR Therapeutics Redwood City, CA	multiple myeloma	Phase II www.gpcr.co.kr
GQ1001 (HER2 antibody drug conjugate)	GeneQuantum Healthcare Suzhou, China	HER2+ solid tumors	Phase I www.genequantum.com
GRANITE (immunotherapy vaccine)	Gritstone bio Emeryville, CA	microsatellite stable colorectal cancer (Fast Track)	Phase II/III www.gritstonebio.com
GRN-300 (SIK2/3 inhibitor)	Greenfire Bio Frisco, TX	ovarian cancer	Phase I www.reenfirebio.com
GS-1811 (anti-CCR8 mAb)	Gilead Sciences Foster City, CA	advanced cancers	Phase I www.gilead.com
GS-4528 (IL-2 variant)	Gilead Sciences Foster City, CA	advanced cancers	Phase I www.gilead.com
GS-9716 (MCL1 inhibitor)	Gilead Sciences Foster City, CA	advanced cancers	Phase I www.gilead.com
GSK2857914 (belantamab) (BCMA binder)	GSK Durham, NC	multiple myeloma	Phase I www.gsk.com
GSK3745417 (STING agonist)	GSK Durham, NC	cancer	Phase I www.gsk.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
GSK4074386 (TSR-033) (LAG3 antibody)	GSK Durham, NC	cancer	Phase I www.gsk.com
GSK4381562 (anti-PVRIG mAb)	GSK Durham, NC	solid tumors	Phase I www.gsk.com
GSK4428859 (belrestotug) (TIGIT inhibitor)	GSK Durham, NC iTeos Therapeutics Watertown, MA	NSCLC (+dostarlimab-gxly)	Phase II www.gsk.com www.iteostherapeutics.com
GSK6097608 (anti-CD96 mAb)	GSK Durham, NC	cancer	Phase I www.gsk.com
GT-103 (complement factor H inhibitor)	Grid Therapeutics Durham, NC	NSCLC	Phase II www.gridtherapeutics.com
GT90001 (ALK1 inhibitor)	Kintor Pharmaceuticals Suzhou, China	liver cancer	Phase II www.kintor.com
GV20-0251 (immunotherapy)	GV20 Therapeutics Cambridge, MA	advanced solid tumors	Phase I www.gv20tx.com
H-002 (EGFR inhibitor)	RedCloud Bio Shanghai, China	NSCLC	Phase I/II www.redcloudbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
H3B-6545 (Erx inhibitor)	Eisai Nutley, NJ	breast cancer	Phase I/II www.eisai.com
		breast cancer (+palbociclib)	Phase I www.eisai.com
H3B-8800 (RVT-2001) (SF3B1 modulator) <small>ORPHAN DRUG</small>	Hemavant Sciences (Roviant) Nutley, NJ	lower risk MDS	Phase I www.hemavant.com
HB0025 (anti-PD-L1 mAb)	Huabo Biopharm Shanghai, China	solid tumors	Phase I www.huabobio.com
HB0036 (TIGIT/PD-L1 modulator)	Huabo Biopharm Shanghai, China	solid tumors	Phase I www.huabobio.com
HB-201 (cancer vaccine)	Hookipa Pharma New York, NY	HPV16+ head and neck cancer (Fast Track)	Phase I/II www.hookipapharma.com
		HPV16+ cervical cancer, HPV16+ oropharynx cancer	early Phase I www.hookipapharma.com
HB-202 (cancer vaccine)	Hookipa Pharma New York, NY	HPV16+ head and neck cancer (Fast Track)	Phase I/II www.hookipapharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
HB-302/HB-301 (cancer vaccine)	Hookipa Pharma New York, NY	metastatic castration-resistant prostate cancer	Phase I/II www.hookipapharma.com
HBI-2376 (SHP2 inhibitor)	HUYA Bioscience San Diego, CA	solid tumors	Phase I www.huyabio.com
HBI-8000 (HDAC inhibitor)	HUYA Bioscience San Diego, CA	1L melanoma	Phase III www.huyabio.com
		2L NSCLC	Phase II www.huyabio.com
HC-1119 (androgen receptor antagonist)	Hinova Pharmaceuticals Chengdu City, China	metastatic castration-resistant prostate cancer	Phase III www.hinovapharma.com
HC-5404 (PERK inhibitor)	HiberCell New York, NY	advanced solid tumors, including renal cell carcinoma, gastric cancer (Fast Track), SCLC (Fast Track)	Phase I www.hibercell.com
HC-7366 (GCN2 modulator)	HiberCell New York, NY	advanced solid tumors, including bladder cancer, colorectal cancer, head and neck cancer	Phase I www.hibercell.com
HCB101 (CD47 inhibitor)	FBD Biologics (Hanchor Biopharma) Taipei City, Taiwan	hematologic malignancies, solid tumors	Phase I www.hanchorbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
HCW9218 (TGFbetaRII/IL-15 fusion protein)	HCW Biologics Miramar, FL	pancreatic cancer	Phase I www.hcwbiologics.com
HDM201 (siremadlin) (MDM2 inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	hematologic malignancies (+MBG453 +venetoclax)	Phase I www.novartis.com
HDP-101 (DNA-directed RNA polymerase inhibitor)	Heidelberg Pharma Munich, Germany	multiple myeloma	Phase I/II www.heidelberg-pharma.com
Helios CELMoD (cereblon E3 ligase modulator)	Bristol Myers Squibb Lawrenceville, NJ	solid tumors	Phase I www.bms.com
Hepzato™ Kit melphalan for injection/hepatic delivery system <small>ORPHAN DRUG</small>	Delcath Systems New York, NY	cholangiocarcinoma	Phase II/III www.delcath.com
HFB200301 (TNFR2 agonist mAb)	HiFiBiO Therapeutics Cambridge, MA	solid tumors	Phase I www.hifibio.com
HFB200603 (BTLA immune checkpoint inhibitor)	HiFiBiO Therapeutics Cambridge, MA	solid tumors	Phase I www.hifibio.com
HFB301001 (OX40 agonistic antibody)	HiFiBiO Therapeutics Cambridge, MA	solid tumors	Phase I www.hifibio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
HH2853 (PRC2/EZH1/2 inhibitor)	HaiHe Biopharma Shanghai, China	non-Hodgkin lymphoma	Phase I/II www.haihepharma.com
HHCYH33 (PI3K α inhibitor)	HaiHe Biopharma Shanghai, China	advanced solid tumors	Phase I www.haihepharma.com
Hiltonol [®] poly ICLC vaccine	Oncovir Washington, DC	malignant pleural mesothelioma	Phase I www.oncovir.com
HLX-02 (trastuzumab biosimilar)	Henlius Biotech Shanghai, China	breast cancer, gastric cancer	application submitted
HMBD-002 (anti-VISTA mAb)	Hummingbird Bioscience Singapore	solid tumors	Phase I www.hummingbirdbioscience.com
HMPL-306 (IDH 1/2 inhibitor)	HUTCHMED Florham Park, NJ	IDHm hematologic malignancies, IDHm solid tumors	Phase I www.hutch-med.com
HMPL-523 (sofleplenisib) (Syk inhibitor)	HUTCHMED Florham Park, NJ	Hodgkin lymphoma, non-Hodgkin lymphoma	Phase I www.hutch-med.com
HPN217 (CD3-BCMA) <small>ORPHAN DRUG</small>	AbbVie North Chicago, IL Harpoon Therapeutics South San Francisco, CA	multiple myeloma in relapse (Fast Track)	Phase I www.harpoontx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
HPN328 (DLL3 T-cell engager) <small>ORPHAN DRUG</small>	Harpoon Therapeutics South San Francisco, CA	SCLC	Phase I www.harpoontx.com
HPN536 (MSLN)	Harpoon Therapeutics South San Francisco, CA	solid tumors, including ovarian cancer	Phase I www.harpoontx.com
HST1011 (CBL B inhibitor)	HotSpot Therapeutics Boston, MA	solid tumors	Phase I www.hotspotthera.com
hSTC810 (nelmastobart) (BTN1A1 inhibitor)	STCube Seoul, South Korea	solid tumors	Phase I www.stcube.com
huMNC2-CAR44 (CAR-T cell therapy)	Minerva Biotechnologies Waltham, MA	breast cancer	Phase I/II www.minervabio.com
HY-0102	HyaMab Biotech Shanghai, China	solid tumors	Phase I www.hyamab.com
HyBryte™ hypericin sodium <small>ORPHAN DRUG</small>	Soligenix Princeton, NJ	cutaneous T-cell lymphoma (CTCL) (Fast Track)	Phase III www.soligenix.com
iadademstat (LSD1 inhibitor) <small>ORPHAN DRUG</small>	Oryzon Genomics Boston, MA	AML	Phase I www.oryzon.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
IAG933 (TEAD inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	mesothelioma	Phase I www.novartis.com
ianalumab (BAFF-R inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	DLBCL, hematologic malignancies (combination therapy)	Phase I www.novartis.com
iberdomide (immunomodulatory therapeutic)	Bristol Myers Squibb Lawrenceville, NJ	2L+ multiple myeloma, multiple myeloma (post-autologous stem cell therapy maintenance, newly-diagnosed)	Phase III www.bms.com
IBI322 (CD47 x PD-L1 bispecific antibody)	Innovent Biologics Suzhou, China	lymphoma, solid tumors	Phase I www.innoventbio.com
Ibrance [®] palbociclib	Pfizer New York, NY	ER+/HER2+ metastatic breast cancer	Phase III www.pfizer.com
		ER+/HER2- metastatic breast cancer (+vepdegestrant)	Phase II www.pfizer.com
ibudilast (MN-166) (PDE4/10 inhibitor/MIF inhibitor) <small>ORPHAN DRUG</small>	MediciNova La Jolla, CA	newly-diagnosed glioblastoma, recurrent glioblastoma	Phase I/II www.medicinova.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Iclusig® ponatinib	Takeda Lexington, MA	1L Ph+ ALL	Phase III www.takeda.com
		Ph+ ALL (pediatric)	Phase I www.takeda.com
ICP-192 (FGFR inhibitor) ORPHAN DRUG	InnoCare Pharma Beijing, China	advanced solid tumors, including cholangiocarcinoma, urothelial cancer	Phase I/II www.innocarepharma.com
ICP-723 (zurletrectinib) (pan-TRK inhibitor)	InnoCare Pharma Boston, MA	solid tumors	Phase I www.innocarepharma.com
ICT01 (anti-CD277 mAb)	ImCheck Therapeutics Marseille, France	advanced hematologic malignancies, advanced solid tumors	Phase I/II www.imchecktherapeutics.com
ICVB-1042 (oncolytic virus therapy)	IconOVir Bio San Diego, CA	solid tumors	Phase I www.iconovir.com
IDE161 (PARG inhibitor)	IDEAYA Biosciences South San Francisco, CA	breast cancer (Fast Track), ovarian cancer (Fast Track)	Phase I www.ideayabio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
IDE397 (MAT2A inhibitor)	IDEAYA Biosciences South San Francisco, CA	esophagogastric cancer, NSCLC	Phase II www.ideayabio.com
		solid tumors	Phase I www.ideayabio.com
IDRX-42 (TYK2 inhibitor) <small>ORPHAN DRUG</small>	IDRx Plymouth, MA	gastrointestinal stromal tumors	Phase I www.idrx.com
IDX-1197 (vendaparib) (PARP inhibitor) <small>ORPHAN DRUG</small>	Idience Seoul, South Korea	gastric cancer	Phase I www.idience.com
IFx Hu2.0 cancer vaccine (personalized cancer vaccine)	Morphogenesis Tampa, FL	Merkel cell carcinoma, non-melanoma skin cancer, cutaneous squamous cell carcinoma	Phase I www.immunogenesis-inc.com
IGM-2323 (imvotamab) (CD20 x CD3 bispecific antibody)	IGM Biosciences Mountain View, CA	non-Hodgkin lymphoma	Phase I www.igmbio.com
IGM-2644 (CD38 x CD3 bispecific T cell engager)	IGM Biosciences Mountain View, CA	multiple myeloma	Phase I www.igmbio.com
IGM-7354 (IL-15 x PD-L1 bispecific antibody)	IGM Biosciences Mountain View, CA	hematologic malignancies, solid tumors	Phase I www.igmbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
IGM-8444 (aplitabart) (TRAIL receptor 2 agonist)	IGM Biosciences Mountain View, CA	AML, colorectal cancer, solid tumors (combination therapy)	Phase I www.igmbio.com
IGV-001 (autologous cell vaccine) ORPHAN DRUG	Imvax Philadelphia, PA	glioblastoma	Phase II www.imvax.com
IK-175 (AHR antagonist)	Bristol Myers Squibb Lawrenceville, NJ Ikena Oncology Boston, MA	AHR-enriched bladder cancer (Fast Track), AHR-enriched head and neck cancer	Phase I www.bms.com www.ikenaoncology.com
IK-930 (TEAD inhibitor) ORPHAN DRUG	Ikena Oncology Boston, MA	hippo-altered solid tumors (Fast Track), including mesothelioma	Phase I www.ikenbaoncology.com
IKS03 (antibody drug conjugate)	Iksuda Therapeutics Newton, MA	B-cell non-Hodgkin lymphoma	Phase I www.iksuda.com
IkT-001Pro (Abl kinase inhibitor) ORPHAN DRUG	Inhibikase Therapeutics Atlanta, GA	stable-phase CML	Phase III www.inhibikase.com
ILC (inhaled liquid cisplatin) ORPHAN DRUG	Eleison Pharmaceuticals Princeton, NJ	osteosarcoma	Phase II completed www.eleison-pharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ilixadencel (dendritic cell vaccine)	Mendus Stockholm, Sweden	kidney cancer	Phase II completed www.mendus.com
IMA203 (adoptive cell therapy)	Immatics US Houston, TX	solid tumors	Phase I www.immatics.com
IMA401 (MAGE A4/8 TCER)	Bristol Myers Squibb Lawrenceville, NJ Immatics US Houston, TX	solid tumors	Phase I www.immatics.com
Imbruvica® ibrutinib	AbbVie North Chicago, IL J&J Innovative Medicine Raritan, NJ	1L CLL (I + V fixed duration)	application submitted www.janssen.com
		follicular lymphoma, mantle cell lymphoma, indolent non-Hodgkin lymphoma	Phase III www.janssen.com
IMC-C103C (bispecific biologic)	Immunocore Conshohocken, PA	solid tumors	Phase I www.immunocore.com
IMC-F106C (bispecific antibody)	Immunocore Conshohocken, PA	solid tumors	Phase I www.immunocore.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
imetelstat (telomerase inhibitor) <small>ORPHAN DRUG</small>	Geron Foster City, CA	MDS (Fast Track)	application submitted www.geron.com
		r/r myelofibrosis (Fast Track)	Phase III www.geron.com
		r/r AML, HR-MDS	Phase II www.geron.com
		1L myelofibrosis, r/r AML (combination therapy)	Phase I www.geron.com
Imfinzi® durvalumab	AstraZeneca Wilmington, DE	esophageal squamous cell carcinoma, muscle invasive bladder cancer, non-muscle invasive bladder cancer, 1L kidney cancer, unresectable stage III NSCLC, gastric cancer, 1L urothelial cancer, 1L limited-stage SCLC, stage II-III NSCLC, stage I-II NSCLC, kidney cancer (adjuvant; (locoregional)	Phase III www.astrazeneca.com
		1L triple negative breast cancer, 1L NSCLC, NSCLC, NSCLC (post-IO), solid tumors (+monalizumab)	Phase II www.astrazeneca.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
IMGC936 (antibody drug conjugate)	ImmunoGen Waltham, MA MacroGenics Rockville, MD	solid tumors	Phase I www.immunogen.com www.macrogenics.com
IMGN151 (antibody drug conjugate)	ImmunoGen Waltham, MA	endometrial, serous epithelial ovarian, peritoneal, fallopian tube cancers	Phase I www.immunogen.com
imlunestrant (SERD)	Lilly Indianapolis, IN	ER+ HER2- metastatic breast cancer, breast cancer (adjuvant)	Phase III www.lilly.com
IMM-1-104 (MEK inhibitor)	Immuneering Cambridge, MA	solid tumors	Phase I www.immuneering.com
IMM2902 (HER2/ERBB2 antagonist)	ImmuneOnco Biopharma Shanghai, China	solid tumors	Phase I www.immuneonco.com
IMNN-001 (IL-12 DNA plasmid vector) <small>ORPHAN DRUG</small>	Imunon Lawrenceville, NJ	ovarian, peritoneal, fallopian tube cancers (Fast Track)	Phase II www.imunon.com
IMP7068 (WEE1 inhibitor)	Impact Therapeutics Shanghai, China	solid tumors	Phase I www.impacttherapeutics.com
IMP9064 (ATP inhibitor)	Impact Therapeutics Shanghai, China	solid tumors	Phase I www.impacttherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
IMPT314 (CAR-T cell therapy)	ImmPACT Bio USA West Hilla, CA	non-Hodgkin lymphoma (Fast Track)	Phase I www.impact-bio.com
IMSA101 (STING agonist)	ImmuneSensor Therapeutics Dallas, TX	oligoprogressive solid tumors, oligometastatic NSCLC, kidney cancer	Phase II www.immunesensor.com
		solid tumors	Phase I www.immunesensor.com
IMT-009 (anti-CD161 mAb)	Immunitas Therapeutics Waltham, MA	hematologic malignancies, solid tumors	Phase I www.immunitastx.com
IMU-201 (PD1-Vaxx) (PD1 vaccine)	Imugene Sydney, Australia	NSCLC	Phase I www.imugene.com
IMX-110 (curcumin/doxorubicin) <small>ORPHAN DRUG</small>	Immixon Biopharma Los Angeles, CA	solid tumors	Phase I/II www.immixonbio.com
IN10018 (PTK2 inhibitor)	InxMed Shanghai, China	metastatic melanoma	Phase I/II www.en.inxmed.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
inavolisib (RG6114) (mPI3K α inhibitor)	Roche/Genentech South San Francisco, CA	1L HR+ metastatic breast cancer, HR+ metastatic breast cancer (post CDKi)	Phase III www.roche.com
		solid tumors	Phase I www.roche.com
INB-100 (immunotherapy)	IN8bio New York, NY	leukemia	Phase I www.inbio.com
INB-200 (immunotherapy)	IN8bio New York, NY	glioblastoma	Phase I www.inbio.com
INB-400 (immunotherapy) <small>ORPHAN DRUG</small>	IN8bio New York, NY	1L glioblastoma	Phase I www.inbio.com
INBRX-105 (PD-L1 x 41BB bispecific antibody)	Inhibrx La Jolla, CA	solid tumors, including head and neck cancer	Phase I www.inhibrx.com
INBRX-106 (hexavalent OX40 agonist)	Inhibrx La Jolla, CA	solid tumors	Phase I www.inhibrx.com
INBRX-109 (tetravalent DR5 agonist) <small>ORPHAN DRUG</small>	Inhibrx La Jolla, CA	chondrosarcoma (Fast Track)	Phase II www.inhibrx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
INCA32459 (LAG-3 x PD-1 bispecific antibody)	Incyte Wilmington, DE Merus Cambridge, MA	advanced malignancies	Phase I www.incyte.com
INCA33890 (TGFR2 x PD-1 bispecific antibody)	Incyte Wilmington, DE Merus Cambridge, MA	solid tumors	Phase I www.incyte.com
INCA33989 (calreticulin inhibitor)	Incyte Cambridge, MA	myelofibrosis	Phase I www.incyte.com
INCAGN2385 (LAG-3 inhibitor)	Agenus Lexington, MA Incyte Cambridge, MA	solid tumors	Phase II www.incyte.com
INCAGN2390 (TIM-3 inhibitor)	Agenus Lexington, MA Incyte Cambridge, MA	solid tumors	Phase II www.incyte.com
INCB57643 (BET inhibitor)	Incyte Cambridge, MA	myelofibrosis	Phase I www.incyte.com
INCB123667 (CDK2 inhibitor)	Incyte Cambridge, MA	solid tumors	Phase I www.incyte.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
INCB99280 (PD-L1 inhibitor)	Incyte Cambridge, MA	solid tumors, including cutaneous squamous cell carcinoma	Phase II www.incyte.com
INCB99318 (PD-L1 inhibitor)	Incyte Cambridge, MA	solid tumors	Phase II www.incyte.com
INKmune™ natural killer cell modulator	INmune Bio Boca Raton, FL	MDS	Phase I www.inmunebio.com
INO-5401 (DNA immunotherapy)	Inovio Pharmaceuticals Plymouth Meeting, PA	glioblastoma	Phase II www.inovio.com
Inqovi® decitabine and cedazuridine	Astex Pharmaceuticals Pleasanton, CA Taiho Oncology Princeton, NJ	AML	Phase II www.astx.com
Inrebic® fedratinib	Bristol Myers Squibb Lawrenceville, NJ	myelofibrosis prevention	Phase III www.bms.com
INT230-6 (cisplatin/vinblastine)	Intensity Therapeutics Westport, CT	solid tumors	Phase I/II www.intensitytherapeutics.com
inupadenant (adenosine A2A receptor antagonist)	iTeos Therapeutics Watertown, MA	NSCLC	Phase II www.iteostherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
INV-1120 (EP4 antagonist)	Ionova Life Sciences Shenzhen, China	solid tumors	Phase I www.ionovabio.com
INX-315 (CDK2 inhibitor)	Incyclix Bio Research Triangle Park, NC	advanced cancer	Phase I/II www.incyclixbio.com
IO102-IO103 (IDO/PD-L1 cancer vaccine)	IO Biotech New York, NY	1L advanced melanoma (Breakthrough Therapy)	Phase III www.iobiotech.com
		1L advanced metastatic solid tumors, including bladder cancer, squamous cell carcinoma, NSCLC	Phase II www.iobiotech.com
		solid tumors (neoadjuvant/adjuvant)	Phase I www.iobiotech.com
IO-108 (LILRB2 inhibitor)	Immune-Onc Therapeutics Palo Alto, CA	solid tumors	Phase I www.immune-onc.com
IO-202 (LILRB4 inhibitor) <small>ORPHAN DRUG</small>	Immune-Onc Therapeutics Palo Alto, CA	AML (Fast Track), CMML, hematologic malignancies, solid tumors	Phase I www.immune-onc.com
Iomab-ACT (CD45) (apamistamab-I-131)	Actinium Pharmaceuticals New York, NY	AML (gene therapy and cell therapy conditioning)	Phase I www.actiniumpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Iomab-B (CD45) (apamistamab-I-131) <small>ORPHAN DRUG</small>	Actinium Pharmaceuticals New York, NY	BMT conditioning in AML	Phase III www.actiniumpharma.com
I/ONTAK (denileukin diftitox purified reformulation) <small>ORPHAN DRUG</small>	Citius Pharmaceuticals Cranford, NJ	CTCL	application submitted www.citiuspharma.com
iopofosine (radiopharmaceutical) <small>ORPHAN DRUG</small>	Cellecstar Biosciences Florham Park, NJ	Waldenstrom macroglobulinemia (Fast Track), highly refractory multiple myeloma (Fast Track)	Phase II www.cellecstar.com
		pediatric malignant tumors	Phase I www.cellecstar.com
IOV-2001 (peripheral blood lymphocyte therapy)	Iovance Biotherapeutics San Carlos, CA	CLL/SLL (post-BTK)	Phase I www.iovance.com
IOV-4001 (PD-1 inactivated TIL)	Iovance Biotherapeutics San Carlos, CA	melanoma, NSCLC	Phase I www.iovance.com
IPG7236 (CCR8 antagonist)	Immunophage Biotech Nanjing, China	solid tumors	Phase I www.immunophage.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
IPH5201 (anti-CD39 checkpoint inhibitor)	AstraZeneca Wilmington, DE Innate Pharma Rockville, MD	NSCLC (+durvalumab) (neoadjuvant/adjuvant)	Phase II www.astrazeneca.com
IPN60210 (EZM0414) (SETD2 inhibitor) ORPHAN DRUG	Ipsen Cambridge, MA	DLBCL (Fast Track), multiple myeloma	Phase I www.ipsen.com
IRX-2 (dendritic cell stimulant) ORPHAN DRUG	Eterna Therapeutics Cambridge, MA	oral squamous cell carcinoma (Fast Track)	Phase II completed www.etermatx.com
ISA101 (cancer vaccine)	ISA Pharmaceuticals Oegstgeest, The Netherlands	oropharynx cancer (Fast Track)	Phase II www.isa-pharma.com
ISB 1342 (CD38 x CD3 bispecific antibody) ORPHAN DRUG	Ichnos Sciences New York, NY	r/r multiple myeloma	Phase I www.ichnossciences.com
ISB 1442 (CD38 x CD47 bispecific antibody)	Ichnos Sciences New York, NY	r/r multiple myeloma	Phase I www.ichnossciences.com
ISM3091 (USP1 inhibitor)	Exelixis Alameda, CA Insilico Medicine New York, NY	solid tumors	Phase I www.exelixis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
isunakinra (IL-1 antagonist)	Buzzard Pharmaceuticals Stockholm, Sweden	solid tumors	Phase I www.buzzardpharma.com
ITI-1000 (dendritic cell therapy)	Immunomic Therapeutics Rockville, MD	glioblastoma	Phase II www.immunomix.com
ITI-1001 (DNA cancer vaccine)	Immunomic Therapeutics Rockville, MD	glioblastoma	Phase I www.immunomix.com
ITI-3000 (DNA cancer vaccine)	Immunomic Therapeutics Rockville, MD	Merkel cell carcinoma (Fast Track)	Phase I www.immunomix.com
ITIL-306 (genetically modified cell therapy)	Instil Bio Dallas, TX	solid tumors, including, NSCLC, kidney cancer, ovarian cancer	Phase I www.instilbio.com
ivaltinostat (HDAC inhibitor)	CG Pharmaceuticals Orinda, CA	pancreatic cancer	Phase I/II www.cgpharma.com
ivonescimab (AK/SMT) (PD-1 x VEGF bispecific antibody)	Summit Therapeutics Menlo Park, CA	NSCLC	Phase III www.smmmtx.com
JAB-21822 (glecirasib) (KRAS inhibitor)	Jacobio Pharmaceuticals Beijing, China	KRAS G12Cm solid tumors, including colorectal cancer, NSCLC	Phase I/II www.jacobiopharma.com
JAB-2485 (aurora A inhibitor)	Jacobio Pharmaceuticals Beijing, China	solid tumors	Phase I/II www.jacobiopharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
JAB-3068 (SHP2 inhibitor)	Jacobio Pharmaceuticals Beijing, China	solid tumors	Phase I www.jacobiopharma.com
JAB-3312 (SHP2 inhibitor)	Jacobio Pharmaceuticals Beijing, China	solid tumors	Phase I www.jacobiopharma.com
JAB-8263 (BET inhibitor)	Jacobio Pharmaceuticals Beijing, China	solid tumors	Phase I www.jacobiopharma.com
Jakafi® XR ruxolitinib XR	Incyte Wilmington, DE	myelofibrosis, polycythemia vera	Phase III www.incyte.com
JANX007 (PSMA x CD3 T-cell engager)	Janux Therapeutics San Diego, CA	prostate cancer	Phase I www.januxrx.com
JANX008 (EGFR x CD3 T-cell engager)	Janux Therapeutics San Diego, CA	solid tumors	Phase I www.januxrx.com
Jaypirca® pirtobrutinib	Lilly Indianapolis, IN	1L CLL (monotherapy), r/r CLL (monotherapy & combinations), r/r mantle cell lymphoma	Phase III www.lilly.com
		B-cell malignancies	Phase II www.lilly.com
JBH492	Novartis Pharmaceuticals East Hanover, NJ	hematologic malignancies	Phase I www.novatis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
JBI-802 (LSD1/HDAC6 inhibitor)	Jubilant Therapeutics Bedminster, NJ	solid tumors	Phase I/II www.jubilanttx.com
JCXH-211 (self-replicating mRNA)	Immorna Biotechnology Research Triangle Park, NC	solid tumors	Phase I www.immorna.com
JDQ443 (KRAS inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	2/3L NSCLC	Phase III www.novartis.com
		colorectal cancer, NSCLC (monotherapy & combinations)	Phase II www.novartis.com
Jemperli® dostarlimab-gxly	GSK Durham, NC	1L endometrial cancer (+niraparib) dMMR/MSI-H colon cancer (perioperative)	Phase III www.gsk.com
		NSCLC, dMMR/MSI-H rectal cancer (neoadjuvant)	Phase II www.gsk.com
JIN-A02 (EGFR inhibitor)	J Ints Bio Seoul, South Korea	NSCLC	Phase I/II www.jintsbio.com
JNJ-4681 (BTK inhibitor)	J&J Innovative Medicine Raritan, NJ	hematologic malignancies	Phase I www.janssen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
JNJ-5322	J&J Innovative Medicine Raritan, NJ	multiple myeloma	Phase I www.janssen.com
JNJ-6420 (ionizing radiation emitter)	J&J Innovative Medicine Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-6617 (MLL1 inhibitor)	J&J Innovative Medicine Raritan, NJ	hematologic malignancies	Phase I www.janssen.com
JNJ-8114 (anti-PSMA T-cell therapy)	J&J Innovative Medicine Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-8343 (CD3 x KLK2 bispecific antibody)	J&J Innovative Medicine Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-8543	J&J Innovative Medicine Raritan, NJ	hematologic malignancies	Phase I www.janssen.com
JNJ-8780 (CD3 x CD22 bispecific antibody)	J&J Innovative Medicine Raritan, NJ	hematologic malignancies	Phase I www.janssen.com
JSP191 (briquilimab) (anti-CD117 mAb)	Jasper Therapeutics Redwood City, CA	lower-risk MDS, MDS/AML conditioning regimen in stem cell transplantation	Phase I www.jaspertherapeutics.com
JTX-4014 (pimivalimab) (PD-1 inhibitor)	Concentra Biosciences Cambridge, MA	NSCLC	Phase II www.concentrabiosciences.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
JTX-8064 (LILRB2 inhibitor)	Concentra Biosciences Cambridge, MA	solid tumors	Phase I www.concentrabiosciences.com
JZP341 (crisantaspase biobetter)	Jazz Pharmaceuticals Philadelphia, PA	solid tumors	Phase I www.jazzpharma.com
JZP815 (pan-raf inhibitor)	Jazz Pharmaceuticals Philadelphia, PA	solid tumors	Phase I www.jazzpharma.com
Kadcyla [®] trastuzumab emtansine	Roche/Genentech South San Francisco, CA	HER2+ early breast cancer (high-risk) (+atezolizumab)	Phase III www.roche.com
KAZ954	Novartis Pharmaceuticals East Hanover, NJ	solid tumors	Phase I www.novartis.com
KB-0742 (CDK9 inhibitor)	Kronos Bio San Mateo, CA	non-Hodgkin lymphoma, solid tumors	Phase I/II www.kronosbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Keytruda® pembrolizumab	Merck Rahway, NJ	1L advanced or unresectable biliary tract cancer, 2L hepatocellular carcinoma, locally advanced or metastatic Merkel cell carcinoma, 1L HER2-locally advanced unresectable or metastatic gastric cancer, resectable stage II, IIIA or IIIB NSCLC	application submitted www.merck.com
		mesothelioma, ovarian cancer, SCLC	Phase III www.merck.com
		advanced solid tumors, prostate cancer	Phase II www.merck.com
KFA115 (novel immunomodulatory agent)	Novartis Pharmaceuticals East Hanover, NJ	solid tumors	Phase I www.novartis.com
Kimtrak® tebentafusp-tebn	Immunocore Conshohocken, PA	melanoma	Phase II/III www.immunocore.com
		cutaneous melanoma	Phase I/II www.immunocore.com
KIN-101 (glatiramer acetate)	Kinimmune St. Louis, MO	solid tumors	Phase I www.kinimmune.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
KIN-2787 (exarafenib) (BRAF inhibitor) <small>ORPHAN DRUG</small>	Kinnate Biopharma San Diego, CA	BRAF-driven solid tumors, NRAS mutant melanoma (Fast Track), FGFR2/3 driven solid tumors, NSCLC	Phase I www.kinnate.com
KIN-3248 (FGFR2/FGFR3 inhibitor)	Kinnate Biopharma San Diego, CA	solid tumors including, urogenital cancer, cholangiocarcinoma (Fast Track)	Phase I www.kinnate.com
KISIMA [®] cancer vaccine (chimeric recombinant protein vaccine)	Boehringer Ingelheim Ridgefield, CT	cancer	Phase I www.boehringer-ingelheim.com
Kisqali[®] ribociclib	Novartis Pharmaceuticals East Hanover, NJ	HR+ HER2- breast cancer (adjuvant)	Phase III www.novartis.com
KITE-222 (CLL-1 CAR-T cell therapy) <small>ORPHAN DRUG</small>	Gilead Sciences Foster City, CA	r/r AML	Phase I www.gilead.com
KITE-363 (CD19/20 CAR-T cell therapy)	Gilead Sciences Foster City, CA	3L+ large B-cell lymphoma	Phase I www.gilead.com
KITE-772 (ddBCMA CAR-T cell therapy)	Gilead Sciences Foster City, CA	r/r multiple myeloma	Phase II www.gilead.com
KPG-121 (angiogenesis inhibitor)	Kangpu Biopharmaceuticals Shanghai, China	castration-resistant prostate cancer	Phase I www.kangpugroup.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
KPG-818 (CRBN protein modulator)	Kangpu Biopharmaceuticals Shanghai, China	hematologic malignancies	Phase I www.kangpugroup.com
Krazati™ adagrasib	Mirati Therapeutics San Diego, CA	2L colorectal cancer (+cetuximab) (Breakthrough Therapy), 2L NSCLC	Phase III www.mirati.com
		colorectal cancer (+cetuximab),, 1L NSCLC, 1L NSCLC (+pembrolizumab), pancreatic cancer	Phase II www.mirati.com
		2L+ colorectal cancer, 2L+ NSCLC (combination therapy)	Phase I www.mirati.com
KSQ-4279 (USP1 inhibitor)	KSQ Therapeutics Lexington, MA	solid tumors	Phase I www.ksqtx.com
KT-253 (MDM2) ORPHAN DRUG	Kymera Therapeutics Watertown, MA	ALL, lymphoma, solid tumors	Phase I www.kymeratx.com
KT-333 (STAT3 degrader) ORPHAN DRUG	Kymera Therapeutics Watertown, MA	non Hodgkin lymphoma, PTCL (Fast Track), CTCL (Fast Track), large granular lymphocytic leukemia, solid tumors	Phase I www.kymeratx.com
KT-413 (IRAK1MiD degrader)	Kymera Therapeutics Watertown, MA	r/r B-cell non-Hodgkin lymphoma	Phase I www.kymeratx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
KTX-1001 (MMSET inhibitor)	K36 Therapeutics Cambridge, MA	multiple myeloma	Phase I www.k36tx.com
KUR-502 (CAR-NK therapy)	Athenex Buffalo, NY	B-cell malignancies	Phase I www.athenex.com
KVA-12123 (VISTA inhibitor)	Kineta Seattle, WA	advanced solid tumors	Phase I www.kinetabio.com
Kyprolis® carfilzomib	Amgen Thousand Oaks, CA	r/r multiple myeloma (weekly dosing combination therapy)	Phase III www.amgen.com
		ALL (pediatric)	Phase II www.astrazeneca.com
KZR-261 (Sec61 inhibitor)	Kezar Life Sciences South San Francisco, CA	solid tumors	Phase I www.kezarlifesciences.com
lacutamab (IPH4102) (KIR3DL2 antagonist) <small>ORPHAN DRUG</small>	Innate Pharma Marseille, France	mycosis fungoid, Sezary Syndrome (Fast Track)	Phase II www.innate-pharma.com
		PTCL	Phase I www.innate-pharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ladiratumumab vedotin (antibody drug conjugate)	Seattle Genetics Bothell, WA	1L metastatic triple negative breast cancer, r/r breast cancer, metastatic solid tumors	Phase II www.seagen.com
LAE002 (afuresertib) (PIKfyve kinase inhibitor)	Laekna Therapeutics Shanghai, China	platinum-resistant ovarian cancer	Phase II www.laekna.com
		HR+/HER2- breast cancer, metastatic castration-resistant prostate cancer	Phase I www.laekna.com
LAM561 (furin inhibitor)	Laminar Pharmaceuticals Palma, Spain	high-grade glioma, pediatric solid tumors	Phase I/II www.laminarpharma.com
Ianraplenib (SYK inhibitor)	Kronos Bio San Mateo, CA	FLT3m AML	Phase II www.kronosbio.com
Iasofoxifene (SERM)	Sermonix Pharmaceuticals Columbus, OH	breast cancer (Fast Track)	Phase III www.sermonixpharma.com
Iatikafusp (AMG 256) (bifunctional fusion protein)	Amgen Thousand Oaks, CA	solid tumors	Phase I www.amgen.com
LAVA-1207 (bispecific T cell engager)	Lava Therapeutics Philadelphia, PA	castration-resistant prostate cancer	Phase I www.lavatherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
LB-100 (PPZA inhibitor)	LIXTE Biotechnology Pasadena, CA	solid tumors	Phase I completed www.lixte.com
LB-101 (PD-L1 x CD47 bispecific antibody)	Centessa Pharmaceuticals Boston, MA	solid tumors	Phase I/II www.centessa.com
LB1908 (CAR-T cell therapy)	Legend Biotech USA Somerset, NJ	gastric cancer, gastroesophageal- junction cancer, esophageal cancer, pancreatic cancer	Phase I www.legendbiotech.com
LB2102 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Legend Biotech USA Somerset, NJ	extensive-stage SCLC	Phase I www.legendbiotech.com
LBL-007 (LAG3 inhibitor)	BeiGene Cambridge, MA	colorectal cancer (combination therapy)	Phase I/II www.beigene.com
L-DOS 47 (Immunoconjugate)	Helix BioPharma Toronto, Canada	pancreatic cancer	Phase II www.helixbiopharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Lenvima® lenvatinib <small>ORPHAN DRUG</small>	Eisai Nutley, NJ Merck Rahway, NJ	1L endometrial cancer, 1L NSCLC, 2L NSCLC, 1L head and neck cancer, 1L liver cancer, 1L esophageal cancer, 1L gastric cancer, 3L colorectal cancer (+ pembrolizumab)	Phase III www.eisai.com www.merck.com
		1L renal cell carcinoma (+ everolimus)	Phase III www.eisai.com www.merck.com
		2L melanoma, biliary tract cancer, 2L head and neck cancer, pancreatic cancer, SCLC	Phase II www.eisai.com www.merck.com
lerapolturev (recombinant oncolytic virus vaccine) <small>ORPHAN DRUG</small>	Istari Oncology Morrisville, NC	glioblastoma, (Breakthrough Therapy), melanoma (Fast Track)	Phase II www.istarioncology.com
		non-muscle invasive bladder cancer	Phase I www.istarioncology.com
lerociclib (EQ132) (CDK4/6 inhibitor)	EQRx Cambridge, MA	metastatic endometrial cancer	Phase III www.eqrx.com
		1L/2L advanced breast cancer	Phase II www.eqrx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
leronlimab (CCR5 antagonist)	CytoDyn Vancouver, WA	solid tumors including, triple negative breast cancer (Fast Track)	Phase II www.cytodyn.com
Libtayo [®] cemiplimab-rwlc	Regeneron Tarrytown, NY	cutaneous squamous cell carcinoma (adjuvant)	Phase III www.regeneron.com
		1L NSCLC (+BNT116), cutaneous squamous cell carcinoma (neoadjuvant), 2L cervical cancer	Phase II www.regeneron.com
lifileucel (LN-144) (tumor infiltrating lymphocyte cell therapy) <small>ORPHAN DRUG</small>	Iovance Biotherapeutics San Carlos, CA	post-anti-PD-1 advanced melanoma (Fast Track)	application submitted www.iovance.com
		1L melanoma (+pembrolizumab), cervical cancer (Fast Track) (Breakthrough Therapy)	Phase III www.iovance.com
		anti-PD-1 naïve melanoma (+pembrolizumab), 1L cervical cancer (+pembrolizumab)	Phase II www.iovance.com
lifirafenib (BGB-283) (BRAF inhibitor)	BeiGene Cambridge, MA	solid tumors (+mirdametinib)	Phase I www.beigene.com
linperlisib (YY-20394) (PI3Kδ inhibitor) <small>ORPHAN DRUG</small>	Yingli Pharmaceutical Shanghai, China	r/r peripheral T/NK cell lymphoma	Phase II www.yl-pharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
linvoseltamab (BCMA x CD3 bispecific antibody)	Regeneron Pharmaceuticals Tarrytown, NY	multiple myeloma (Fast Track)	Phase II www.regeneron.com
Lipocurc™ curcumin liposomal	SignPath Pharma Sandy, UT	glioblastoma	Phase I/II www.signpathpharma.com
LM-108 (anti-CCR8 antibody)	LaNova Medicines Shanghai, China	solid tumors	Phase I www.lanovamedicines.com
LMY-920 (CAR-T cell therapy)	Luminary Therapeutics Minneapolis, MN	non-Hodgkin lymphoma	Phase I www.luminarytx.com
LN-145 (tumor infiltrating lymphocyte cell therapy)	Iovance Biotherapeutics San Carlos, CA	2L NSCLC	Phase III www.iovance.com
		head and neck cancer, 2-4L NSCLC, melanoma	Phase II www.iovance.com
LN-145 Gen 3 (tumor infiltrating lymphocyte cell therapy)	Iovance Biotherapeutics San Carlos, CA	head and neck cancer, melanoma, NSCLC	Phase II www.iovance.com
LN-145-S1 (tumor infiltrating lymphocyte cell therapy)	Iovance Biotherapeutics San Carlos, CA	head and neck cancer, melanoma	Phase II www.iovance.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
LNS8801 (GPER agonist)	Linnaeus Therapeutics Haddonfield, NJ	solid tumors	Phase I www.linnaeustx.com
LNTH-1095 (ionizing radiation emitter)	Lantheus Bedford, MA	metastatic prostate cancer	Phase II www.lantheus.com
lorigerlimab (PD-1 x CTLA-4 bispecific antibody)	MacroGenics Rockville, MD	metastatic castration-resistant prostate cancer, MSS-colorectal cancer, melanoma, NSCLC	Phase II www.macrogenics.com
LP-100 (irofulven) (DNA synthesis inhibitor)	Lantern Pharma Dallas, TX	homologous repair deficient cancer	Phase I www.lanternpharma.com
LP-108 (Bcl-2 inhibitor)	Newave Pharmaceuticals Guangzhou, China	hematologic malignancies	Phase I www.newavepharma.com
LP-118 (BCL-2/BCL-XL inhibitor)	Newave Pharmaceuticals Guangzhou, China	hematologic malignancies	Phase I www.newavepharma.com
LP-168 (small molecule)	Newave Pharmaceuticals Guangzhou, China	hematologic malignancies	Phase I www.newavepharma.com
LP-184 (2nd-generation irofulven)	Lantern Pharma Dallas, TX	solid tumors	Phase I www.lanternpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
LP-300 (dimesna) (glutaredoxin/thioredoxin modulator)	Lantern Pharma Dallas, TX	NSCLC	Phase II www.lanternpharma.com
LSAM-DTX (docetaxel nanoformulation)	Nanology Houston, TX	bladder cancer	Phase II www.nanology.com
LSAM-PTX (paclitaxel nanoformulation)	Nanology Houston, TX	NSCLC, pancreatic cancer, SCLC	Phase II www.nanology.com
LSTA1 (cyclic peptide)	Lisata Therapeutics Basking Ridge, NJ	cholangiocarcinoma, esophageal cancer, head and neck cancer	Phase II www.lista.com
LTX-315 (ruxotemitide) (oncolytic immunotherapy)	Lytix Biopharma Oslo, Norway	advanced melanoma (+pembrolizumab)	Phase II www.lytixtherapeutics.com
Lu177-edotreotide (ionizing radiation emitter)	ITM Solucin Munich, Germany	neuroendocrine tumors (Fast Track)	Phase III www.itm-radiopharma.com
Lu177-PSMA-I&T (ionizing radiation emitter)	Curium US Saint Louis, MO	metastatic castration-resistant prostate cancer	Phase III www.curiumpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Lumakras [®] sotorasib	Amgen Thousand Oaks, CA	advanced colorectal cancer (combination therapy)	Phase III www.amgen.com
		NSCLC, solid tumors	Phase II www.amgen.com
		NSCLC (combination therapy)	Phase I www.amgen.com
LUNA18 (RAS inhibitor)	Chugai Pharma USA Berkeley Heights, NJ	solid tumors	Phase I www.chugai-pharm.com
Lunsumio [®] mosunetuzumab-axgb	Roche/Genentech South San Francisco, CA	2L+ follicular lymphoma (+lenalidomide) 2L+ DLBCL (+polatuzumab vedotin-piiq)	Phase III www.roche.com
		hematologic malignancies	Phase I www.roche.com
Lutathera [®] lutetium Lu 177 dotatate	Novartis Pharmaceuticals East Hanover, NJ	1L G2/3 gastroenteropancreatic neuroendocrine tumors (GEP-NET)	Phase III www.novartis.com
		GEP-NET (pediatric), glioblastoma, 1L extensive-stage SCLC	Phase II www.novartis.com
lutetium-177-rhPSMA-10.1 (ionizing radiation emitter)	Blue Earth Therapeutics Oxford, United Kingdom	prostate cancer	Phase I/II www.blueearththerapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
luveltamab tazevibulin (antibody drug conjugate)	Sutro Biopharma South San Francisco, CA	endometrial cancer, ovarian cancer (Fast Track)	Phase I www.sutrobio.com
luxetpinib (CG-806) (BTK/FLT3 inhibitor) ORPHAN DRUG	Aptose Biosciences San Diego, CA	AML, CLL/SLL, MDS, non-Hodgkin lymphoma	Phase I www.aptose.com
LVGN6051 (CD137/4-1BB agnostic mAb)	Lyvgen Biopharma Shanghai, China	cancer	Phase I www.lyvgen.com
LVGN7409 (CD40 agonist antibody)	Lyvgen Biopharma Shanghai, China	cancer	Phase I www.lyvgen.com
LX-101 (IGF-1R antagonist)	Lirum Therapeutics New York, NY	cancer	Phase I completed www.lirumtx.com
LY3537982 (KRAS G12C II inhibitor)	Lilly Indianapolis, IN	solid tumors	Phase I www.lilly.com
LY3838915 (LOXO-260) (RET inhibitor II)	Lilly Indianapolis, IN Loxo Oncology Stamford, CT	RET fusion+ solid tumors	Phase I www.lilly.com
LY3849524 (LOXO-783) (PI3K α inhibitor)	Lilly Indianapolis, IN Loxo Oncology Stamford, CT	solid tumors including, breast cancer	Phase I www.lilly.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
LY3866288 (LOXO-435) (FGFR3 inhibitor)	Lilly Indianapolis, IN Loxo Oncology Stamford, CT	solid tumors including, urogenital cancer	Phase I www.lilly.com
LYL797 (CAR-T cell therapy)	Lyell Immunopharma South San Francisco, CA	solid tumors, including NSCLC, triple negative breast cancer	Phase I www.lyell.com
LYL845 (TIL therapy)	Lyell Immunopharma South San Francisco, CA	solid tumors, including colorectal cancer, melanoma, NSCLC	Phase I www.lyell.com
Lynparza® olaparib	AstraZeneca Wilmington, DE Merck Rahway, NJ	1L ovarian cancer (+durvalumab+ bevacizumab), 1L endometrial cancer (+durvalumab), 1L BRCAwt ovarian cancer, NSCLC (+pembrolizumab), SCLC (+pembrolizumab)	Phase III www.astrazeneca.com
		HRRm cancer, advanced solid tumors (+pembrolizumab)	Phase II www.astrazeneca.com
LYT-200 (anti-galectin-9 antibody)	PureTech Health Boston, MA	AML, MDS	Phase I www.puretechhealth.com
Lytgobi® futibatinib	Taiho Oncology Princeton, NJ	breast cancer, esophageal cancer, urothelial cancer, FGFRm solid tumors	Phase II www.taihooncology.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
M1774 (tuvusertib) (ATR inhibitor)	EMD Serono Rockland, MA	solid tumors	Phase I www.emdserono.com
M4076 (ATM inhibitor)	EMD Serono Rockland, MA	solid tumors	Phase I www.emdserono.com
M6223 (anti-TIGIT mAb)	EMD Serono Rockland, MA	solid tumors	Phase I www.emdserono.com
M9140 (antibody drug conjugate)	EMD Serono Rockland, MA	solid tumors	Phase I www.emdserono.com
magrolimab (anti-CD47 mAb) <small>ORPHAN DRUG</small>	Gilead Foster City, CA	1L unfit AML (+venetoclax +azacitidine)	Phase III www.gilead.com
		metastatic triple negative breast cancer, head and neck cancer, metastatic colorectal cancer, multiple myeloma, solid tumors (combination therapy)	Phase II www.gilead.com
		DLBCL (Fast Track) (combination therapy)	Phase I/II www.gilead.com
maplirpcept (TTI-622) (CD47-SIRPα fusion protein)	Pfizer New York, NY	hematologic malignancies	Phase II www.pfizer.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
mavorixafor (CXCR4 inhibitor) <small>ORPHAN DRUG</small>	X4 Pharmaceuticals Boston, MA	Waldenstrom macroglobulinemia	Phase I completed www.x4pharma.com
MB-102 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Mustang Bio Worcester, MA	blastic plasmacytoid dendritic cell neoplasm	Phase I/II www.mustangbio.com
MB-106 (CAR-T cell therapy)	Mustang Bio Worcester, MA	CLL, B-cell non-Hodgkin lymphoma	Phase I/II www.mustangbio.com
MBM-02 (free radical scavenger antioxidant)	Matrix Biomed Irvine, CA	glioblastoma, prostate cancer	Phase II www.matrixbiomed.com
MCLA-129 (EGFR x c-Met bispecific antibody)	Merus Cambridge, MA	solid tumors, including NSCLC	Phase II www.merus.nl
MCLA-145 (CD137 x PD-L1 bispecific antibody)	Merus Cambridge, MA	solid tumors	Phase I www.merus.nl
MCLA-158 (petosemtamab) (EGFR x LGR5 bispecific antibody)	Merus Cambridge, MA	solid tumors, colorectal cancer, gastric cancer, gastroesophageal junction cancer, NSCLC, squamous cell carcinoma (Fast Track)	Phase I/II www.merus.nl
MDK-703 (IL-7 agonist)	Medikine Menlo Park, CA	solid tumors	Phase I www.medikine.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MDNA11 (IL-2 superkine)	Medicenna Therapeutics Houston, TX	solid tumors	Phase I www.medicenna.com
MDNA55 (bizaxofusp) (recombinant chimeric protein) <small>ORPHAN DRUG</small>	Medicenna Therapeutics Houston, TX	recurrent glioblastoma (Fast Track)	Phase II completed www.medicenna.com
MEDI1191 (IL-2 mRNA therapeutic)	Moderna Therapeutics Cambridge, MA	solid tumors	Phase I www.modernatx.com
MEM-288 (viral cancer immunotherapy)	Memgen Houston, TX	solid tumors, including NSCLC	Phase I www.memgenbio.com
MEN1611 (PI3K inhibitor)	Menarini Florence, Italy Stemline Therapeutics New York, NY	colorectal cancer	Phase II www.menarini.com
		breast cancer	Phase I www.menarini.com
MEN1703 (PIM/FLT3 inhibitor) <small>ORPHAN DRUG</small>	Menarini Florence, Italy Stemline Therapeutics New York, NY	AML	Phase II www.menarini.com
mezigdomide (CC-924800) (CRBN modulator)	Bristol Myers Squibb Lawrenceville, NJ	2L+ multiple myeloma (combination therapy)	Phase III www.bms.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MGD024 (CD123 x CD3 bispecific antibody)	MacroGenics Rockville, MD	hematologic malignancies	Phase I www.macrogenics.com
MGY825 (KARS inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	NSCLC	Phase I www.novatis.com
MIK665 (MCL1 inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	hematologic malignancies	Phase I www.novatis.com
milademetan (MDM2-p53 inhibitor) <small>ORPHAN DRUG</small>	Rain Oncology Newark, CA	dedifferentiated liposarcoma	Phase III www.raianoncology.com
		solid tumors (MDMA amplified)	Phase II www.rainoncology.com
minnelide (HSP70 heat shock inhibitor)	Minneamrita Therapeutics Tampa, FL	solid tumors	Phase I
mirdametinib (MEK inhibitor)	BeiGene Boston, MA SpringWorks Therapeutics Stamford, CT	solid tumors (+BGB-3245)	Phase I www.springworkstx.com
MK-0482	Merck Rahway, NJ	NSCLC (+pembrolizumab)	Phase II www.merck.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MK-1084 (KRAS inhibitor)	Merck Rahway, NJ	KRAS G12Cm solid tumors	Phase I www.merck.com
MK-1308 (quavonlimab) (CTLA4 antagonist)	Merck Rahway, NJ	NSCLC (+pembrolizumab)	Phase I www.merck.com
MK-1308A (quavonlimab + pembrolizumab)	Merck Rahway, NJ	renal cell carcinoma	Phase III www.merck.com
		colorectal cancer, hepatocellular carcinoma, melanoma, SCLC	Phase II www.merck.com
MK-2140 (zilovetamab vedotin) (antibody drug conjugate) <small>ORPHAN DRUG</small>	Merck Rahway, NJ	bladder cancer, breast cancer, gastric cancer, hematologic malignancies, NSCLC, ovarian cancer, pancreatic cancer	Phase II www.merck.com
MK-2870 (SKB264) (TROP2 antibody drug conjugate)	Klus Pharma East Windsor, NJ Merck Rahway, NJ	solid tumors (+/- pembrolizumab)	Phase II www.merck.com
MK-3475A (pembrolizumab + hyaluronidase subcutaneous)	Merck Rahway, NJ	NSCLC	Phase III www.merck.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MK-4280 (favezelimab) (CD223 inhibitor)	Merck Rahway, NJ	NSCLC (+pembrolizumab)	Phase II www.merck.com
MK-4280A (favezelimab/pembrolizumab)	Merck Rahway, NJ	colorectal cancer, hematologic malignancies	Phase III www.merck.com
		bladder cancer, esophageal cancer, melanoma, renal cell carcinoma, SCLC	Phase II www.merck.com
MK-4464	Merck Rahway, NJ	solid tumors	Phase I www.merck.com
MK-4830 (LILRB2 inhibitor)	Merck Rahway, NJ	colorectal cancer, esophageal cancer, melanoma, NSCLC, ovarian cancer, renal cell carcinoma, SCLC (+pembrolizumab)	Phase II www.merck.com
MK-5684 (CYP11A1 inhibitor)	Merck Rahway, NJ Orion Espoo, Finland	metastatic castration-resistant prostate cancer	Phase II www.merck.com
MK-5890 (boseralimab) (CD27 antigen stimulant)	Merck Rahway, NJ	NSCLC, SCLC (+pembrolizumab)	Phase II www.merck.com
MK-6598	Merck Rahway, NJ	solid tumors	Phase I www.merck.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MK-7684A (vibostolimab + pembrolizumab)	Merck Rahway, NJ	melanoma, NSCLC, SCLC	Phase III www.merck.com
		biliary cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, hematologic malignancies, head and neck cancer, liver cancer, ovarian cancer, prostate cancer	Phase II www.merck.com
modakafusp alfa (anti-CD38 antibody) <small>ORPHAN DRUG</small>	Takeda Cambridge, MA	r/r multiple myeloma	Phase II www.takeda.com
		solid tumors	Phase I www.takeda.com
ModraDoc006/r (boosted oral docetaxel)	Modra Pharmaceuticals Amsterdam, The Netherlands	prostate cancer	Phase II completed www.modrapharmaceuticals.com
Monjuvi [®] tafasitamab-cxix <small>ORPHAN DRUG</small>	Incyte Wilmington, DC MorphoSys US Boston, MA	1L DLBCL, follicular lymphoma, marginal zone lymphoma	Phase III www.incyte.com www.morphosys.com
motixafortide (BL-8040) (CXCR4 receptor antagonist) <small>ORPHAN DRUG</small>	BioLineRx Modi'in, Israel	1L pancreatic cancer	Phase II www.biolinerx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MPT-0118 (MALT1 inhibitor)	Monopteros Therapeutics Boston, MA	solid tumors	Phase I www.monopterostrx.com
MRG-002 (antibody drug conjugate)	Miracogen Shanghai, China	solid tumors including, gastric cancer, gastroesophageal junction cancer	Phase I/II www.miracogen.com
MRG-004 (antibody drug conjugate)	Miracogen Shanghai, China	solid tumors	Phase I/II www.miracogen.com
mRNA-2752 (mRNA therapeutic)	Moderna Therapeutics Cambridge, MA	lymphoma, solid tumors	Phase I www.modernatx.com
mRNA-4157 (V940) (individualized neoantigen therapy)	Merck Rahway, NJ Moderna Therapeutics Cambridge, MA	high-risk stage III/IV melanoma (+pembrolizumab) (Breakthrough Therapy)	Phase II www.merck.com www.modernatx.com
mRNA-4359 (checkpoint RNA vaccine)	Moderna Therapeutics Cambridge, MA	solid tumors	Phase I www.modernatx.com
mRNA-5671 (KRAS RNA vaccine)	Moderna Therapeutics Cambridge, MA	colorectal cancer, NSCLC, pancreatic cancer	Phase I www.modernatx.com
MRT-2359 (GSPT1 degrader) <small>ORPHAN DRUG</small>	Monte Rosa Therapeutics Boston, MA	solid tumors including, DLBCL, NSCLC (Fast Track), SCLC	Phase I/II www.monterosatx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MRTX0902 (SOS1 inhibitor)	Mirati Therapeutics San Diego, CA	solid tumors (Fast Track)	Phase I www.mirati.com
MRTX1133 (KRAS inhibitor)	Mirati Therapeutics San Diego, CA	solid tumors including, colorectal cancer, NSCLC, pancreatic cancer	Phase I www.mirati.com
MRTX1719 (KRAS inhibitor)	Mirati Therapeutics San Diego, CA	MTAP-deleted cancers, including mesothelioma (Fast Track), NSCLC (Fast Track)	Phase I/II www.mirati.com
MRX-2843 (MerTK/FLT-3 inhibitor)	Meryx Chapel Hill, NC	AML, ALL, mixed phenotype leukemia, solid tumors	Phase I
MS-553 (PKC-β inhibitor)	MingSight Pharmaceuticals San Diego, CA	CLL/SLL, aggressive lymphoma	Phase I/II www.mingsigt.com
MT-0169 (CD38) ORPHAN DRUG	Molecular Templates Austin, TX	multiple myeloma	Phase I www.mtem.com
MT-101 (mRNA engineered CAR therapy)	Myeloid Therapeutics Cambridge, MA	PTCL (Fast Track), CTCL	Phase I/II www.myeloidtx.com
MT-302 (mRNA engineered CAR therapy)	Myeloid Therapeutics Cambridge, MA	epithelial tumors	Phase I www.myeloidtx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MT-401 (zedenoleucel) (T cell therapy) <small>ORPHAN DRUG</small>	Marker Therapeutics Houston, TX	AML	Phase II www.markertherapeutics.com
MT-601 (T cell therapy) <small>ORPHAN DRUG</small>	Marker Therapeutics Houston, TX	non-Hodgkin lymphoma	Phase I www.markertherapeutics.com
MT-6402 (PD-L1)	Molecular Templates Austin, TX	solid tumors, including NSCLC	Phase I www.mtem.com
MT-8421 (anti-CTLA-4)	Molecular Templates Austin, TX	solid tumors (+/-nivolumab)	Phase I www.mtem.com
MT-8633 (TR1801-ADC) (antibody drug conjugate)	Mitsubishi Tanabe Pharma Osaka, Japan	solid tumors	Phase I www.mt-pharma.co.jp
MTB-9655 (ACSS2 inhibitor)	Metabomed Yavne, Israel	solid tumors	Phase I
MTI-201 (ionizing radiation emitter)	Modulation Therapeutics Morgantown, WV	uveal melanoma	Phase I www.modulationtherapeutics.com
MTL-CEBPA (RNA interference)	MiNA Therapeutics London, United Kingdom	liver cancer	Phase II www.minatx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Multikine® leukocyte interleukin <small>ORPHAN DRUG</small>	CEL-SCI Vienna, VA	head and neck cancer	Phase III completed www.cel-sci.com
mupadolimab (CPI-006) (anti-CD73 mAb)	Corvus Pharmaceuticals Burlingame, CA	advanced cancers	Phase I www.corvuspharma.com
MV-NIS (attenuated oncolytic virus)	Vyriad Rochester, MN	bladder cancer	Phase I www.vyriad.com
MVR-T3011 (oncolytic herpes simplex virus therapy)	Immivira Pharma Shenzhen, China	solid tumors	Phase I/II www.immviragroup.com
MYTX-011 (antibody drug conjugate)	Mythic Therapeutics Waltham, MA	NSCLC (Fast Track)	Phase I www.mythictx.com
namodenoson (A3AR agonist) <small>ORPHAN DRUG</small>	Can-Fite BioPharma Petah-Tikva, Israel	liver cancer (Fast Track)	Phase II completed www.canfite.com
NanO2 (perflenapent nanoparticles) <small>ORPHAN DRUG</small>	NuvOx Pharma Tucson, AZ	glioblastoma	Phase II www.nuvoxpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
nana-val (nanatinostat + valganciclovir) <small>ORPHAN DRUG</small>	Viracta Therapeutics Cardiff, CA	r/r EBV+ lymphoma (Fast Track)	Phase II www.viracta.com
		r/r EBV+ solid tumors	Phase I www.viracta.com
nanrilkefusp alfa (IL-15 superagonist)	SOTIO Amsterdam, The Netherlands	solid tumors	Phase II www.sotio.com
naporafenib (ERAS-254) (Raf inhibitor)	Erasca San Diego, CA	NRASm melanoma	Phase II www.erasca.com
		pan-RAS Q61X tissue agnostic solid tumors	Phase I www.erasca.com
naptumomab estafenatox (recombinant fusion protein)	NeoTX Therapeutics Rehovot, Israel	NSCLC (Fast Track)	Phase II www.neotx.com
naratuximab emtansine (Debio 1562) (antibody drug conjugate) <small>ORPHAN DRUG</small>	Debiopharm Lausanne, Switzerland	DLBCL, non-Hodgkin lymphoma	Phase II completed www.debiopharm.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
narazaciclib (CDK4/CDK6/Ark5 inhibitor)	Onconova Therapeutics Newtown, PA	2L/3L low-grade endometrial cancer	Phase I/II www.onconova.com
		solid tumors	Phase I www.onconova.com
navicixizumab (anti-DLL4 x VEGF bispecific antibody)	OncXerna Therapeutics Waltham, MA	platinum-resistant ovarian cancer (Fast Track)	Phase III www.oncxerna.com
		colorectal cancer, triple negative breast cancer, gastric cancer, ovarian cancer	Phase II www.oncxerna.com
navitoclax (BCL-XL/BCL-2 inhibitor)	AbbVie North Chicago, IL	myelofibrosis	Phase III www.abbvie.com
navtemadlin (KRT-232) (MDM2 inhibitor)	Kartos Therapeutics Redwood City, CA	myelofibrosis	Phase III www.kartosthera.com
		B-cell malignancies, endometrial cancer, Merkel cell carcinoma, NSCLC	Phase II www.kartosthera.com
	Kartos Therapeutics Redwood City, CA Telios Pharma Redwood City, CA	myelofibrosis (+TL-895)	Phase I www.kartosthera.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NBF-006 (RNA interference)	Nitto BioPharma San Diego, CA	colorectal cancer, NSCLC, pancreatic cancer	Phase I www.nittobiopharma.com
NBXR3 (free radical stimulant)	J&J Innovative Medicine Raritan, NJ Nanobiotix Cambridge, MA	head and neck squamous cell carcinoma (Fast Track)	Phase III www.nanobiotix.com
		advanced solid tumors	Phase I www.nanobiotix.com
NC410 (LAIR-2 inhibitor)	NextCure Beltsville, MD	solid tumors (+pembrolizumab)	Phase I www.nextcure.com
NC525 (LAIR-1 inhibitor)	NextCure Beltsville, MD	AML	Phase I www.nextcure.com
NC762 (B7-H4 inhibitor)	NextCure Beltsville, MD	solid tumors	Phase I www.nextcure.com
NDI-101150 (HPK1 inhibitor)	Nimbus Therapeutics Boston, MA	solid tumors	Phase I/II www.nimbustx.com
nemtabrutinib (MK-1026) (BTK inhibitor) ORPHAN DRUG	Merck Rahway, NJ	hematologic malignancies	Phase III www.merck.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
nemvaleukin alfa (IL-2 agonist) <small>ORPHAN DRUG</small>	Alkermes Waltham, MA	platinum-resistant ovarian cancer (+pembrolizumab) (Fast Track)	Phase III www.alkermes.com
		mucosal melanoma (Fast Track)	Phase II www.alkermes.com
NEO100 (perillyl alcohol intranasal) <small>ORPHAN DRUG</small>	Neonc Technologies Los Angeles, CA	glioma, meningioma	Phase I/II www.neonctech.com
NEO-201 (IgG1 mAb)	Precision Biologics Bethesda, MD	solid tumors	Phase I www.precision-biologics.com
neoantigen specific T-cell therapy	Alaunos Therapeutics Houston, TX	solid tumors	Phase I/II www.alaunos.com
Nerlynx® neratinib	Puma Biotechnology Los Angeles, CA	HER2+ breast cancer (adjuvant), metastatic breast cancer with brain metastases	Phase II completed www.pumabiotehnology.com
Nerofe (tumor cell apoptosis factor) <small>ORPHAN DRUG</small>	Immune System Key Jerusalem, Israel	AML, MDS	Phase I www.immunesk.com
NEV801 (camptothecin/podophyllotoxin)	Neovia Oncology Bellevue, WA	solid tumors	Phase I www.neoviaoncology.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NEXI-001 (adoptive T-cell therapy)	NexImmune Gaithersburg, MD	AML, MDS	Phase I/II www.neximmune.com
NEXI-002 (adoptive T-cell therapy)	NexImmune Gaithersburg, MD	multiple myeloma	Phase I/II www.neximmune.com
NEXI-003 (adoptive T-cell therapy)	NexImmune Gaithersburg, MD	HPV-associated malignancies	Phase I/II www.neximmune.com
NG-350A (anti-CD40 mAb)	Akamis Bio Cambridge, MA	advanced epithelial tumors	Phase I www.akamisbio.com
NGM120 (GFRAL inhibitor)	NGM Biopharmaceuticals South San Francisco, CA	pancreatic cancer	Phase II www.ngmbio.com
NGM438 (LAIR1 inhibitor)	NGM Biopharmaceuticals South San Francisco, CA	solid tumors	Phase I www.ngmbio.com
NGM707 (LT2/ILT4 inhibitor)	NGM Biopharmaceuticals South San Francisco, CA	solid tumors	Phase I www.ngmbio.com
NGM831 (ILT3 antagonist)	NGM Biopharmaceuticals South San Francisco, CA	solid tumors	Phase I www.ngmbio.com
Ninlaro [®] ixazomib	Takeda Pharmaceuticals Lexington, MA	multiple myeloma (maintenance) (post-SCT)	Phase III www.takeda.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
nirogacestat (gamma secretase inhibitor)	SpringWorks Therapeutics Stamford, CT	ovarian granulosa cell tumors	Phase II www.springworkstx.com
NIS793 (TGFB1 inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	1L metastatic colorectal cancer	Phase II www.novartis.com
nivolumab + relatlimab	Bristol Myers Squibb Lawrenceville, NJ	1L/2L liver cancer, 1L stage IV NSCLC	Phase II www.bms.com
nivolumab subcutaneous	Bristol Myers Squibb Lawrenceville, NJ	2L kidney cancer (+rHuPH20)	Phase III www.bms.com
NKT2152 (HIF2 α inhibitor)	NiKang Therapeutics Wilmington, DE	clear cell renal cell carcinoma	Phase I/II www.nikangtx.com
NKTR-255 (IL-15 receptor agonist)	Nektar Therapeutics San Francisco, CA	large B-cell lymphoma	Phase II/III www.nektar.com
		solid tumors, including colorectal cancer, cervical cancer, NSCLC	Phase I/II www.nektar.com
		multiple myeloma, non-Hodgkin lymphoma	Phase I www.nektar.com
NKX019 (CAR-NK cell therapy)	Nkarta Therapeutics South San Francisco, CA	B-cell malignancies	Phase I www.nkartatx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NKX101 (CAR-NK cell therapy) <small>ORPHAN DRUG</small>	Nkarta Therapeutics South San Francisco, CA	AML, MDS	Phase I www.nkartatx.com
NLM001	Nelum Cary, NC	pancreatic ductal adenocarcinoma (combination therapy)	Phase I/II www.nelumpharma.com
NM1F injection (TG2) (anti-PVRIG mAb)	TG ImmunoPharma Anhui, China	advanced solid tumors	Phase I www.tgimmunopharma.com
NM21-1480 (trispesific antibody)	Numab Therapeutics Horgen, Switzerland	solid tumors	Phase I/II www.numab.com
NMS-03305293 (PARP-1 inhibitor)	Nerviano Medical Sciences Nerviano, Italy	glioblastoma, solid tumors	Phase I www.nervianoms.com
NMS-03597812 (EIF2/EIF2AK4 inhibitor)	Nerviano Medical Sciences Nerviano, Italy	multiple myeloma	Phase I www.nervianoms.com
nofaznimab (CS-1003) (anti-PD-1 mAb) <small>ORPHAN DRUG</small>	CStone Pharmaceuticals Shanghai, China EQRx Cambridge, MA	liver cancer	Phase III www.cstonepharma.com www.erqx.com
NOUS-209 (neoantigen genetic vaccine)	Nouscom Basel, Switzerland	microsatellite unstable solid tumors	Phase I www.nouscom.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NP751 (fb-PMT) (integrin alphaVbeta3 antagonist) <small>ORPHAN DRUG</small>	NanoPharmaceuticals Rensselaer, NY	glioblastoma	Phase I www.nanopharmaceuticals.com
NP-G2-044 (fascin protein inhibitor)	Novita Pharmaceuticals New York, NY	solid tumors	Phase I/II
NPX267 (anti-KIR3DL2 mAb)	NextPoint Therapeutics Cambridge, MA	HHLA- expressing solid tumors	Phase I www.nextpoint.com
NRC-2694-A (EGFR antagonist)	Natco Pharma Hyderabad, India	head and neck cancer	Phase II www.natcopharma.co.in
NT-125 (TCR therapy)	AstraZeneca Wilmington, DE	solid tumors	Phase I www.astrazeneca.com
NT219 (IRS1/2 / STAT3 inhibitor)	Purple Biotech Rehovot, Israel	solid tumors, including head and neck cancer	Phase I/II www.purple-biotech.com
NTX-1088 (anti-PVR mAb)	Nectin Therapeutics Fort Lee, NJ	solid tumors	Phase I www.nectintx.com
Nubeqa [®] darolutamide	Bayer Pharmaceuticals Whippany, NJ	metastatic hormone-sensitive prostate cancer, prostate cancer (adjuvant), prostate cancer with biochemical recurrence after curative radiotherapy	Phase III www.bayer.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NUC-3373 (DNA synthesis inhibitor)	Nucana BioMed Newton, MA	colorectal cancer	Phase II www.nucana.com
NUV-868 (BET inhibitor)	Nuvation Bio New York, NY	solid tumors (combination therapy)	Phase I/II www.nuvationbio.com
NVL-520 (ROS1 inhibitor)	Nuvalent Cambridge, MA	solid tumors, including NSCLC	Phase I www.nuvalent.com
NVL-655 (ALK inhibitor)	Nuvalent Cambridge, MA	solid tumors, including NSCLC	Phase I www.nuvalent.com
NX-019	Nalo Therapeutics Palo Alto, CA	EGFRm cancer	Phase I www.nalotherapeutics.com
NX-1207 (fexapotide) (pro-apoptotic protein)	Nymox Pharmaceutical Irvine, CA	early stage prostate cancer	Phase II www.nymox.com
NX-1607 (CBL-B inhibitor)	Nurix San Francisco, CA	advanced malignancies	Phase I www.nurixtx.com
NX-2127 (BTK inhibitor)	Nurix San Francisco, CA	B-cell malignancies	Phase I www.nurixtx.com
NX-5948 (HSF1 inhibitor)	Nurix San Francisco, CA	B-cell malignancies	Phase I www.nurixtx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NXP800 (HSF1 inhibitor)	Nuvectis Pharma For Lee, NJ	solid tumors, including ovarian cancer (Fast Track)	Phase I www.nuvectis.com
obecabtagene autoleucel (obe-cel) (CAR-T cell therapy) ORPHAN DRUG	Autolus London, United Kingdom	ALL	Phase I/II www.autolus.com
OBI-3424 (DNA crossing agent)	OBI Pharma San Diego, CA	solid tumors, including pancreatic cancer	Phase I www.obipharma.com
OBI-999 (antibody drug conjugate)	OBI Pharma San Diego, CA	solid tumors	Phase I www.obipharma.com
OBT076/MENN1309 (DM4 antibody drug conjugate)	Oxford BioTherapeutics Oxford, United Kingdom Menarini Florence, Italy	solid tumors	Phase I www.oxfordbiotherapeutics.com
OBX-115 (TIF cell therapy)	Obsidian Therapeutics Cambridge, MA	melanoma	Phase I/II www.obsidiantx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ociperlimab (BGB-A1217) (anti-TIGIT mAb)	BeiGene Cambridge, MA	1L PD-L1 high advanced NSCLC (+tislelizumab), stage III unresectable NSCLC (+tislelizumab +concurrent chemotherapy)	Phase III www.beigene.com
		2L PD-L1+ esophageal cancer (+tislelizumab), 1L NSCLC (+tislelizumab and chemotherapy, limited-stage SCLC (+tislelizumab +concurrent chemotherapy), 2L cervical cancer (+tislelizumab)	Phase II www.beigene.com
		advanced solid tumors (+tislelizumab)	Phase I www.beigene.com
odetiglucan (dectin-1 stimulant)	HiberCell New York, NY	colorectal cancer-based liver metastases, pancreatic cancer	Phase I www.hibercell.com
ODM 208 (CYP11A1 inhibitor)	Orion Pharma Espoo, Finland	prostate cancer	Phase I www.orion.fi
odronextamab (CD20 x CD3 bispecific antibody) <small>ORPHAN DRUG</small>	Regeneron Tarrytown, NY	follicular lymphoma (Fast Track), DLBCL (Fast Track)	application submitted www.regeneron.com
		B-cell malignancies	Phase I www.regeneron.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
OKI-179 (HDAC1 inhibitor)	OnKure Therapeutics Boulder, CO	NRAS-mutated melanoma, solid tumors in the RAS pathway	Phase I/II www.onkuretherapeutics.com
OKN-007 (sulfatase inhibitor) ORPHAN DRUG	Oblato Princeton, NJ	recurrent glioblastoma	Phase II www.oblatoinc.com
		high-grade glioblastoma	Phase I www.oblatoinc.com
olafertinib (EGFR inhibitor) ORPHAN DRUG	Checkpoint Therapeutics Waltham, MA	1L EGFRm NSCLC	Phase III www.checkpointtx.com
oleclumab (CD73 inhibitor)	AstraZeneca Wilmington, DE	metastatic pancreatic cancer (combination therapy)	Phase II www.astrazeneca.com
olverembatinib (HQP1351) (BCR-ABL/KIT inhibitor) ORPHAN DRUG	Ascentage Pharma Rockville, MD	refractory CML (Fast Track), Ph+ ALL	Phase I www.ascentage.com
olimulogene nanivacirepvec (oncolytic virus therapy)	Genelux Westlake Village, CA	ovarian cancer	Phase III www.genelux.com
omburtamab I-124 (theranostic mAb)	Y-mAbs Therapeutics New York, NY	diffuse intrinsic pontine glioma (pediatric)	Phase I completed www.ymabs.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
omburtamab I-131 (theranostic mAb) <small>ORPHAN DRUG</small>	Y-mAbs Therapeutics New York, NY	CNS/leptomeningeal metastases from neuroblastoma (pediatric) (Breakthrough Therapy), desmoplastic small round cell tumor (pediatric)	Phase II www.ymabs.com
		CNS/leptomeningeal metastases (intrathecal immunotherapy)	Phase I www.ymabs.com
ompenaclid (RGX-202) (SLC6A8 inhibitor)	Inspirna New York, NY	colorectal cancer	Phase I/II www.inspirna.com
OMTX705 (antibody drug conjugate)	Oncomatryx Biopharma Bizkaia, Spain	solid tumors	Phase I www.oncomatryx.com
ONC201 (dordaviprone) (DRD2/3 antagonist) <small>ORPHAN DRUG</small>	Chimerix Durham, NC	H3 K27M-mutant high-grade glioma (Fast Track)	Phase III www.chimerix.com
		neuroendocrine tumors (pheochromocytoma/paraganglioma)	Phase II www.chimerix.com
ONC206 (DRD2 antagonist)	Chimerix Durham, NC	solid tumors	Phase I www.chimerix.com
ONCT-534 (DAAR inhibitor)	Oncternal Therapeutics San Diego, CA	metastatic castration-resistant prostate cancer	Phase I/II www.oncternal.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ONCT-808 (CAR-T cell therapy)	Oncternal Therapeutics San Diego, CA	B-cell non-Hodgkin lymphoma	application submitted www.oncternal.com
Onivyde® Irinotecan sucrosfate	Ipsen Cambridge, MA	IL pancreatic ductal adenocarcinoma (+5-FU/LV+oxaplatin)	application submitted www.ipsen.com
ONO-4685 (PD-1 x CD3 bispecific antibody)	Ono Pharmaceutical Osaka, Japan	T-cell lymphoma	Phase I www.ono-pharma.com
ONO-7018 (MALT1 inhibitor)	Ono Pharmaceutical Osaka, Japan	CLL, non-Hodgkin lymphoma	Phase I www.ono-pharma.com
ontorpcept (TTI-621) (Fc fusion protein)	Pfizer New York, NY	leiomyosarcoma	Phase I/II www.pfizer.com
Onureg® azacitidine tablets	Bristol Myers Squibb Lawrenceville, NJ	MDS	Phase II www.bms.com
onvansertib (PLK1 inhibitor)	Cardiff Oncology San Diego, CA	metastatic colorectal cancer (Fast Track)	Phase II/III www.cardiffoncology.com
		pancreatic ductal adenocarcinoma	Phase I/II www.cardiffoncology.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
OP-1250 (estrogen receptor antagonist/SERD)	Olema Pharmaceuticals San Francisco, CA	2/3L ER+ HER2- breast cancer (monotherapy and combinations) (Fast Track)	Phase II www.olema.com
		2/3L ER+ HER2- breast cancer (combination therapy)	Phase I www.olema.com
opaganib (SK2 inhibitor) <small>ORPHAN DRUG</small>	RedHill Biopharma Tel-Aviv, Israel	cholangiocarcinoma	Phase II completed www.redhillbio.com
OPB-111077 (STAT inhibitor)	Otsuka Pharmaceutical Rockville, MD	hematologic malignancies	Phase I www.otsuka-us.com
Opdivo [®] nivolumab	Bristol Myers Squibb Lawrenceville, NJ	NSCLC (periadjuvant), stage IB-III A NSCLC (adjuvant), liver cancer (adjuvant), muscle invasive urothelial cancer (periadjuvant)	Phase III www.bms.com
Opdivo [®] + Yervoy [®] nivolumab + ipilimumab	Bristol Myers Squibb Whippany, NJ	1L bladder cancer, stage III unresectable NSCLC, 1L liver cancer, 1L MSI-high colorectal cancer	Phase III www.bms.com
Opdualag [™] nivolumab and relatlimab-rmbw	Bristol Myers Squibb Whippany, NJ	melanoma (adjuvant), 2L/3L colorectal cancer (microsatellite stable)	Phase III www.bms.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
OR2805 (T lymphocyte stimulant)	OncoResponse Seattle, WA	solid tumors	Phase I www.oncoresponse.com
ORB-011 (immunotherapy)	Orion Biosciences Waltham, MA	solid tumors	Phase I www.orionisbio.com
Orca-Q (T-cell therapy)	Orca Bio Menlo Park, CA	acute leukemia	Phase I www.orcabio.com
Orca-T (T-cell therapy) <small>ORPHAN DRUG</small>	Orca Bio Menlo Park, CA	ALL, AML, MDS ----- myelofibrosis, mixed-phenotype acute leukemia	Phase III www.orcabio.com Phase I/II www.orcabio.com
oregovomab (cancer vaccine) <small>ORPHAN DRUG</small>	CanariaBio Seoul, South Korea	ovarian cancer	Phase III www.canariabio.com
orelabrutinib (BTK inhibitor) <small>ORPHAN DRUG</small>	InnoCare Pharma Beijing, China	B-cell malignancies (Breakthrough Therapy)	Phase I www.innocrepharma.com
ORIC-114 (EGFR/HER2 inhibitor)	ORIC Pharmaceuticals South San Francisco, CA	solid tumors, including breast cancer, NSCLC, tumor agnostic	Phase I www.oricpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ORIC-533 (CD73 inhibitor)	ORIC Pharmaceuticals South San Francisco, CA	multiple myeloma	Phase I www.oricpharma.com
ORIC-944 (PRV2 inhibitor)	ORIC Pharmaceuticals South San Francisco, CA	prostate cancer	Phase I www.oricpharma.com
ORIN1001 (ERN2 inhibitor)	Orinove Newbury Park, CA	solid tumors, including breast cancer (Fast Track)	Phase I/II www.orinove.com
ORM-5029 (antibody neo-degrader conjugate)	Orum Therapeutics USA Cambridge, MA	solid tumors	Phase I www.orumrx.com
Orpathys® savolitinib	AstraZeneca Wilmington, DE HUTCHMED Florham Park, NJ	1L papillary kidney cancer (+durvalumab)	Phase III www.astrazeneca.com
Orserdu® elacestrant	Stemline Therapeutics New York, NY	ER+ HER2- breast cancer (+abemaciclib)	Phase II www.stemline.com
OSE2101 (Tedopi) (cancer vaccine) <small>ORPHAN DRUG</small>	Immunotherapeutics Nantes, France	NSCLC	Phase II completed www.ose-immuno.com
OST31-164 (listeria monocytogenes-based immunotherapy) <small>ORPHAN DRUG</small>	OS Therapies Cambridge, MA	osteosarcoma (Fast Track)	Phase II www.ostherapies.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
OTS167 (MELK inhibitor)	OncoTherapy Science Kawasaki, Japan	advanced breast cancer, triple negative breast cancer	Phase I www.oncotherapy.co.jp
OTX-2002 (mRNA therapeutic) ORPHAN DRUG	Omega Therapeutics Cambridge, MA	liver cancer	Phase I/II www.omegatherapeutics.com
OXi4503 (combretastatin A1-diphosphate) ORPHAN DRUG	Oncotelic Agoura Hills, CA	AML (Fast Track), MDS	Phase I completed www.oncotelic.com
P-300 (CBP/p300 inhibitor)	Pathos Cambridge, MA	prostate cancer	Phase I www.pathos.com
Padcev® enfortumab vedotin-ejfv	Astellas Pharma US Northbrook, IL Seagen Bothell, WA	perioperative muscle invasive bladder cancer (+pembrolizumab) (cisplatin eligible & ineligible)	Phase III www.astellas.com www.seagen.com
		locally advanced or metastatic urothelial cancer (+/- pembrolizumab), solid tumors	Phase II www.astellas.com www.seagen.com
		non-muscle invasive bladder cancer	Phase I www.astellas.com www.seagen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
padeliporfin VTP (photodynamic therapy) <small>ORPHAN DRUG</small>	ImPact Biotech Ness Ziona, Israel	upper tract urothelial cancer (Fast Track)	Phase III www.impactbiotech.com
paltusotine (SST2 agonist)	Crinetics Pharmaceuticals San Diego, CA	malignant carcinoid syndrome	Phase II www.crinetics.com
pamparib (SST2 agonist)	BeiGene Cambridge, MA	solid tumors (+temozolozide)	Phase I www.beigene.com
pamrevlumab (CTGF inhibitor) <small>ORPHAN DRUG</small>	FibroGen San Francisco, CA	locally advanced pancreatic cancer (Fast Track)	Phase III www.fibrogen.com
panobinostat (MTX110) (nanoparticle formulation) <small>ORPHAN DRUG</small>	Biodexa Pharmaceuticals Cardiff, United Kingdom	glioblastoma (Fast Track)	Phase I www.biodexapharma.com
patritumab deruxtecan (HER3-DXd) (antibody drug conjugate)	Daiichi Sankyo Basking Ridge, NJ	2L EGFRm NSCLC (Breakthrough Therapy)	Phase III www.daiichisankyo.com
		3L EGFRm NSCLC	Phase II www.daiichisankyo.com
		HER3+ breast cancer, EGFRm NSCLC (+osimertinib), NSCLC	Phase I www.daiichisankyo.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
paxalisib (GDC-0084) (PI3K/mTOR inhibitor) <small>ORPHAN DRUG</small>	Kazia Therapeutics Sydney, Australia	glioblastoma (Fast Track)	Phase II www.kaziatherapeutics.com
PBCAR19B (CAR-T cell therapy)	Precision BioSciences Durham, NC	CD19-expressing hematologic malignancies	Phase I www.precisionbiosciences.com
P-BCMA-ALLO1 (RG6538) (CAR-T cell therapy)	Poseida Therapeutics San Diego, CA Roche/Genentech South San Francisco, CA	multiple myeloma	Phase I www.poseida.com www.roche.com
PBI-200 (TRK inhibitor) <small>ORPHAN DRUG</small>	Pyramid Biosciences Waltham, MA	NTRK-fusion+ solid tumors	Phase I www.pyramidbio.com
PBP1510 (ulenistamab) (anti-PAUF/ZG16B mAb) <small>ORPHAN DRUG</small>	Prestige BioPharma Singapore	ovarian cancer, pancreatic cancer (Fast Track)	Phase I/II www.prestigebiopharma.com
PC-002 (sepantronium bromide) (DUB inhibitor)	Cothera Bioscience San Mateo, CA	high-grade lymphoma	Phase II www.cotherabio.com
PC14586 (tumor agnostic therapy)	PMV Pharmaceuticals Princeton, NJ	solid tumors with p53-Y220C-mutation (Fast Track)	Phase I/II www.pmvpharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
P-CD19CD20-ALLO1 (CAR-T cell therapy)	Poseida Therapeutics San Diego, CA Roche/Genentech South San Francisco, CA	B-cell malignancies	Phase I www.poseida.com www.roche.com
PCS3117 (RNA synthesis inhibitor) <small>ORPHAN DRUG</small>	Processa Pharmaceuticals Hanover, MD	pancreatic cancer	Phase I www.processa.com
PCS6422 (eniluracil) (DPD inhibitor)	Processa Pharmaceuticals Hanover, MD	refractory gastrointestinal tract cancer (+capecitabine)	Phase I www.processa.com
PDS0101 (HPV-specific immunotherapy)	PDS Biotechnology Florham Park, NJ	recurrent/metastatic HPV16+ head and neck cancer (Fast Track)	Phase II www.pdsbiotech.com
PEEL-224 (DNA topoisomerase I inhibitor)	PEEL Therapeutics Salt Lake City, UT	solid tumors	Phase I www.peeltx.com
pegargiminase (ADI-PEG 20) (arginine deiminase replacement) <small>ORPHAN DRUG</small>	Polaris Pharmaceuticals San Diego, CA	mesothelioma, soft tissue sarcoma	Phase III www.polarispharma.com
		hepatocellular carcinoma	Phase II www.polarispharma.com
		AML, glioblastoma	Phase I www.polarispharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
pelabresib (BET inhibitor) <small>ORPHAN DRUG</small>	MorphoSys Boston, MA	myelofibrosis (Fast Track)	Phase III www.morphosys.com
pelareorep (immuno-oncolytic reovirus)	Oncolytics Biotech San Diego, CA	HR+/HER2- breast cancer (Fast Track)	Phase II www.oncolyticsbiotech.com
Pemazyre® pemigatinib	Incyte Wilmington, DE	1L cholangiocarcinoma	Phase III www.incyte.com
		glioblastoma	Phase II www.incyte.com
penpulimab (AK105) (PD-1 mAb) <small>ORPHAN DRUG</small>	Akeso Biopharma Fremont, CA	nasopharyngeal cancer (Breakthrough Therapy)	Phase III www.akesobio.com
pepinemab (anti-SEMA4D mAb)	Vaccinex Rochester, NY	head and neck cancer, pancreatic cancer	Phase II www.vaccinex.com
pexastimogene devacirepvec (Pexa-Vec) (oncolytic vaccinia poxvirus)	SillaJen Biotherapeutics San Francisco, CA	renal cell carcinoma	Phase I/II www.sillajen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PF-06821497 (EZH2 inhibitor)	Pfizer New York, NY	prostate cancer (+enzalutamide)	Phase II www.pfizer.com
		follicular lymphoma, castration-resistant prostate cancer, SCLC	Phase I www.pfizer.com
PF-06940434 (integrin alpha-V/beta-8 antagonist)	Pfizer New York, NY	solid tumors	Phase I www.pfizer.com
PF-07062119 (GUCY2 x CD3 bispecific antibody)	Pfizer New York, NY	advanced/metastatic gastrointestinal cancer	Phase I www.pfizer.com
PF-07104091 (CDK2 inhibitor)	Pfizer New York, NY	metastatic breast cancer, ovarian cancer, SCLC	Phase I www.pfizer.com
PF-07104091 + PF-07220060 (CDK2 inhibitor + CDK2 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07220060 (CDK4 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase II www.pfizer.com
		prostate cancer (+enzalutamide)	Phase I www.pfizer.com
PF-07248144 (KAT6 epigenetic modifier)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PF-07248144 + PF-07220060 (KAT6 epigenetic modifier + CDK4 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07257876 (CD47 x PD-L1 bispecific antibody)	Pfizer New York, NY	NSCLC	Phase I www.pfizer.com
PF-07260437 (B7H4 x CD3 bispecific antibody)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07265028 (HPK1 inhibitor)	Pfizer New York, NY	solid tumors	Phase I www.pfizer.com
PF-07284892 (SHP2 inhibitor)	Pfizer New York, NY	solid tumors	Phase I www.pfizer.com
PF-07799544 (MEK brain penetrant inhibitor)	Pfizer New York, NY	solid tumors	Phase I www.pfizer.com
PF-07799933 (BRAF class 1/class 2 inhibitor)	Pfizer New York, NY	solid tumors	Phase I www.pfizer.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PH-762 (adoptive cell therapy)	Phio Pharmaceuticals Marlborough, MA	cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma	Phase I www.phiopharma.com
	Phio Pharmaceuticals Marlborough, MA AgonOx Portland, OR	solid tumors (+tumor infiltrating lymphocytes)	Phase I www.phiopharma.com www.agonox.com
PHE885 (BCMA CAR-T cell therapy)	Novartis Pharmaceuticals East Hanover, NJ	4L multiple myeloma	Phase II www.novartis.com
Phesgo® OBI pertuzumab, trastuzumab and hyaluronidase-zzxf	Roche/Genentech South San Francisco, CA	HER2+ breast cancer (on body delivery system)	Phase I www.roche.com
pimasertib (MEK1/2 inhibitor)	DayOne Pharmaceuticals Brisbane, CA	MAPK-altered solid tumors	Phase I www.dayonebio.com
Piqray® alpelisib	Novartis Pharmaceuticals East Hanover, MA	ovarian cancer	Phase III www.novartis.com
PIT565	Novartis Pharmaceuticals East Hanover, NJ	B-cell malignancies	Phase I www.novartis.com
pivekimab sunirine (MGN632) (anti-CD123 antibody drug conjugate) <small>ORPHAN DRUG</small>	ImmunoGen Waltham, MA	AML (combination therapy), blastic plasmacytoid dendritic cell neoplasm (Breakthrough Therapy)	Phase II www.immunogen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
plamotamab (CD20 x CD3 bispecific antibody)	Xencor Pasadena, CA	B-cell malignancies	Phase I www.xencor.com
plinabulin (tumor vascular disrupting agent)	BeyondSpring Pharmaceuticals New York, NY	NSCLC	Phase III completed www.beyondspringpharma.com
plogosertib (PLK1 inhibitor)	Cyclacel Pharmaceuticals Berkeley Heights, NJ	solid tumors	Phase I/II www.cyclacel.com
Pluvicto [®] lutetium Lu 177 vipivotide tetraxetan	Novartis Pharmaceuticals East Hanover, NJ	metastatic hormone-sensitive prostate cancer, metastatic castration- resistant prostate cancer (pre-taxane)	Phase III www.novartis.com
PLX038 (Topo1 inhibitor)	ProLynx San Francisco, CA	solid tumors	Phase I completed www.prolynxinc.com
PM54	PharmaMar Madrid, Spain	solid tumors	Phase I www.pharmamar.com
PMB-CT01 (BAFF CAR-T cell therapy)	Pepromene Bio Irvine, CA	ALL, non-Hodgkin lymphoma	Phase I www.pepromenebio.com
PMD-026 (RSK inhibitor)	Phoenix Molecular Designs La Jolla, CA	metastatic breast cancer, triple negative breast cancer	Phase I www.phoenixmd.ca

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
P-MUC1C-ALLO1 (CAR-T cell therapy)	Poseida Therapeutics San Diego, CA	solid tumors	Phase I www.poseida.com
PNT2002 (ionizing radiation emitter)	Lantheus Bedford, MA	metastatic prostate cancer (Fast Track)	Phase III www.lantheus.com
PNT2003 (ionizing radiation emitter)	Lantheus Bedford, MA	neuroendocrine tumors, GEP-NET	Phase III www.lantheus.com
polyclonal antibody stimulator (peptide conjugate) <small>ORPHAN DRUG</small>	Cancer Advances Durham, NC	gastric cancer, pancreatic cancer	Phase III www.canceradvances.com
PolyPEPI1018 (immunotherapy vaccine)	Treos Bio London, United Kingdom	colorectal cancer	Phase II www.treosbio.com
poziotinib (pan-HER/EGFR inhibitor)	Spectrum Pharmaceuticals Boston, MA	HER2 NSCLC with exon 20 insertion (Fast Track)	Phase II www.sppirx.com
P-PSMA-ALLO1 (CAR-T cell therapy)	Poseida Therapeutics San Diego, CA	prostate cancer	Phase I www.poseida.com
prexigebersen (GRB2 adapter inhibitor) <small>ORPHAN DRUG</small>	Bio-Path Holdings Houston, TX	AML	Phase II www.biopathholdings.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PRGN-2009 (DNA cancer vaccine)	Precigen Germantown, MD	HPV+ solid tumors	Phase II www.precigen.com
PRGN-3005 (CAR-T cell therapy)	Precigen Germantown, MD	ovarian cancer	Phase I www.precigen.com
PRGN-3006 (CAR-T cell therapy) ORPHAN DRUG	Precigen Germantown, MD	AML (Fast Track), MDS	Phase I www.precigen.com
PRGN-3007 (CAR-T cell therapy)	Precigen Germantown, MD	hematologic malignancies, solid tumors	Phase I www.precigen.com
pritumumab (IgG1κ antibody)	Nascent Biotech North Palm Beach, FL	brain cancer	Phase II www.nascentbiotech.com
prizloncabtogene autoleucel (C-CAR039) (CAR-T cell therapy) ORPHAN DRUG	Cellular Biomedicine Rockville, MD	B-cell non-Hodgkin lymphoma	Phase I www.cellbiomedgroup.com
PRJ-3024 (HPK1 inhibitor)	MingMed Biotechnology Guangzhou, China	solid tumors	Phase I www.ming-med.com
PRL-02 (abiraterone decanoate)	Propella Therapeutics Pittsboro, NC	prostate cancer	Phase I/II www.propellatx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PRL3-zumab (anti-PRL-3 antibody)	INTRA-IMMUSG Singapore	solid tumors	Phase II www.intra-immusg.com
PRO1160 (CD70 inhibitor)	ProfoundBio Woodinville, WA	nasopharyngeal carcinoma, non-Hodgkin lymphoma, renal cell carcinoma	Phase I/II www.profoundbio.com
PRO1184 (FR α inhibitor)	ProfoundBio Woodinville, WA	solid tumors	Phase I/II www.profoundbio.com
ProAgio (integrin α V β 3 antagonist)	ProDa BioTech Marietta, GA	solid tumors	Phase I
proxalutamide (GT0918) (androgen receptor antagonist)	Kintor Pharmaceuticals Suzhou, China	metastatic castration-resistant prostate cancer	Phase II www.kintor.com.cn
PRS344 (anti-PD-L1 x 401BB bispecific antibody)	Pieris Pharmaceuticals Boston, MA	solid tumors	Phase I/II www.pieris.com
PRT1419 (MCL1 inhibitor)	Prelude Therapeutics Wilmington, DE	r/r myeloid or B-cell malignancies, solid tumors	Phase I www.preludetx.com
PRT2527 (CDK9 inhibitor)	Prelude Therapeutics Wilmington, DE	hematologic malignancies, solid tumors	Phase I www.preludetx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PRT3645 (CDK4/6 inhibitor)	Prelude Therapeutics Wilmington, DE	solid tumors, including malignant mesothelioma, NSCLC	Phase I www.preludetx.com
PRT3789 (SMARCA2 inhibitor)	Prelude Therapeutics Wilmington, DE	solid tumors with SMARCA4 mutation	Phase I www.preludetx.com
PRTH-101 (DDR1 inhibitor)	Parthenon Therapeutics Boston, MA	solid tumors	Phase I www.parthenontx.com
PRV111 (cisplatin transmucosal patch) <small>ORPHAN DRUG</small>	Privo Technologies Peabody, MA	oral squamous cell carcinoma	Phase II www.privotechnologies.com
PSB202 (bispecific antibody)	Sound Biologics Bothell, WA	B-cell malignancies	Phase I www.soundbiologics.com
PSB205 (bispecific antibody)	Sound Biologics Bothell, WA	solid tumors	Phase I www.soundbiologics.com
PSMA-TAC	Lantheus Bedford, MA	prostate cancer	Phase II www.lantheus.com
PSMA-targeted indium-111 labeled trillium compound (ionizing radiation emitter)	Ratio Therapeutics Boston, MA	prostate cancer	Phase early 1 www.ratiotx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PT-112 (imifoplatin) (phosphaplatin) <small>ORPHAN DRUG</small>	Promontory Therapeutics New York, NY	metastatic castration-resistant prostate cancer, NSCLC (+avelumab)	Phase II www.promontorytx.com
		multiple myeloma, solid tumors	Phase I www.promontorytx.com
PT199 (anti-CD73 antibody)	Phanes Therapeutics San Diego, CA	solid tumors	Phase I www.phanesthera.com
PT217 (anti-DLL3 x anti-CD47 bispecific antibody)	Phanes Therapeutics San Diego, CA	DLL3-expressing solid tumors	Phase I www.phanesthera.com
PT886 (anti-Claudin 18.2 x anti-CD47 bispecific antibody) <small>ORPHAN DRUG</small>	Phanes Therapeutics San Diego, CA	gastric cancer, gastroesophageal junction cancer, pancreatic cancer	Phase I www.phanesthera.com
PUR001 (CD39 antigen inhibitor)	Purinomia Biotech Woburn, MA	solid tumors	Phase I www.purinomia.com
PV-10 (rose bengal sodium) <small>ORPHAN DRUG</small>	Provectus Biopharmaceuticals Knoxville, TN	liver cancer, melanoma	Phase I www.provectusbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
PVX-410 (multi-peptide cancer vaccine) <small>ORPHAN DRUG</small>	OncoPep Cambridge, MA	triple negative breast cancer	Phase I www.oncopep.com
PXS-5505 (LOX inhibitor) <small>ORPHAN DRUG</small>	Pharmaxis Frenchs Forest, Australia	myelofibrosis	Phase I/II www.pharmaxis.com.au
PY159 (TREM1 agonist)	Ikena Oncology Boston, MA	solid tumors	Phase I www.ikenaoncology.com
PY314 (TREM2 agonist)	Ikena Oncology Boston, MA	solid tumors	Phase I www.ikenaoncology.com
pyronaridine (cell cycle inhibitor)	Armaceutica El Paso, TX	ALL, AML	Phase II www.armaceutica.com
pyrotinib (EGFR/ErbB2 inhibitor)	Hengrui Pharmaceuticals Shanghai, China	HER2+ NSCLC with exon 20 insertion	Phase III www.hengrui.com
PYX-106 (anti-siglec15 mAb)	Pyxis Oncology Boston, MA	solid tumors	Phase I www.pyxisoncology.com
PYX-201 (antibody drug conjugate)	Pyxis Oncology Boston, MA	solid tumors	Phase I www.pyxisoncology.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Q702 (AXL/Mer/CSF1R inhibitor)	Qurient Gyeonggi-do, Korea	advanced solid tumors	Phase I/II www.qurient.com
Q901 (CDK7 inhibitor)	Qurient Gyeonggi-do, Korea	advanced solid tumors	Phase I/II www.qurient.com
QBS72S	Quagriga BioSciences Los Altos, CA	solid tumors	Phase I www.quadrigabiosciences.com
QEQ278 (NKG2D/-L pathway modulator)	Novartis Pharmaceuticals East Hanover, NJ	NSCLC	Phase I www.novartis.com
Qinlock® ripretinib	Deciphera Pharmaceuticals Waltham MA	2L gastrointestinal stromal tumors with KIT Exon 11 + 17/18	Phase III www.deciphera.com
Qtorin™ sirolimus topical gel	Palvella Therapeutics Wayne, PA	prevention of basal cell carcinomas in Gorlin syndrome	Phase II www.palvellatx.com
quemliclustat (CD73 inhibitor)	Arcus Biosciences Hayward, CA Gilead Sciences Foster City, CA	metastatic pancreatic ductal cancer (+zimirerlimb)	Phase II www.gilead.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RAPA-201 (autologous rapamycin resistant T-cell therapy)	Rapa Therapeutics Rockville, MD	multiple myeloma (Fast Track)	Phase II
		solid tumors	Phase I/II
rapcabtagene autoleucel (CD19 CAR-T cell therapy)	Novartis Pharmaceuticals East Hanover, NJ	1L high-risk large B-cell lymphoma	Phase II www.novartis.com
		ALL (adults)	Phase I www.novartis.com
RBN-2397 (PARP7 inhibitor)	Ribon Therapeutics Cambridge, MA	squamous NSCLC, solid tumors	Phase I www.ribontx.com
RBS2418 (ENPP1 inhibitor)	Riboscience Sunnyvale, CA	solid tumors	Phase I www.riboscience.com
Reblozyl [®] luspatercept-aamt	Bristol Myers Squibb Lawrenceville, NJ	1L non-transfusion-dependent MDS associated anemia, 1L transfusion-dependent myelofibrosis-associated anemia	Phase III www.bms.com
REGN4336 (PSMA x CD3 bispecific antibody)	Regeneron Tarrytown, NY	prostate cancer	Phase I www.regeneron.com
REGN5093 (MET bispecific antibody)	Regeneron Tarrytown, NY	MET-altered NSCLC	Phase I www.regeneron.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
REGN5093-M114 (MET bispecific antibody)	Regeneron Tarrytown, NY	MET-overexpressing cancer, including NSCLC	Phase I www.regeneron.com
REGN5668 (MUC16 x CD28 bispecific antibody)	Regeneron Tarrytown, NY	platinum-resistant ovarian cancer	Phase I www.regeneron.com
REGN5678 (PSMA x CD28 bispecific antibody)	Regeneron Tarrytown, NY	prostate cancer	Phase I www.regeneron.com
REGN5837 (CD22 x CD28 bispecific antibody)	Regeneron Tarrytown, NY	B-cell non-Hodgkin lymphoma	Phase I www.regeneron.com
REGN6569 (anti-GITR antibody)	Regeneron Tarrytown, NY	solid tumors	Phase I www.regeneron.com
REGN7075 (EGFR x CD28 bispecific antibody)	Regeneron Tarrytown, NY	solid tumors	Phase I www.regeneron.com
REIC gene therapy (MTG201) (adenovirus-vectored gene therapy) <small>ORPHAN DRUG</small>	Momotaro-Gene Okayama, Japan	malignant pleural mesothelioma	Phase II www.mt-gene.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
relacorilant (GR II antagonist)	Corcept Therapeutics Menlo Park, CA	platinum-resistant ovarian cancer	Phase III www.corcept.com
		adrenal cancer with cortisol excess	Phase I www.corcept.com
relatlimab-rmbw subcutaneous (LAG3 inhibitor)	Bristol Myers Squibb Lawrenceville, NJ Halozyme San Diego, CA	1L melanoma (+nivolumab +rHuPH20)	Phase III www.bms.com
REM-001 (photodynamic therapy) <small>ORPHAN DRUG</small>	Kintara Therapeutics San Diego, CA	basal cell carcinoma, Nevus syndrome	Phase I www.kintara.com
RenovoGem™ gemcitabine <small>ORPHAN DRUG</small>	RenovoRx San Jose, CA	pancreatic cancer	Phase III www.renovorx.com
repotrectinib (ALK/ROS 1 inhibitor) <small>ORPHAN DRUG</small>	Bristol Myers Squibb Lawrenceville, NJ	ROS1 NSCLC (Fast Track) (Breakthrough Therapy)	application submitted www.bms.com
		NTRK Pan-solid tumors (Fast Track) (Breakthrough Therapy)	Phase II www.bms.com
Reqorsa® quaratusugene ozeplasmid	Genprex Austin, TX	NSCLC (Fast Track), SCLC	Phase I www.genprex.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Retsevmo® selpercatinib	Lilly Indianapolis, IN	RET+ NSCLC (adjuvant), 1L medullary thyroid cancer	Phase III www.lilly.com
revumenib (SNDX-5613) (MLL inhibitor) <small>ORPHAN DRUG</small>	Syndax Pharmaceuticals Waltham, MA	acute leukemia with KMT2 gene rearrangement, acute leukemia with NPM1 mutation (Fast Track) (Breakthrough Therapy), colorectal cancer	Phase I/II www.syndax.com
		acute leukemia, acute leukemia (+chemotherapy)	Phase I www.syndax.com
RG6007 (HLA-A2-WT1 x CD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	AML	Phase I www.roche.com
RG6076 (englumafusp alfa) (CD19 x 4-1BBL bispecific antibody)	Roche/Genentech South San Francisco, CA	hematologic malignancies	Phase I www.roche.com
RG6139 (tobemstomig) (PD-1 x LAG3 bispecific antibody)	Roche/Genentech South San Francisco, CA	solid tumors	Phase II www.roche.com
RG6156 (EGFRVIII x CD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	glioblastoma	Phase I www.roche.com
RG6160 (cevastamab) (FcRH5 x CD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	multiple myeloma	Phase I www.roche.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RG6189 (FAP x CD40 bispecific antibody)	Roche/Genentech South San Francisco, CA	solid tumors (+/- atezolizumab)	Phase I www.roche.com
RG6194 (runimotamab) (GER2 x CD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	breast cancer	Phase I www.roche.com
RG6234 (forimtamig) (GPRC5D x CD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	multiple myeloma	Phase I www.roche.com
RG6279 (eciskafusp alfa) (PD-1/IL-2 fusion protein)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6286	Roche/Genentech South San Francisco, CA	colorectal cancer	Phase I www.roche.com
RG6292 (CD25 mAb combinations)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6333 (CD19 x CD28 bispecific antibody)	Roche/Genentech South San Francisco, CA	r/r non-Hodgkin lymphoma (+glofitamab)	Phase I www.roche.com
RG6344 (BRAF inhibitor)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6353 (HLA-G x CD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RG6411	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6433 (SHP2 inhibitor)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6440 (anti-latent TG-β1)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6524 (DLL3/CD3/CD137 trispecific antibody)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG6526 (camonsertib) (ATR inhibitor)	Repare Therapeutics Cambridge, MA Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.reparerx.com www.roche.com
RG6537 (androgen receptor degrader)	Roche/Genentech South San Francisco, CA	metastatic castration-resistant prostate cancer	Phase I www.roche.com
RG7802 (cibisatamab) (T-cell bispecific antibody)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
RG7827 (FAP-4-1BBL)	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RGT-264 (HPK1 inhibitor)	Regor Therapeutics Cambridge, MA	solid tumors	Phase I www.regor.com
RGT-419B (CDK2/4/6 inhibitor)	Regor Therapeutics Cambridge, MA	HR+ HER2- metastatic breast cancer	Phase I www.regor.com
rhenium (186Re) obisbameda (ionizing radiation emitter) <small>ORPHAN DRUG</small>	Plus Therapeutics Austin, TX	glioblastoma (Fast Track)	Phase II www.plustherapeutics.com
		leptomeningeal metastases (Fast Track)	Phase I www.plustherapeutics.com
rhenium-188 P 2045 (ionizing radiation emitter)	Andarix Pharmaceuticals Somerville, MA	NSCLC, SCLC	Phase I/II www.andarix.com
rilvegostomig (AZD2936) (TIGIT inhibitor)	AstraZeneca Wilmington, DE	solid tumors	Phase II www.astrazeneca.com
RiMO-301 (immunotherapeutic)	RiMO Therapeutics Elk Grove Village, IL	head and neck cancer	Phase I
rituximab-ADNAB (rituximab biosimilar)	Sorrento Therapeutics San Diego, CA	B-cell lymphoma	Phase I www.sorrentotherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
rivoceranib (VEGFR-2 inhibitor) <small>ORPHAN DRUG</small>	Elevor Therapeutics Fort Lee, NJ	1L hepatocellular carcinoma	application submitted www.elevartherapeutics.com
		gastric cancer	Phase III www.elevartherapeutics.com
		adenoid cystic carcinoma, colorectal cancer	Phase II www.elevartherapeutics.com
RLY-2608 (PI3K α inhibitor)	Relay Therapeutics Cambridge, MA	solid tumors	Phase I www.relaytx.com
RLY-4008 (FGFR2 inhibitor)	Relay Therapeutics Cambridge, MA	solid tumors	Phase I www.relaytx.com
RLY-5836 (PI3K α inhibitor)	Relay Therapeutics Cambridge, MA	solid tumors, including breast cancer	Phase I www.relaytx.com
RMC-4630 (vociprotafib) (SHP2 inhibitor)	Revolution Medicines Redwood City, CA	solid tumors, including colorectal cancer, NSCLC, pancreatic ductal adenocarcinoma	Phase II www.revmed.com
RMC-5552 (MTORC1 inhibitor)	Revolution Medicines Redwood City, CA	solid tumors	Phase I www.revmed.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RMC-6236 (Ras inhibitor)	Revolution Medicines Redwood City, CA	solid tumors, including colorectal cancer, NSCLC, pancreatic ductal adenocarcinoma	Phase I www.revmed.com
RMC-6291 (KRAS inhibitor)	Revolution Medicines Redwood City, CA	solid tumors, including colorectal cancer, NSCLC, pancreatic ductal adenocarcinoma	Phase I www.revmed.com
RMC-9805 (KRAS inhibitor)	Revolution Medicines Redwood City, CA	KRAS G12D solid tumors	Phase I www.revmed.com
RNK-05047 (BRD4 protein degrader)	Ranok Therapeutics Waltham, MA	DLBCL, solid tumors	Phase I/II www.ranoktherapeutics.com
RO7589831	Roche/Genentech South San Francisco, CA	solid tumors	Phase I www.roche.com
ropidoxuridine (radiation sensitizer) <small>ORPHAN DRUG</small>	Shuttle Pharmaceuticals Rockville, MD	brain tumors, sarcoma	Phase I www.shuttepharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RP1 (vusolimogene oderparepvec) (oncolytic immunotherapy)	Replimune Woburn, MA	cutaneous squamous cell carcinoma (+cemiplimab)	Phase II www.replimune.com
		melanoma, non-melanoma skin cancer, MSI-H skin cancer (+nivolumab)	Phase II www.replimune.com
		skin cancers in organ transplantation	Phase I/II www.replimune.com
RP2 (oncolytic immunotherapy)	Replimune Woburn, MA	solid tumors (+nivolumab)	Phase I www.replimune.com
RP2/RP3 (oncolytic immunotherapy)	Replimune Woburn, MA	3L colorectal cancer (combination therapy)	Phase II www.replimune.com
RP3 (oncolytic immunotherapy)	Replimune Woburn, MA	hepatocellular carcinoma, head and neck cancer	Phase II www.replimune.com
		solid tumors (+nivolumab)	Phase I www.replimune.com
RP-6306 (PYMYT1 inhibitor)	Repare Therapeutics Cambridge, MA	solid tumors (Fast Track)	Phase I www.reparerx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RRx-001 (anti-CD47) <small>ORPHAN DRUG</small>	EpigentRx La Jolla, CA	3L+ SCLC	Phase III www.epigentrx.com
RSC-1255 (ras gene inhibitor)	RasCal Therapeutics Palo Alto, CA	solid tumors	Phase I www.rascaltherapeutics.com
rSIFN-co (crystalline recombinant interferon)	Huiyang Life Science and Technology Sichuan, China	solid tumors	Phase I www.huiyanglife.com
RSO-021 (peroxidase inhibitor)	RS Oncology Cambridge, MA	malignant pleural mesothelioma, malignant disease to the lungs, pleural effusion	Phase I www.rsoncology.com
rucosopasem manganese (small molecule) <small>ORPHAN DRUG</small>	Galera Therapeutics Malvern, PA	NSCLC, pancreatic cancer	Phase II www.galeratx.com
RXC004 (PORCN inhibitor)	Redx Pharma Macclesfield, United Kingdom	colorectal cancer	Phase II www.redxpharma.com
Rybrevant® amivantamab-vmjw	J&J Innovative Medicine Raritan, NJ	1L NSCLC (+chemotherapy)	application submitted www.jansen.com
		NSCLC (subcutaneous)	Phase III www.janssen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Rydapt® midostaurin	Novartis Pharmaceuticals East Hanover, NJ	AML (pediatric)	Phase II www.novartis.com
RYZ101 (actinium-225 dotate)	RayzeBio San Diego, CA	neuroendocrine tumors, SCLC	Phase I www.rayzebio.com
S95018 (Syn023) (anti-TIM3 mAb)	Servier Boston, MA	solid tumors	Phase I/II www.servier.us
S95024 (Sym024) (anti-CD73 mAb)	Servier Boston, MA	solid tumors	Phase I/II www.servier.us
S95027 (Sym015) (cMet inhibitor)	Servier Boston, MA	NSCLC	Phase II www.servier.us
S95029 (Sym025) (anti-NKG2A antibody)	Servier Boston, MA	solid tumors	Phase I/II www.servier.us
sabatolimab (TIM3 antagonist) <small>ORPHAN DRUG</small>	Novartis Pharmaceuticals East Hanover, MA	MDS (Fast Track)	Phase III www.novartis.com
		AML (maintenance), unfit AML	Phase II www.novartis.com
		low-risk MDS	Phase I www.novartis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SAIL66	Chugai Pharma USA Berkeley Heights, NJ	CLDN6+ solid tumors	Phase I www.chugai-pharm.com
Saltikva [®] IL2 immunotherapy <small>ORPHAN DRUG</small>	Salspera Cambridge, MA	pancreatic cancer (Fast Track)	Phase II www.salspera.com
samuraciclib (CT7001) (CDK7 inhibitor)	Carrick Therapeutics Boston, MA	breast cancer (Fast Track)	Phase II www.carricktherapeutics.com
sananimab (PF-06801591) (anti-PD-1 antibody)	Pfizer New York, NY	non-muscle invasive bladder cancer (+BCG)	Phase III www.pfizer.com
SAR442257 (CD38/CD28/CD3 T-cell engager)	Sanofi Bridgewater, NJ	multiple myeloma (Fast Track), non-Hodgkin lymphoma	Phase I www.sanofi.com
SAR443216 (CD3/CD28/HER2 T-cell engager)	Sanofi Bridgewater, NJ	gastric cancer	Phase I www.sanofi.com
SAR443579 (IPH-6101) (trifunctional anti-CD123 NK cell engager)	Innate Pharma Marseille, France Sanofi Bridgewater, NJ	AML (Fast Track)	Phase I www.sanofi.com
SAR444200 (anti-GPC3/TCR nanobody)	Sanofi Bridgewater, NJ	solid tumors	Phase I www.sanofi.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SAR444245 (pegenzileukin) (non-alpha IL-2 synthorin)	Sanofi Bridgewater, NJ	solid tumors	Phase I www.sanofi.com
SAR444881 (BND-22) (anti-ILT2 mAb)	Biond Biologics Misgav, Israel Sanofi Bridgewater, NJ	solid tumors	Phase I www.biondbio.com www.sanofi.com
SAR445419 (NK cell-based immunotherapy)	Sanofi Bridgewater, NJ	AML	Phase I www.sanofi.com
SAR445514 (trifunctional anti-BCMA NK cell engager)	Sanofi Bridgewater, NJ	r/r multiple myeloma	Phase I www.sanofi.com
SAR445710 (anti-PD-L1/IL-15 fusion protein)	Sanofi Bridgewater, NJ	solid tumors	Phase I www.sanofi.com
SAR445877 (anti-PD1/IL-15 fusion protein)	Sanofi Bridgewater, NJ	solid tumors	Phase I www.sanofi.com
SAR446309 (HER2 T-cell engager)	Sanofi Bridgewater, NJ	solid tumors	Phase I www.sanofi.com
SAR-BBN (theranostic)	Clarity Pharmaceuticals Eveleigh, Australia	prostate cancer	Phase I/II www.claritypharmaceuticals.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SAR-bisPSMA (theranostic)	Clarity Pharmaceuticals Eveleigh, Australia	prostate cancer	Phase I www.claritypharmaceuticals.com
Sarclisa® isatuximab-irfc	Sanofi Bridgewater, NJ	1L newly-diagnosed multiple myeloma, (transplant eligible and ineligible), smoldering multiple myeloma, 1/2L AML, ALL (pediatric), r/r multiple	Phase III www.sanofi.com
		1/2L AML, ALL (pediatric), r/r multiple myeloma	Phase II www.sanofi.com
Sartate (theranostic) <small>ORPHAN DRUG</small>	Clarity Pharmaceuticals Eveleigh, Australia	neuroblastoma	Phase I www.claritypharmaceuticals.com
SB 11285 (STING agonist)	f-Star Therapeutics Cambridge, MA	solid tumors	Phase I www.f-star.com
SBP-101 (poly[ADP-ribose] inhibitor) <small>ORPHAN DRUG</small>	Panbela Therapeutics Waconia, MN	1L metastatic pancreatic ductal adenocarcinoma (Fast Track)	Phase II www.panbela.com
		pancreatic ductal adenocarcinoma (neoadjuvant)	Phase I www.panbela.com
SC291 (CAR-T cell therapy)	Sana Biotechnology Seattle, WA	CLL (Fast Track), non-Hodgkin lymphoma	Phase I www.sana.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Scemblix® asciminib	Novartis Pharmaceuticals East Hanover, NJ	1L CML	Phase III www.novartis.com
		2L CML (pediatric)	Phase II www.novartis.com
SD-101 (TLR9 agonist)	TriSalus Life Sciences Westminster, CO	hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma	Phase I www.trisalusifesci.com
SEA-CD70 (antibody drug conjugate)	Seagen Bothell, WA	AML, MDS	Phase I www.seagen.com
SEA-TGT (TIGIT inhibitor)	Seagen Bothell, WA	lymphoma, solid tumors	Phase I www.seagen.com
seclidemstat (SP-2577) (LSD1 inhibitor) <small>ORPHAN DRUG</small>	Salaris Pharmaceuticals Houston, TX	Ewing's sarcoma (Fast Track)	Phase I www.salarispharma.com
sEphB4-HAS (recombinant fusion protein)	VasGene Therapeutics Los Angeles, CA	Kaposi's sarcoma, urothelial cancer (+pembrolizumab)	Phase II www.vasgene.com
serplulimab (HLX10) (anti-PD1 mAb) <small>ORPHAN DRUG</small>	Henlius Biotech Shanghai, China	NSCLC, extensive-stage SCLC, limited-stage SCLC	Phase III www.henlius.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
setanaxib (NOX1/NOX4 inhibitor)	Calliditas Therapeutics Hoboken, NJ	head and neck cancer (+pembrolizumab)	Phase II www.calliditas.se
seviprotimut-L (cancer vaccine) ORPHAN DRUG	Polynoma San Diego, CA	melanoma (Fast Track)	Phase II completed www.polynoma.com
SG2501 (CD38 x CD47 bispecific antibody)	Sumgen Biotech Hangzhou, China	hematologic malignancies	Phase I www.sungenbio.com
SGN1 (bacterial replacement therapy)	Sinogen Pharmaceutical Guangzhou, China	solid tumors	Phase I www.huajinpharmtech.com
SGN-ALPV (antibody drug conjugate)	Seagen Bothell, WA	solid tumors	Phase I www.seagen.com
SGN-B6A (antibody drug conjugate)	Seagen Bothell, WA	solid tumors	Phase I www.seagen.com
SGN-B7H4V (antibody drug conjugate)	Seagen Bothell, WA	solid tumors	Phase I www.seagen.com
SGN-BB228 (PRS-346) (CD228 x 4-1BB bispecific antibody)	Pieris Pharmaceuticals Boston, MA Seagen Bothell, WA	melanoma, solid tumors	Phase I www.pieris.com www.seagen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SGN-PDL1V (antibody drug conjugate)	Seagen Bothell, WA	solid tumors	Phase I www.seagen.com
SGN-STNV (antibody drug conjugate)	Seagen Bothell, WA	solid tumors	Phase I www.seagen.com
SGR-1505 (MALT1 inhibitor)	Schrödinger New York, NY	B-cell malignancies	Phase I www.schrodinger.com
SGR-2921 (CDC7 inhibitor)	Schrödinger New York, NY	AML, MDS	Phase I www.schrodinger.com
SGT-53 (gene therapy)	SynerGene Therapeutics Potomac, MD	pancreatic cancer	Phase II
SH-105	Shorla Oncology Cambridge, MA	breast cancer, ovarian cancer	application submitted www.shorlaoncology.com
SHR-A1811 (antibody drug conjugate)	Hengrui Pharmaceuticals Shanghai, China	solid tumors	Phase I www.hengrui.com
SIM1811-03 (IgG1 mAb)	Simcere Pharmaceutical Nanjing, China	CTCL, solid tumors	Phase I www.en.simcere.com
sintilimab (IgG4 mAb)	Innovent Biologics Jiangsu, China	esophageal cancer	Phase III www.innoventbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SIRPant-M (activated macrophage immunotherapy)	SIRPant Immunotherapeutics Hummelstown, PA	non-Hodgkin lymphoma	Phase I www.sirpantimmunotx.com
SKI-G-801 (FLT3 inhibitor)	Genosco Billerica, MA Oscotec Gyeonggi-do, South Korea	AML	Phase I www.genosco.com www.oscotec.com
SKL27969 (PRMT5 inhibitor)	SK Life Science Paramus, NJ	solid tumors	Phase I www.sklifesciencesinc.com
SL-172154 (recombinant fusion protein)	Shattuck Labs Austin, TX	AML, MDS, ovarian cancer (combination therapy)	Phase I www.shattucklabs.com
SL-701 (dendritic cell cancer vaccine) <small>ORPHAN DRUG</small>	Stemline Therapeutics New York, NY	glioblastoma	Phase II www.stemline.com
SL-901 (PI3K inhibitor)	Stemline Therapeutics New York, NY	solid tumors	Phase I www.stemline.com
SLATE-KRAS (neoantigen vaccine)	Gritstone bio Emeryville, CA	KRAS-driven solid tumors, including NSCLC	Phase II www.gritstonebio.com
SLC-391 (AXL inhibitor)	Signal Chem Lifesciences Richmond, Canada	NSCLC (+pembrolizumab)	Phase I/II www.signalchemlifesciences.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SMART-101 (T-cell progenitor therapy) <small>ORPHAN DRUG</small>	Smart Immune Paris, France	hematologic malignancies (Fast Track)	Phase I/II www.smart-immune.com
SNK01 (natural killer cell therapy)	NKGen Biotech Irvine, CA	solid tumors, including NSCLC (+AFM24)	Phase I www.nkgenbiotech.com
SNK02 (natural killer cell therapy)	NKGen Biotech Irvine, CA	solid tumors	Phase I www.nkgenbiotech.com
SNS-101 (VISTA inhibitor)	Sensei Biotherapeutics Rockville, MD	solid tumors	Phase I www.senseibio.com
SNX281 (STING agonist)	Stingthera Boston, MA	lymphoma, solid tumors (+pembrolizumab)	Phase I
Sofusa® anti-CTLA4 (CTLA4 inhibitor)	Sorrento Therapeutics San Diego, CA	melanoma	Phase I www.sorrentotherapeutics.com
Sofusa® anti-PD-1 (anti-PD-1 antagonist)	Sorrento Therapeutics San Diego, CA	CTCL, melanoma	Phase I www.sorrentotherapeutics.com
SON-1010 (IL-2 based fusion construct)	Sonnet Biotherapeutics Princeton, NJ	ovarian cancer (+atezolizumab)	Phase I/II www.sonnetbio.com
		advanced solid tumors	Phase I www.sonnetbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
sotigalimab (CD40 agonist) <small>ORPHAN DRUG</small>	Pyxis Oncology Boston, MA	liposarcoma, melanoma	Phase II www.pyxisoncology.com
sovilnesib (KIF18A inhibitor)	Volastra Therapeutics New York, NY	solid tumors	Phase I www.volastratx.com
SPYK04	Chugai Pharma USA Berkeley Heights, NJ	solid tumors	Phase I www.chugai-pharm.com
SQ3370 (type II DNA topoisomerase inhibitor)	Shasqi San Francisco, CA	solid tumors	Phase I www.shasqi.com
SQZ-AAC-HPV (cell therapy)	SQZ Biotechnologies Watertown, MA	HPV16+ solid tumors	Phase I www.sqzbiotech.com
SQZ-eAPC-HPV (cell therapy)	SQZ Biotechnologies Watertown, MA	HPV16+ solid tumors (Fast Track)	Phase I www.sqzbiotech.com
SRK-181 (TGFβ1 inhibitor)	Scholar Rock Cambridge, MA	solid tumors	Phase I www.scholarrock.com
ST-067 (IL-18 activator)	Simcha Therapeutics New Haven, CT	solid tumors	Phase I/II www.simchatx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ST101 (C/EBP β inhibitor) <small>ORPHAN DRUG</small>	Sapience Therapeutics Tarrytown, NY	breast cancer, glioblastoma, melanoma, prostate cancer	Phase I/II www.sapiencetherapeutics.com
ST316 (β -catenin antagonist)	Sapience Therapeutics Tarrytown, NY	solid tumors	Phase I/II www.sapiencetherapeutics.com
STA551 (CD37 switch antibody)	Chugai Pharma USA Berkeley Heights, NJ	solid tumors	Phase I www.chugai-pharm.com
STAR0602 (TCR bifunctional antibody-fusion)	Marengo Therapeutics Cambridge, MA	solid tumors	Phase I/II www.marengotx.com
STAR-LLD (lenalidomide continuous delivery)	Starton Therapeutics Paramus, NJ	CLL, multiple myeloma	Phase I completed www.startontx.com
STC-15 (METTL3 inhibitor)	STORM Therapeutics Cambridge, United Kingdom	advanced solid tumors	Phase I www.stormtherapeutics.com
stenoparib (PARP/tankyrase inhibitor)	Allarity Therapeutics Boston, MA	3L ovarian cancer	Phase II www.allarity.com
STI-1386 (oncolytic virus therapy)	Sorrento Therapeutics San Diego, CA	CNS tumors, solid tumors	Phase I www.sorrentotherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
STI-1492 (CD38 DAR-T)	Sorrento Therapeutics San Diego, CA	multiple myeloma	Phase I www.sorrentotherapeutics.com
STI-3031 (danburstotug) (anti-PD-L1 antibody)	Sorrento Therapeutics San Diego, CA	cervical cancer	Phase III www.sorrentotherapeutics.com
STI-6129 (CD38 ADC)	Sorrento Therapeutics San Diego, CA	esophageal cancer, multiple myeloma, T-cell ALL	Phase I www.sorrentotherapeutics.com
STI-6643 (CD47 mAb)	Sorrento Therapeutics San Diego, CA	advanced solid tumors	Phase I www.sorrentotherapeutics.com
Stivarga [®] regorafenib	Bayer Pharmaceuticals Whippany, NJ	solid tumors (+nivolumab)	Phase II www.bayer.com
STK-009 + SYNCAR-001 (CAR-T cell therapy)	SyntheKine Menlo Park, CA	hematologic malignancies	Phase I www.synthekine.com
STK-012 (IL-2 partial agonist)	SyntheKine Menlo Park, CA	solid tumors	Phase I www.synthekine.com
STM-416 (TLR-7/8 agonist)	Surge Therapeutics Cambridge, MA	non-muscle invasive bladder cancer	Phase I www.surgetx.com
STP1002 (tankyrase inhibitor)	ST Pharm Seoul, South Korea	solid tumors	Phase I www.stpharm.co.kr

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
STP705 (TGF-β1/COX-2 inhibitor)	Sirnaomics Germantown, MD	basal cell carcinoma, squamous cell carcinoma	Phase II www.siraomics.com
		liver cancer	Phase I www.siraomics.com
STP707 (TGF-β1/COX-2 inhibitor)	Sirnaomics Germantown, MD	liver cancer, squamous cell carcinoma, NSCLC, solid tumors	Phase I www.siraomincs.com
STP938 (CTPS1 inhibitor)	Step Pharma Saint-Genis-Pouilly, France	B-cell lymphoma, T-cell lymphoma	Phase I/II www.step-ph.com
STRO-001 (antibody drug conjugate)	Sutro Biopharma South San Francisco, CA	lymphoma, multiple myeloma	Phase I www.sutrobio.com
STRO-002 (antibody drug conjugate)	Sutro Biopharma South San Francisco, CA	ovarian cancer (Fast Track), ovarian cancer (+bevacizumab), endometrial cancer	Phase I www.sutrobio.com
STX-478 (PI3Kα inhibitor)	Scorpion Therapeutics Boston, MA	solid tumors	Phase I/II www.scorpiontx.com
STX-721 (EGFR antagonist)	Scorpion Therapeutics Boston, MA	NSCLC	Phase I/II www.scorpiontx.com
subasumstat (TAK-981) (SUMO inhibitor)	Takeda Lexington, MA	multiple myeloma, non-Hodgkin lymphoma, solid tumors	Phase II www.takeda.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
sudocetaxel zendusortide (TH1902) (SORT1 inhibitor)	Theratechnologies Jersey City, NJ	advanced solid tumors (Fast Track)	Phase I www.theratech.com
sugemalimab (anti-PD-L1 antibody) ORPHAN DRUG	EQRx Cambridge, MA CStone Pharmaceuticals Suzhou, China	1L metastatic NSCLC, locally advanced unresectable NSCLC	Phase III www.eqr.com
		extranodal natural killer T-cell lymphoma (Breakthrough Therapy)	Phase II completed www.eqr.com
SurVaxM (peptide cancer vaccine) ORPHAN DRUG	MimiVax Buffalo, NY	newly-diagnosed glioblastoma (+temozolomide) (Fast Track)	Phase II www.mimivx.com
sutetinib (small molecule)	Teligene US Thousand Oaks, CA	NSCLC	Phase II www.teligenebio.com
SX-682 (CXCR1/2 inhibitor)	Syntrix Biosystems Auburn, MA	metastatic melanoma, MDS	Phase I www.syntrixbio.com
SY-2101 (arsenic trioxide oral) ORPHAN DRUG	Syros Pharmaceuticals Cambridge, MA	acute promyelocytic leukemia	Phase II www.syros.com
SY-5609 (CDK7 inhibitor) ORPHAN DRUG	Syros Pharmaceuticals Cambridge, MA	colorectal cancer, pancreatic cancer	Phase I www.syros.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
SynKIR-110 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Verismo Therapeutics Philadelphia, PA	mesothelin-expressing ovarian cancer, cholangiocarcinoma, mesothelioma (Fast Track)	Phase I www.verismotherapeutics.com
TAB004 (tifemalimab) (anti-BTLA mAb)	Junshi Biosciences Shanghai, China	solid tumors	Phase I www.junshipharma.com
tabelecleucel (tab-cel) (EBV-specific T-cell therapy) <small>ORPHAN DRUG</small>	Atara Biotherapeutics Thousand Oaks, CA	EBV+ post-transplant lymphoproliferative disease (Breakthrough Therapy)	Phase III www.atarabio.com
		EBV+ cancers	Phase II www.atarabio.com
TAC-001 (TLR9 agonist)	Tallac Therapeutics Burlingame, CA	solid tumors	Phase I/II www.tallactherapeutics.com
TAC01-CLDN18.2 (T cell therapy)	Triumvira Immunologics Austin, TX	solid tumors	Phase I www.triumvira.com
TAC01-HER2 (T cell therapy)	Triumvira Immunologics Austin, TX	solid tumors	Phase I www.triumvira.com
TACH101 (KDM4 inhibitor)	Tachyon Therapeutics Houston, TX	advanced solid tumors	Phase I www.tachyontx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TAEk-VAC (HERBy cancer vaccine)	Bavarian Nordic Durham, NC	HER2/brachyury-expressing solid tumors	Phase I www.bavarian-nordic.com
Tagrisso® osimertinib	AstraZeneca Wilmington, DE HUTCHMED Florham Park, NJ	1L EGFRm NSCLC (+CTx), advanced EGFRm NSCLC	Phase III www.astrazeneca.com
		2L EGFRm osimertinib-resistant NSCLC, advanced EGFRm NSCLC	Phase II www.astrazeneca.com
		advanced EGFRm NSCLC (+savolitinib or selumetinib)	Phase I www.astrazeneca.com
TAK-007 (CD19 CAR-NK cell therapy)	Takeda Pharmaceuticals Lexington, MA	hematologic malignancies	Phase II www.takeda.com
TAK-012 (cell therapy)	Takeda Pharmaceuticals Lexington, MA	r/r AML	Phase I www.takeda.com
TAK-102 (GPC3 CAR-T cell therapy)	Takeda Pharmaceuticals Lexington, MA	solid tumors	Phase I www.takeda.com
TAK-103 (mesothelin CAR-T cell therapy)	Takeda Pharmaceuticals Lexington, MA	solid tumors	Phase I www.takeda.com
TAK-186 (T cell engager)	Takeda Pharmaceuticals Lexington, MA	EGFR expressing solid tumors	Phase I www.takeda.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TAK-280 (T cell engager)	Takeda Pharmaceuticals Lexington, MA	B7-H3 expressing solid tumors	Phase I www.takeda.com
TAK-500 (STING agonist)	Takeda Pharmaceuticals Lexington, MA	solid tumors	Phase I www.takeda.com
TAK-676 (STING agonist)	Takeda Pharmaceuticals Lexington, MA	solid tumors, including NSCLC	Phase I www.takeda.com
TAK-940 (CAR-T cell therapy)	Takeda Pharmaceuticals Lexington, MA	hematologic malignancies	Phase I www.takeda.com
taletrectinib (ROR1 inhibitor)	AnHeart Therapeutics New York, NY	1L/2L ROS1+ NSCLC (Breakthrough Therapy)	Phase III www.anheart.com
Talvey™ talquetamab	J&J Innovative Medicine Raritan, NJ	r/r multiple myeloma A-CD38 naïve	Phase III www.janssen.com
Talzenna® talazoparib	Pfizer New York, NY	DNA damage repair-deficient metastatic castration-sensitive prostate cancer (+enzalutamide)	Phase III www.pfizer.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tamibarotene (RAR α agonist) <small>ORPHAN DRUG</small>	Syros Pharmaceuticals Cambridge, MA	MDS (Fast Track)	Phase III www.syros.com
		AML	Phase II www.syris.com
TAR-200 (RIS/gemcitabine + cetrelimab)	J&J Innovative Medicine Raritan, NJ	muscle invasive bladder cancer, non-muscle invasive bladder cancer (BCG-naïve high risk)	Phase III www.janssen.com
		non-muscle invasive bladder cancer	Phase II www.janssen.com
TARA-002 (picibanil biosimilar) <small>ORPHAN DRUG</small>	Protara Therapeutics New York, NY	non-muscle invasive bladder cancer	Phase I www.protaratx.com
tarlatamab (AMG 757) (DLL3 x CD3 bispecific T-cell engager)	Amgen Thousand Oaks, CA	SCLC	Phase III www.amgen.com
		neuroendocrine prostate cancer, SCLC (combination therapy)	Phase I www.amgen.com
TAS0612 (RSK inhibitor)	Taiho Oncology Princeton, NJ	solid tumors	Phase I www.taihooncology.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TAS0728 (HER2 inhibitor)	Taiho Oncology Princeton, NJ	solid tumors	Phase I/II www.taihooncology.com
TAS0953/HM06 (vepafestinin) (RET inhibitor)	Helsinn Iselin, NJ	RET-altered solid tumors, including NSCLC	Phase I/II www.helsinn.com
TAS-116 (pimipitespib) (HSP90 inhibitor)	Taiho Oncology Princeton, NJ	solid tumors	Phase I www.taihooncology.com
TAS-117 (Akt inhibitor)	Taiho Oncology Princeton, NJ	solid tumors with germline PTEN mutations	Phase II www.taihooncology.com
TAS1440 (LSD1 inhibitor)	Astex Pharmaceuticals Pleasanton, CA	AML	Phase I www.astx.com
TAS2940 (ERBB inhibitor)	Taiho Oncology Princeton, NJ	solid tumors, including NSCLC	Phase I/II www.taihooncology.com
TAS3351 (EGFR inhibitor)	Taiho Oncology Princeton, NJ	NSCLC	Phase I/II www.taihooncology.com
TAS3681 (androgen receptor antagonist)	Taiho Oncology Princeton, NJ	prostate cancer	Phase I www.taihooncology.com
TAVO412 (cMet x EGFR x VEGF trispecific antibody)	Tavotek Biotherapeutics Lower Gwynedd, PA	solid tumors	Phase I www.tavotek.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tavokinogene telseplasmid (DNA-based IL-12) <small>ORPHAN DRUG</small>	OncoSec Medical Ewing, NJ	melanoma (Breakthrough Therapy) (Fast Track), triple negative breast cancer	Phase II www.oncosec.com
TAVT-45 (abiraterone acetate granules for oral suspension)	Tavanta Therapeutics King of Prussia, PA	prostate cancer	Phase III www.tavanta.com
Tazverik® tazemetostat	Ipsen Cambridge, MA	2L follicular lymphoma (combination therapy)	Phase III www.ipsen.com
		metastatic castration-resistant prostate cancer	Phase II www.ipsen.com
TBC-1002 (Lipax) (proliposomal paclitaxel)	LIPAC Oncology Pomona, CA	non-muscle invasive bladder cancer	Phase II completed www.lipaconology.com
TBio-4101 (TIDAL-01) (TIL cell therapy)	Turnstone Biologics La Jolla, CA	solid tumors	Phase I www.turnstonebio.com
TC-510 (T cell therapy)	TCR2 Therapeutics Cambridge, MA	mesothelioma, pleural mesothelioma, malignant mesothelioma peritoneum, ovarian cancer, pancreatic cancer, colorectal cancer, triple negative breast cancer	Phase I/II www.tcr2.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tebotelimab (PD-1 x LAG3 bispecific antibody)	MacroGenics Rockville, MD	hematologic malignancies	Phase I www.macrogenics.com
TEC-001 (tirapazamine) (type II DNA topoisomerase inhibitor)	Teclison Princeton, NJ	colorectal cancer, gastric cancer, liver cancer, NSCLC	Phase II www.teclison.com
		neuroendocrine cancer	Phase I www.teclison.com
Tecartus [®] brexucabtagene sutoeucel	Gilead Sciences Foster City, CA	ALL/non-Hodgkin lymphoma (pediatric), rare B-cell malignancies	Phase II www.gilead.com
Tecentriq [®] atezolizumab	Roche/Genentech South San Francisco, CA	unresectable/metastatic hepatocellular carcinoma (subcutaneous)	application submitted www.roche.com
		NSCLC (periadjuvant), high-risk non-muscle invasive bladder cancer, head and neck cancer (adjuvant), 1L triple negative breast cancer, liver cancer (adjuvant), muscle invasive bladder cancer (ctDNA+ high risk), 1L SCLC	Phase III www.roche.com
		solid tumors (Morpheus platform)	Phase I www.roche.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Tecvayli® teclistamab-cgyv <small>ORPHAN DRUG</small>	J&J Innovative Medicine Raritan, NJ	multiple myeloma 1-3PLs (transplant maintenance), newly- diagnosed multiple myeloma, r/r multiple myeloma (CD38 exposed)	Phase III www.janssen.com
tegavivant (beta catenin inhibitor)	Iterion Therapeutics Houston, TX	advanced liver cancer	Phase I/II www.iteriontherapeutics.com
telisotuzumab vedotin (ABBV-399) (c-Met antagonist)	AbbVie North Chicago, IL	NSCLC (Breakthrough Therapy)	Phase III www.abbvie.com
Tepmetko® tepotinib	EMD Serono Rockland, MA	EGFRm MET-amplified NSCLC	Phase II www.emdserono.com
TG-1701 (BTK inhibitor)	TG Therapeutics Morrisville, NC	B-cell malignancies	Phase I www.tgtherapeutics.com
TG-1801 (CD47 x CD19 bispecific antibody)	TG Therapeutics Morrisville, NC	B-cell lymphoma, CLL	Phase I www.tgtherapeutics.com
TG4001 (tipapkinogene sovacivec) (vaccina virus cancer vaccine)	Transgene Boston, MA	HPV-related solid tumors	Phase I/II www.transgene.fr
TG4050 (neoantigen cancer vaccine)	Transgene Boston, MA	head and neck cancer, ovarian cancer	Phase I www.transgene.fr

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
THIO-101 (telomere targeting agent)	MAIA Biotechnology Chicago, IL	NSCLC	Phase II www.maiabiotech.com
Tibsovo® ivosidenib	Servier Boston, MA	IDH1m MDS (Breakthrough Therapy)	application submitted www.servier.com
		hematologic malignancies, solid tumors	Phase I/II www.servier.com
tigilanol tiglate (protein kinase C stimulant)	QBiotics Brisbane, Australia	soft tissue sarcoma	Phase II www.qbiotics.com
TILT-123 (human 5/3 chimeric adenovirus)	TILT Biotherapeutics Cambridge, MA	ovarian cancer (+pembrolizumab)	www.tiltbio.com
tinostamustine (HDAC inhibitor) <small>ORPHAN DRUG</small>	Mundipharma Cambridge, United Kingdom	hematologic malignancies, solid tumors	Phase I www.mundipharma.com
tipifarnib (CXCL inhibitor)	Kura Oncology San Diego, CA	PI3KCA-dependent head and neck squamous cell carcinoma (+alpelisib) (Fast Track)	Phase I www.kuraoncology.com
tirabrutinib (BTK inhibitor) <small>ORPHAN DRUG</small>	Ono Pharma USA Cambridge, MA	primary CNS lymphoma	Phase II www.ono-pharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tiragolumab (TIGIT inhibitor)	Roche/Genentech South San Francisco, CA	1L PD-L1 high NSCLC, 1L esophageal cancer, locally advanced esophageal cancer, 1L stage III unresectable NSCLC, 1L non-squamous NSCLC (+atezolizumab) (Breakthrough Therapy)	Phase III www.roche.com
		NSCLC, NSCLC (neoadjuvant/adjuvant), cervical cancer, 1L PD-L1 head and neck cancer (+atezolizumab)	Phase II www.roche.com
		hematologic malignancies, solid tumors (combinations)	Phase I www.roche.com
tislezumab (PD1 inhibitor) <small>ORPHAN DRUG</small>	BeiGene Cambridge, MA Novartis Pharmaceuticals East Hanover, NJ	2L esophageal squamous cell carcinoma	application submitted www.beigene.com www.novartis.com
		localized esophageal squamous cell carcinoma, NSCLC (adjuvant/neoadjuvant), 1L urothelial cancer, 1L gastric cancer/gastroesophageal junction cancer, 1L esophageal squamous cell carcinoma, 1L head and neck cancer, 2L/3L NSCLC, 1L SCLC	Phase III www.beigene.com www.novartis.com
		advanced solid tumors (+/- combination therapy), 1L/2L gastric cancer/gastroesophageal junction cancer (combination therapy), r/r non-Hodgkin lymphoma	Phase II www.beigene.com www.novartis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Tivdak® tisotumab vedotin	Genmab Plainsboro, NJ Seagen Bothell, WA	2L/3L metastatic/recurrent cervical cancer	Phase III www.genmab.com www.seagen.com
		1L/2L recurrent or metastatic cervical cancer, metastatic solid tumors	Phase II www.genmab.com www.seagen.com
TJ210 (anti-C5aR antibody)	I-MAB Biopharma Rockville, MD	solid tumors	Phase I completed www.i-mabbiopharma.com
TJD5 (differentiated CD73 antibody)	I-MAB Biopharma Rockville, MD	solid tumors	Phase I www.i-mabbiopharma.com
TL895 (BTK inhibitor)	Telios Pharma Redwood City, CA	myelofibrosis	Phase II
	Telios Pharma Redwood City, CA Kartos Therapeutics Redwood City, CA	AML (+KRT-232), B-cell malignancies	Phase I
TLD-1433 (intravesical photodynamic therapy)	Theralase Technologies Toronto, Canada	non-muscle invasive bladder cancer (Fast Track)	Phase II www.theralase.com
TLPLDC (tumor lysate particle loaded dendritic cell vaccine)	Elios Therapeutics Austin, TX	melanoma (adjuvant)	Phase II www.eliotherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TLPO (tumor lysate particle only vaccine)	Elios Therapeutics Austin, TX	melanoma (adjuvant)	Phase III www.eliotherapeutics.com
		solid tumors	Phase I/II www.eliotherapeutics.com
TNG260 (synthetic lethal inhibitor)	Tango Therapeutics Boston, MA	STK111m solid tumors	Phase I www.tangotx.com
TNG908 (PRMT5 inhibitor) <small>ORPHAN DRUG</small>	Tango Therapeutics Boston, MA	MTAP-deleted solid tumors (Fast Track)	Phase I www.tangotx.com
TNO155 (SHP2 inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	solid tumors	Phase II www.novartis.com
TOL2506 (subcutaneous leuprorelin acetate)	Tolmar Buffalo Grove, IL	breast cancer	Phase III www.tolmar.com
tolinapant (ASTX660) (IAP inhibitor) <small>ORPHAN DRUG</small>	Astex Therapeutics Pleasanton, CA	lymphoma, solid tumors	Phase II www.astx.com
tomivosertib (eFT-508) (MNK inhibitor)	Effector Therapeutics Solana Beach, CA	1L NSCLC (+pembrolizumab)	Phase II www.effector.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
toripalimab (anti-PD-1 antibody) <small>ORPHAN DRUG</small>	Coherus BioSciences Redwood City, CA	1L nasopharyngeal cancer (+chemo) (Breakthrough Therapy), 2L/3L nasopharyngeal cancer	application submitted www.coherus.com
TORL-1-23 (antibody drug conjugate)	TORL Biotherapeutics Los Angeles, CA	advanced solid tumors	Phase I www.torlbio.com
TORL-2-307-ADC (antibody drug conjugate)	TORL Biotherapeutics Los Angeles, CA	advanced solid tumors	Phase I www.torlbio.com
TORL-2-307-MAB (immunomodulator)	TORL Biotherapeutics Los Angeles, CA	advanced solid tumors	Phase I www.torlbio.com
TORL-3-600 (antibody drug conjugate)	TORL Biotherapeutics Los Angeles, CA	solid tumors	Phase I www.torlbio.com
TOS-358 (PI3K α inhibitor)	Totus Medicines Emeryville, CA	solid tumors	Phase I www.totusmedicines.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tovorafenib (type II pan-Raf kinase inhibitor) <small>ORPHAN DRUG</small>	Day One Biopharmaceuticals Brisbane, CA	1L low-grade glioma (pediatric) (Breakthrough Therapy)	application submitted www.dayonebio.com
		relapsed low-grade glioma	Phase II www.dayonebio.com
		RAF-altered solid tumors	Phase I www.dayonebio.com
TP-1287 (CDK9 inhibitor) <small>ORPHAN DRUG</small>	Sumitomo Pharma Oncology Cambridge, MA	advanced solid tumors, including Ewing sarcoma	Phase I www.oncology.sumitomo-pharma.com
TP-1454 (PKM2 inhibitor)	Sumitomo Pharma Oncology Cambridge, MA	advanced solid tumors	Phase I www.oncology.sumitomo-pharma.com
TP-3654 (PIM1 inhibitor) <small>ORPHAN DRUG</small>	Sumitomo Pharma Oncology Cambridge, MA	myelofibrosis	Phase I/II www.oncology.sumitomo-pharma.com
TPST-1120 (PPAR α antagonist)	Tempest Therapeutics Brisbane, CA	solid tumors	Phase I www.tempesttx.com
TPST-1495 (EP2/4 antagonist)	Tempest Therapeutics Brisbane, CA	solid tumors	Phase I www.tempesttx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
trabedersen (OT-101) (antisense against TGF- β 2) <small>ORPHAN DRUG</small>	Oncotelic Agoura Hills, CA	glioblastoma, melanoma, pancreatic cancer	Phase II completed www.oncotelic.com
TransCon IL-2 beta/gamma	Ascendis Pharma Hellerup, Denmark	solid tumors	Phase I/II www.ascendispharma.com
TransCon TLR 7/8 agonist	Ascendis Pharma Hellerup, Denmark	solid tumors	Phase I/II www.ascendispharma.com
trastuzumab duocarmazine (antibody drug conjugate)	Byondis Nijmegen, The Netherlands	3L HER2+ metastatic breast cancer (Fast Track)	application submitted www.byondis.com
TRC102 (DNA repair inhibitor)	TRACON Pharmaceuticals San Diego, CA	advanced localized lung cancer	Phase II www.traconpharma.com
		solid tumors, lung cancer	Phase I www.traconpharma.com
TRE-515 (dCK inhibitor)	Trethera Sherman Oaks, CA	solid tumors	Phase I www.trethera.com
tremtelectogene empogeditemcel (stem cell therapy) <small>ORPHAN DRUG</small>	Vor Biopharma Cambridge, MA	AML (Fast Track)	Phase I/II www.vorbio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
treosulfan (sulfonate alkylating agent)	Medexus Pharmaceuticals Chicago, IL	preparative regimen for allogeneic hematopoietic stem cell transplantation	application submitted www.medexus.com
TRK-950 (tumor-associated antigen mAb)	Toray Industries Tokyo, Japan	solid tumors (combination therapy)	Phase I www.toray.com
Trodelvy® sacituzumab govitecan-hziy	Gilead Sciences Foster City, CA	1L metastatic triple negative breast cancer, 1L metastatic triple negative breast cancer (+pembrolizumab), triple negative breast cancer (adjuvant), 2-3L NSCLC, 1L NSCLC (+pembrolizumab), HR+ HER2- chemotherapy naïve breast cancer, 2L urothelial cancer	Phase III www.gilead.com
		1L NSCLC (+pembrolizumab), 1L metastatic urothelial cancer (combination therapy), solid tumors	Phase II www.gilead.com
TRPH-222 (antibody drug conjugate)	Triphase Research & Development Toronto, Canada	lymphoma	Phase I completed
TSC-100 (T lymphocyte cell therapy)	TScan Therapeutics Waltham, MA	ALL, AML, MDS	Phase I www.tscan.com
TSC-101 (T lymphocyte cell therapy)	TScan Therapeutics Waltham, MA	ALL, AML, MDS	Phase I www.tscan.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TSN084 (CDK8/19 inhibitor)	Tyligand Bioscience Shanghai, China	solid tumors	Phase I www.tyligand.com.cn
TST001 (anti-claudin18.2 mAb) ORPHAN DRUG	Transcenta Therapeutics Suzhou, China	solid tumors, including gastric cancer and pancreatic cancer	Phase I www.transcenta.com
TST003 (EMT inhibitor)	Transcenta Therapeutics Suzhou, China	solid tumors	Phase I www.transcenta.com
TST005 (PD-L1 inhibitor)	Transcenta Therapeutics Suzhou, China	solid tumors	Phase I www.transcenta.com
TT-10 (PORT6) (A2AR antagonist)	Portage Biotech Tortola, British Virgin Islands	solid tumors	Phase I www.portagebiotech.com
TT11 (CD30 CAR-T cell therapy)	Tessa Therapeutics Singapore	classical Hodgkin lymphoma	Phase II www.tessacell.com
TT11X (CD30 CAR-T cell therapy)	Tessa Therapeutics Singapore	non-Hodgkin lymphoma	Phase II www.tessacell.com
TT-816 (CB2 receptor antagonist)	Teon Therapeutics Redwood City, CA	NSCLC, ovarian cancer, renal cell carcinoma	Phase I www.teontherapeutics.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TT-00420 (tinengotinib) (multiple kinase inhibitor) <small>ORPHAN DRUG</small>	TransThera Biosciences Nanjing, China	cholangiosarcoma (Fast Track)	Phase II www.transthera.com
		solid tumors	Phase I www.transthera.com
TT-01488 (BTK inhibitor)	TransThera Sciences Nanjing, China	B-cell malignancies	Phase I www.transthera.com
TTC-352 (ER α partial agonist)	TTC Oncology Edina, MN	breast cancer	Phase I completed www.ttoncology.com
TTI-101 (STAT3 inhibitor) <small>ORPHAN DRUG</small>	Tvardi Therapeutics Sugar Land, TX	HR+ HER2- breast cancer, liver cancer	Phase II www.tvarditherapeutics.com
		advanced solid tumors	Phase I www.tvarditherapeutics.com
TTX-030 (CD389 inhibitor)	AbbVie North Chicago, IL Trishala Therapeutics South San Francisco, CA	solid tumors	Phase I www.abbvie.com
TTX-080 (HLA-G inhibitor)	Tizona Therapeutics South San Francisco, CA	solid tumors	Phase I www.tizonatx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
TTX-MC138-NODAGA-Cu64 (microRNA inhibitor)	TransCode Therapeutics Boston, MA	solid tumors	early Phase I www.transcodetherapeutics.com
TU2218 (TGF-β1/VEGFR2 inhibitor)	TiumBio Gyeonggi-do, South Korea	solid tumors	Phase I/II www.tiumbio.com
Tukysa® tucatinib	Merck Rahway, NJ Seagen Bothell, WA	1L/2L metastatic HER2+ breast cancer, high-risk HER2+ breast cancer (adjuvant), 1L HER2+ breast cancer (maintenance), 1L HER2 metastatic colorectal cancer	Phase III www.seagen.com
		2L HER2+ metastatic breast cancer, r/r HER2+ metastatic colorectal cancer, 2L HER2+ gastroesophageal cancer, solid tumors with HER2 alterations (combination therapy), including biliary tract cancer, bladder cancer, cervical cancer, endometrial cancer, NSCLC	Phase II www.seagen.com
		1L HER2+ metastatic gastrointestinal cancer	Phase I www.seagen.com
tulmimetostat (CPI-0209) (EZH2 inhibitor)	MorphoSys Munich, Germany	hematologic malignancies, solid tumors, including mesothelioma	Phase I/II www.morphosys.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tusamitamab ravtansine (anti-CEACAM5 antibody drug conjugate)	Sanofi Bridgewater, NJ	2L/3L NSCLC	Phase III www.sanofi.com
		2L/3L NSCLC (+ramucirumab), 1L NSCLC (+pembrolizumab), gastric cancer (+ramucirumab) solid tumors	Phase II www.sanofi.com
tuspentinib (FLT3/SKY inhibitor) <small>ORPHAN DRUG</small>	Aptose Biosciences San Diego, CA	AML (Fast Track)	Phase I/II www.aptose.com
TVI-Brain-1 (cancer vaccine) <small>ORPHAN DRUG</small>	TVAX Biomedical Olathe, KS	astrocytoma, glioblastoma, glioma (Fast Track)	Phase I/II completed www.tvaxbiomedical.com
TX-05 (trastuzumab biosimilar)	Tanvex BioPharma Taipei City, Taiwan	breast cancer	application submitted www.tanvex.com
TY-2136 (ROS1/ALK/NTRK inhibitor)	TYK Medicines Shanghai, China	solid tumors	Phase I www.tykmedicines.com
TYRA-300 (FGFR3 inhibitor)	Tyra Biosciences Carlsbad, CA	solid tumors FGFR3 gene alterations, including urothelial cancer	Phase I/II www.tyra.bio
ubamatamab (MUC16 x CD3 bispecific antibody)	Regeneron Pharmaceuticals Tarrytown, NY	platinum-resistant ovarian cancer	Phase II www.regenreon.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
UCART123 (CAR-T cell therapy)	Cellectis Paris, France	AML	Phase I www.cellectis.com
UCARTCS1A (CAR-T cell therapy)	Cellectis Paris, France	multiple myeloma	Phase I www.cellectis.com
UCART20x22 (CAR-T cell therapy)	Cellectis Paris, France	B-cell non-Hodgkin lymphoma	Phase I www.cellectis.com
UCART22 (CAR-T cell therapy)	Cellectis Paris, France	B-cell ALL	Phase I www.cellectis.com
UCB6114 (anti-Gremlin 1 antibody)	UCB Smyrna, GA	solid tumors	Phase I/II www.ucb.com
UCT-01-097 (kinase inhibitor)	1200 Pharma Pasadena, CA	solid tumors	Phase I
UCT-03-008 (kinase inhibitor)	1200 Pharma Pasadena, CA	solid tumors	Phase I
UGN-102 (DNA synthesis inhibitor) <small>ORPHAN DRUG</small>	UroGen New York, NY	non-muscle invasive bladder cancer (Breakthrough Therapy)	Phase III www.urogen.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
UGN-301 (anti-CTLA4)	UroGen New York, NY	non-muscle invasive bladder cancer	Phase I www.urogen.com
ulixertinib (ERK1/2 inhibitor)	BioMed Valley Discoveries Kansas City, MO	gastrointestinal cancer (Fast Track)	Phase II www.biomed-valley.com
unesbulin (BMI1 inhibitor)	PTC Therapeutics South Plainfield, NJ	diffuse intrinsic pontine glioma, leiomyosarcoma (Fast Track)	Phase II/III www.ptcbio.com
uproleselan (E-selectin inhibitor) <small>ORPHAN DRUG</small>	GlycoMimetics Rockville, MD	r/r acute myeloid leukemia (Fast Track) (Breakthrough Therapy)	Phase III www.glycomimetics.com
		newly-diagnosed unfit AML	Phase II www.glycomimetics.com
UV1 vaccine (hTERT vaccine) <small>ORPHAN DRUG</small>	Ultimovacs Oslo, Norway	melanoma (combination therapy) (Fast Track)	Phase II www.ultimovacs.com
VAC85135 (viral vector-based cancer vaccine)	J&J Innovative Medicine Raritan, NJ	hematologic malignancies	Phase I www.janssen.com
VAL-083 (DNA-targeting agent) <small>ORPHAN DRUG</small>	Kintara Therapeutics San Diego, CA	glioblastoma (Fast Track)	Phase II www.kintara.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
VAL-413 (DNA topoisomerase I inhibitor)	Valent Technologies Menlo Park, CA	recurrent solid tumors (pediatric)	Phase I
valemetostat (EZH 1/2 inhibitor)	Daiichi Sankyo Basking Ridge, NJ	PTCL	Phase II www.daiichisankyo.com
VAX014 (integrin targeted oncolytic)	Vaxiion Therapeutics San Diego, CA	non-muscle invasive bladder cancer	Phase I www.vaxiion.com
VAXinia (CF33-hNIS) (oncolytic virus gene therapy)	Imugene Sydney, Australia	solid tumors	Phase I www.imugene.com
VB10.NEO (DNA cancer vaccine)	Nykode Therapeutics Oslo, Norway	solid tumors (+atezolizumab)	Phase I/II www.nykode.com
VBI 1901 (bivalent eVLP cancer vaccine) ORPHAN DRUG	VBI Vaccines Cambridge, MA	glioblastoma (Fast Track)	Phase II www.vbivaccines.com
VCAR33 (CAR-T cell therapy)	Vor Biopharma Cambridge, MA	AML	Phase I/II www.vorbio.com
VCN-01 (oncolytic adenovirus)	Theriva Biologics Rockville, MD	pancreatic cancer	Phase II www.therivobio.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
VE800 (live biotherapeutic product)	Vedanta Biosciences Cambridge, MA	solid tumors (+nivolumab)	Phase I completed www.vedantabio.com
Venclexta [®] venetoclax	AbbVie North Chicago, IL Roche/Genentech South San Francisco, CA	AML (post transplant), multiple myeloma, Phase III 1L MDS (Breakthrough Therapy)	www.abbvie.com
		ALL, r/r MDS (+azacitidine)	Phase I www.abbvie.com
vepedgestrant (ARV-471) (ER-targeting protein degrader)	Pfizer New York, NY Arvinas New Haven, CT	ER+ HER2- metastatic breast cancer	Phase III www.pfizer.com
		ER+ HER2- early breast cancer	Phase II www.pfizer.com
Verity-BCG (cancer vaccine)	Verity Pharmaceuticals Ewing, NJ	non-muscle invasive bladder cancer	Phase II www.veritypharma.com
Verzenio [®] abemaciclib	Lilly Indianapolis, IN	metastatic breast cancer sequencing, castration resistant prostate cancer, hormone sensitive prostate cancer	Phase III www.lilly.com
VG161 (oncolytic virus gene therapy) <small>ORPHAN DRUG</small>	Virogin Biotech Richmond, Canada	cholangiosarcoma, liver cancer (Fast Track)	Phase II www.virogin.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
VG2025 (oncolytic virus gene therapy)	Virogin Biotech Richmond, Canada	solid tumors	Phase I www.virogin.com
vidutolimod (TLR9 immune activator) ORPHAN DRUG	Regeneron Pharmaceuticals Tarrytown, NY	solid tumors	Phase II www.regeneron.com
Vigil [®] gemogenovatucl-T	Gradalis Carrollton, TX	gynecologic cancer, ovarian cancer	Phase II www.gradalisinc.com
vilobelimab (IFX-1) (ant-complement C5a mAb)	InflaRx Jena, Germany	cutaneous squamous cell carcinoma	Phase II www.inflarx.com
VIP152 (CDK9 inhibitor)	Vincerx Pharma Palo Alto, CA	CLL, Richter syndrome, solid tumors	Phase I www.vincerx.com
VIP236 (DNA topoisomerase I inhibitor)	Vincerx Pharma Palo Alto, CA	solid tumors	Phase I www.vincerx.com
VIP943 (antibody drug conjugate)	Vincerx Pharma Palo Alto, CA	CD123+ hematologic malignancies	Phase I www.vincerx.com
VOB560	Novartis Pharmaceuticals East Hanover, MA	cancer	Phase I www.novartis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
vobramitamab duocarmazine (B7-H3 antibody drug conjugate)	MacroGenics Rockville, MD	metastatic castration-resistant prostate cancer	Phase II www.macrogenics.com
		solid tumors	Phase I www.macrogenics.com
vodobatinib (K0706/SCO-088) (Bcr-Abl1 inhibitor)	Sun Pharma Advanced Research Mumbai, India	CML	Phase I/II www.sparc.life
volrustomig (bispecific antibody)	AstraZeneca Wilmington, DE	solid tumors	Phase II www.astrazeneca.com
		advanced kidney cancer (+lenvatinib)	Phase I www.astrazeneca.com
vorasidenib (IDH1.2 inhibitor)	Servier Boston, MA	IDH1/2m low grade glioma	Phase III www.servier.us
		IDH1/2m grade 2-3 glioma (+pembrolizumab)	Phase I www.servier.us
voruciclib (CDK9 inhibitor)	MEI Pharma San Diego, CA	AML	Phase I www.meipharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Voyager-V1 (genetically engineered oncolytic vesicular stomatitis factor)	Vyriad Rochester, NY	head and neck cancer, NSCLC (+pembrolizumab), solid tumors (+cemiplimab)	Phase II www.vyriad.com
VP301 (CD38 x ICAM-1 bispecific antibody)	Virtuoso Therapeutics San Mateo, CA	lymphoma, multiple myeloma, solid tumors	Phase I www.virtuosotherapeutics.com
VT101 (alpha-tocopherolxyacetic acid)	Veana Therapeutics Portland, OR	HER2+ breast cancer	Phase I www.veana-therapeutics.com
VT1021 (thrombospondin1 agonist)	Vigeo Therapeutics Cambridge, MA	solid tumors	Phase I www.vigeotherapeutics.com
VT3989 (TEAD inhibitor)	Vivace Therapeutics San Mateo, CA	mesothelioma, solid tumors	Phase I www.vivacetherapeutics.com
VTP-850 (prime-boost vaccine)	Vaccitech Germantown, MD	prostate cancer	Phase I/II www.vaccitech.com
VTR-297 (HDAC inhibitor)	Vanda Pharmaceuticals Washington, DC	hematologic malignancies	Phase II www.vandapharma.com
vudalimab (PD1 x CTLA4 bispecific antibody)	Xencor Pasadena, CA	metastatic castration-resistant prostate cancer, gynecologic/genitourinary malignancies	Phase II www.xencor.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Vyxeos® cytarabine/daunorubicin	Jazz Pharmaceuticals Philadelphia, PA	1L AML	Phase I www.jazzpharma.com
Welireg™ belzutifan	Merck Rahway, NJ	renal cell carcinoma (+/- pembrolizumab) (Breakthrough Therapy)	application submitted www.merck.com
		biliary cancer, colorectal cancer, endometrial cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, rare cancers (+/- pembrolizumab)	Phase II www.merck.com
WGI-0301 (c-Akt inhibitor)	WhiteOak Group Rockville, MD	solid tumors	Phase I thewogroupinc.com
WP1066 (STAT3 inhibitor) <small>ORPHAN DRUG</small>	Moleculin Biotech Houston, TX	glioblastoma	Phase I www.moleculin.com
WP1122 (metabolism/glycosylation inhibitor)	Moleculin Biotech Houston, TX	solid tumors	Phase I www.moleculin.com
WTX-124 (IL-2 replacement)	Werewolf Therapeutics Watertown, MA	solid tumors	Phase I www.werewolftx.com
WTX-330 (IL-12 replacement)	Werewolf Therapeutics Watertown, MA	non-Hodgkin lymphoma, solid tumors	Phase I www.werewolftx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
WU-CART-007 (CAR-T cell therapy) <small>ORPHAN DRUG</small>	Wugen St. Louis, MO	T-cell ALL, lymphoblastic leukemia (Fast Track)	Phase I/II www.wugen.com
WU-NK-101 (natural killer cell therapy)	Wugen St. Louis, MO	AML	Phase I/II www.wugen.com
X-396 (ensartinib) (ALK inhibitor)	Xcovery Palm Beach Gardens, FL	NSCLC	Phase III www.xcovery.com
xaluritamig (AMG 509) (bivalent T-cell engager)	Amgen Thousand Oaks, CA	prostate cancer (Fast Track)	Phase I www.amgen.com
XB002 (antibody drug conjugate)	Exelixis Alameda, CA	solid tumors	Phase I www.exelixis.com
XB2001 (IL-1 α inhibitor)	XBiotech Austin, TX	pancreatic cancer	Phase I/II www.xbiotech.com
xevinapant (IAP Inhibitor)	EMD Serono Rockland, MA	head and neck cancer cisplatin-eligible unresected (Breakthrough Therapy), head and neck cancer cisplatin- ineligible resected	Phase III www.emdserono.com
XL102 (CDK7 inhibitor)	Exelixis Alameda, CA	solid tumors	Phase I www.exelixis.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
XmAb104 (izuralimab) (PD-1 x ICOS bispecific antibody)	Xencor Pasadena, CA	solid tumors	Phase I www.xencor.com
XmAb306 (RG6323) (IL15 x IL15Ra-FX bispecific antibody)	Roche/Genentech South San Francisco, CA Xencor Pasadena, CA	solid tumors	Phase I www.roche.com www.xencor.com
XmAb808 (B7-H3 x CD38 bispecific antibody)	Xencor Pasadena, CA	solid tumors (+pembrolizumab)	Phase I www.xencor.com
XmAb819 (ENPP3 x CD3 bispecific antibody)	Xencor Pasadena, CA	kidney cancer	Phase I www.xencor.com
XmAb968 (CD38 x CD3 bispecific antibody)	Xencor Pasadena, CA	T-ALL, T-LBL, AML	Phase I www.xencor.com
XMT-1536 (upifitamab rilsodotin) (NaPi2b)	Mersana Therapeutics Cambridge, MA	recurrent platinum-resistant ovarian cancer (maintenance) (Fast Track)	Phase III www.mersana.com
		platinum-resistant ovarian cancer	Phase II www.mersana.com
		platinum-sensitive ovarian cancer	Phase I www.mersana.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
XMT-1660 (antibody drug conjugate)	Mersana Therapeutics Cambridge, MA	solid tumors, including triple negative breast cancer (Fast Track), endometrial cancer, ovarian cancer	Phase I www.mersana.com
XMT-2056 (STING antibody drug conjugate)	Mersana Therapeutics Cambridge, MA	solid tumors	Phase I www.mersana.com
Xospata® gilteritinib	Astellas Pharma US Northbrook, IL	AML (post-treatment maintenance), newly-diagnosed AML (high intensity induction of chemo, AML (pediatric)	Phase III www.astellas.com
		newly-diagnosed AML (low intensity induction of chemo)	Phase I www.astellas.com
X-PACT (psoralen activated cancer therapy)	ImmunoLight Detroit, MI	solid tumors	Phase I www.immunolight.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Xpovio® selinexor <small>ORPHAN DRUG</small>	Karyopharm Therapeutics Newton, MA	DLBCL (+R-GDP), endometrial cancer (maintenance), p53 wild-type endometrial cancer, 2L+ multiple myeloma (combination therapy)	Phase III www.karyopharm.com
		r/r multiple myeloma (combination therapy)	Phase II www.karyopharm.com
		myelofibrosis (treatment naïve)	Phase I www.karyopharm.com
XRD-0394 (kinase inhibitor)	XRad Therapeutics Durham, NC	solid tumors	Phase I
XS004 (dasatinib) (amorphous solid formulation) <small>ORPHAN DRUG</small>	Xspray Pharma Solna, Sweden	CML, precursor cell lymphoblastic leukemia-lymphoma	application submitted www.xspraypharma.com
Xtandi® enzalutamide	Astellas Pharma US Northbrook, IL Pfizer New York, NY	non-metastatic castration-sensitive prostate cancer	application submitted www.astellas.com www.pfizer.com
GTX101 (CTLA4 inhibitor)	Xilio Therapeutics Waltham, MA	solid tumors	Phase I www.xiliotx.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
XTX202 (IL-2 replacement)	Xilio Therapeutics Waltham, MA	solid tumors	Phase II www.xiliotx.com
XTX301 (IL-12 replacement)	Xilio Therapeutics Waltham, MA	solid tumors	Phase I www.xiliotx.com
Yescarta [®] axicabtagene ciloleucel	Gilead Sciences Foster City, CA	2L+ high-risk follicular lymphoma, 1L high-risk large B-cell lymphoma	Phase III www.gilead.com
		2L large B-cell lymphoma (outpatient)	Phase II www.gilead.com
YH001 (anti-CTLA4 antibody)	TRACON Pharmaceuticals San Diego, CA	liver cancer, NSCLC, soft tissue sarcoma, solid tumors	Phase II www.traconpharma.com
YH003 (agnostic CKPT antibody)	Eucure Biopharma Beijing, China	solid tumors	Phase II www.eucure.com
YIV 906 (Chinese botanical therapy) <small>ORPHAN DRUG</small>	Yiviva New Haven, CT	liver cancer	Phase II www.yiviva.com
YL-13027 (TGF-βR1 inhibitor)	Yingli Pharmaceutical Shanghai, China	solid tumors	Phase I www.yl-pharma.com
YL-15293 (KRAD inhibitor)	Yingli Pharmaceutical Shanghai, China	solid tumors	Phase I www.yl-pharma.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
YL201 (antibody drug conjugate)	MediLink Therapeutics Suzhou, China	solid tumors	Phase I www.medilinkthera.com
YL202 (antibody drug conjugate)	MediLink Therapeutics Suzhou, China	breast cancer, NSCLC	Phase I www.medilinkthera.com
zamtocabtagene autoleucel (CAR-T cell therapy)	Miltenyi Biotec San Jose, CA	DLBCL	Phase II www.miltenyibiotec.com
zanidatamab (anti-HER2 bispecific antibody) <small>ORPHAN DRUG</small>	BeiGene Cambridge, MA Jazz Pharmaceuticals Philadelphia, PA Zymeworks Seattle, WA	1L HER2+ gastroesophageal cancer, 1L HER2+ gastrointestinal cancer (Fast Track), lymphoma	Phase III www.beigene.com www.zymeworks.com
		2L+ HER2+ biliary tract cancer (Fast Track) (Breakthrough Therapy), breast cancer, B-cell lymphoma, 1L HER2+ gastric cancer/gastro-esophageal cancer	Phase II www.beigene.com www.zymeworks.com
zanidatamab zovodotin (antibody drug conjugate)	Zymeworks Seattle, WA BeiGene Cambridge, MA	HER2-expressing cancers	Phase I www.beigene.com www.zymeworks.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
zanzalintinib (tyrosine kinase inhibitor)	Exelixis Alameda, CA	colorectal cancer, non-clear cell kidney cancer	Phase III www.exelixis.com
		solid tumors	Phase I www.exelixis.com
ZB131 (ibentatug) (anti-CSP1 mAb) <small>ORPHAN DRUG</small>	ZielBio Charlottesville, VA	advanced solid tumors, including bile duct cancer, pancreatic ductal adenocarcinoma, ovarian cancer	Phase I www.zielbio.com
ZE46-0134 (pan-FLT3 inhibitor)	Eilean Therapeutics Dover, DE	hematologic malignancies	Phase I www.eileantherapeutics.com
Zejula [®] niraparib	GSK Durham, NC	1L maintenance NSCLC (+pembrolizumab) 1L maintenance ovarian cancer (+dostarlimab)	Phase III www.gsk.com
ZEN-3694 (BET inhibitor)	Zenith Epigenetics San Francisco, CA	metastatic castration-resistant prostate cancer, triple negative breast cancer	Phase II www.zenithepigenetics.com
zenocutuzumab (MCLA-1280) (HER2 x HER3 bispecific antibody) <small>ORPHAN DRUG</small>	Merus Cambridge, MA	solid tumors harboring an NRG1 fusion, metastatic castration-resistant prostate cancer, NRG1+ NSCLC (Breakthrough Therapy), NRG1+ pancreatic cancer (Breakthrough Therapy)	Phase II www.merus.nl

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Zepzelca® lurbinectedin	Jazz Pharmaceutical Philadelphia, PA PharmaMar Madrid, Spain	advanced solid tumors	Phase II www.jazzpharma.com
		Ewing sarcoma (pediatric)	Phase I/II www.jazzpharma.com
zevorcabtagene autoleucel (CAR-T cell therapy) <small>ORPHAN DRUG</small>	CARsgen Shanghai, China	multiple myeloma	Phase I/II www.carsgen.com
ziftomenib (selective menin inhibitor) <small>ORPHAN DRUG</small>	Kura Oncology San Diego, CA	ALL, AML (monotherapy and combinations)	Phase I/II www.kuraoncology.com
zilovertamab (ROR1 mAb)	Oncternal Therapeutics San Deigo, CA	hematologic malignancies, solid tumors	Phase I www.oncternal.com
zilurgisertib (ALK2 inhibitor)	Incyte Wilmington, DE	anemia due to hematologic disorders, including malignancies	Phase I www.incyte.com
zipalertinib (CLN081/TAS6417) (EGFR inhibitor)	Cullinan Oncology Cambridge, MA Taiho Oncology Princeton, NJ	NSCLC with insertion exon 20 mutations (Breakthrough Therapy)	Phase II www.cullinanoncology.com www.taihooncology.com
ZL-1211 (anti-CLDN18.2 mAb)	ZAI Lab Shanghai, China	solid tumors	Phase I www.zailaboratory.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ZL-1218 (anti-CCCR8 antibody)	ZAI Lab Shanghai, China	solid tumors	Phase I www.zailaboratory.com
ZN-A-1041 (TK inhibitor)	Roche/Genentech South San Francisco, CA Zanrong Pharmaceutical Suzhou, China	solid tumors	Phase I www.zionpharma.com
ZN-c3 (azenosertib) (wee1 inhibitor) <small>ORPHAN DRUG</small>	Zentalis Pharmaceuticals New York, NY	uterine serous cancer (Fast Track), solid tumors	Phase II www.zentalis.com
		colorectal cancer, ovarian cancer, osteosarcoma, pancreatic cancer	Phase I www.zentalis.com
ZN-d5 (BCL-2 inhibitor)	Zentalis Pharmaceuticals New York, NY	AML (Fast Track), non-Hodgkin lymphoma	Phase I/II www.zentalis.com
zolbetuximab (IMAB362) (anti-Claudin 18.2 antibody) <small>ORPHAN DRUG</small>	Astellas Pharma US Northbrook, IL	gastric cancer, gastroesophageal junction adenocarcinoma (Fast Track)	application submitted www.astellas.com
		pancreatic cancer	Phase II www.astellas.com
zotatifin (eFT226) (eIF4A inhibitor)	Effector Therapeutics Solana Beach, CA	KRAS-mutant NSCLC	Phase II www.effector.com

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ZX-4081 (PI3K inhibitor)	Zenshine Pharmaceuticals Nanjing, China	solid tumors	Phase I www.zenshine-pharma.com
Zynlonta® loncastuximab tesirine-lpyl	ADC Therapeutics New Providence, NJ	NTE DLBCL	Phase III www.adctherapeutics.com
		non-Hodgkin lymphoma	Phase I www.adctherapeutics.com
Zynyz® retifanlimab-dlwr <small>ORPHAN DRUG</small>	Incyte Wilmington, De	squamous cell anal cancer (Fast Track), NSCLC	Phase III www.incyte.com
		MSI-H endometrial cancer (Fast Track)	Phase II www.incyte.com
ZZ06	Intellicrown Pharmaceutical Changchun, China	solid tumors	Phase I

The content of this report has been obtained through public, government and industry sources, and the Springer "Adis Insight" database based on the latest information. Report current as of **October 16, 2023**. The medicines in this listing include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. Some products may not be in active clinical trials. The information may not be comprehensive. For more, specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA's website: www.phrma.org.

Definitions

Application Submitted—An application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA).

Breakthrough Therapy—Upon request by a sponsor, the FDA can grant this designation to expedite the development and review of a drug or biologic intended, alone or in combination with one or more other drugs, to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically-significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug or biologic is designated as a Breakthrough Therapy, the FDA will expedite the development and review. With this designation, all Fast Track features convey to the medicine.

Fast Track—Upon request by a sponsor, the FDA can grant this designation to facilitate the development and expedite the review of a drug or biologic to treat a serious condition and fill an unmet medical need. When considering a biopharmaceutical company's request for Fast Track designation for an investigational drug or biologic, the FDA evaluates whether it will affect factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one, and whether a condition can be adequately addressed by available therapy. With Fast Track designation, early and frequent communication between the FDA and the biopharmaceutical company is encouraged throughout the entire drug development and review process to help to quickly resolve any questions or issues that arise, potentially leading to an earlier approval and access by patients.

Orphan Designation—Upon request by a sponsor, the FDA can grant special status (“orphan status”) to a drug or biologic to treat a rare disease or condition. In order to receive an orphan designation, a qualifying drug or biologic must be intended for the treatment, diagnosis, or prevention of a rare disease or condition that affects usually fewer than 200,000 people in the United States.

Phase I—Researchers test the investigational drug or biologic in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Phase II—The investigational drug or biologic is given to volunteer patients, usually between 100 and 500, to determine whether it is effective, identify an optimal dose, and to further evaluate its short-term safety.

Phase III—The investigational drug or biologic is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients (but sometimes any more), to generate statistically significant evidence to confirm its safety and effectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world.